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Bleeding symptoms such as easy bruising, menorrhagia and bleeding a&er surgery and 
trauma, are common in the overall population.1-4 Diagnosing patients with a suspected 
bleeding diathesis can be challenging in clinical practice. However, establishing a 
diagnosis in these patients is essential to provide patients with appropriate treatment. 
Although some patients are diagnosed with a speci$c bleeding disorder like hemophilia 
or von Willebrand disease, many remain without a diagnosis.5, 6 !ere is a signi$cant 
subset of patients with only a mild coagulation abnormality. In the Netherlands, there is 
no information about these patients with rare bleeding disorders (RBDs) so far regarding 
their clinical characteristics, natural course of the bleeding disorder and treatment. At 
an international level, the only available information comes from a limited European 
registry.7 !erefore, more information on RBDs is necessary to gain insight in these 
disorders, which is the main goal of this thesis. !e currently available diagnostic assays 
are not adequate, and there is a need for better diagnostics to eventually diagnose more 
patients with a speci$c bleeding disorder and realize personalized based treatment.
HEMOSTATIC BALANCE
Hemostasis is the essential physiological process of blood changing from liquid to solid to 
form a blood clot and to stop bleeding. !is process of blood clot formation is the result 
of a delicate balance between anticoagulant and procoagulant factors. !ree distinct 
phases can be described: primary hemostasis, secondary hemostasis and $brinolysis. 
Primary hemostasis is the $rst step a&er rupture of a blood vessel. It results from complex 
interactions between platelets, vessel wall and adhesive proteins leading to the formation 
of an initial platelet plug as platelets attach to the damaged area of the endothelium with 
the help of von Willebrand factor (VWF).8, 9 Next, platelet aggregation will occur due to 
autocrine activation of other platelets who undergo a shape change and consequently form 
a platelet rich plug.10 Simultaneously, tissue factor (TF) located in the subendothelium will 
be exposed and consequently activates the coagulation cascade leading to the generation 
of thrombin. !is part is the secondary hemostasis, and is divided into 3 phases: the 





of secondary hemostasis, $brinolysis and anticoagulant factors is shown in $gure 1. !e 
initiation phase starts with the release of TF, activating factor VII (FVII). !e activated 
FVII (FVIIa) activates FX into FXa. FXa activates FV and subsequently together with 
FVa FII (prothrombin) to form thrombin (FIIa).11 Once thrombin is formed, it activates 
$brinogen to form $brin, and activates FXIII into FXIIIa. FXIIIa is essential in the 
formation of a solid $brin network as it cross links $brin $bers ultimately forming a 
stable platelet-$brin thrombus.9, 10, 12 !rombin formed during the initiation phase is not 
su'cient enough to form a stable clot and activates the propagation phase, through the 
activation of FXI and FVIII. In addition, TF-FVIIa activates FIX.9 !e propagation phase 
can also be activated through FXII. However, this pathway is not important for bleeding, 














Red: initiation phase. Blue: propagation phase. Green: "brinolysis. Yellow: anticoagulant factors. Full 
lines are stimulating, dotted lines are inhibitory.
To prevent unlimited thrombus formation and systemic coagulation a&er initiation, the 
generation of thrombin is inhibited by several negative feedback loops, shown in yellow 
in $gure 1. Antithrombin (AT) is an inhibitor for most of the enzymes generated during 
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activation of coagulation, especially for FIIa and FXa.10, 12 In addition, thrombin binds 
to thrombomodulin, leading to the loss of thrombin’s procoagulant activities as the 
thrombin-thrombomodulin complex activates protein C to activated protein C (APC).14 
Subsequently, APC inactivates FVIIIa and FVa. Protein S is an important cofactor for 
this reaction.[10] Finally, tissue factor pathway inhibitor (TFPI) inhibits TF-FVIIa, an 
interaction that is dependent on FXa.15
FIGURE 2. 
A. Hemostatic balance. B. Disbalance in hemostasis caused by coagulation factor de"ciency, 



































Fibrinolysis is the process of $brin clot solubilization. !e key component of $brinolysis 
is plasmin, a serine protease that degrades the $brin network. !e zymogen plasminogen 
is the pro-enzyme for plasmin and can be converted by tissue type plasminogen activator 
(tPA) or urokinase type plasminogen activator (uPA).16, 17 Once formed, plasmin cleaves 
$brin, generating $brin degradation products such as d-dimers.17 Inhibitors of this 
process are present to regulate the $brinolytic pathway. !e main physiological plasmin 
inhibitor is α2-AP.18 !rombin activatable $brinolysis inhibitor (TAFI) attenuates plasmin 
generation a&er being activated by thrombomodulin bound thrombin, free thrombin 
or plasmin. TAFI removes carboxy-terminal lysine residues from $brin, resulting in 
a decreased plasmin generation and stabilization of $brin containing thrombi.16, 17 
Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of tPA and uPA. 
All pathways described above are intertwined and occur parallel of each other. In a 
normal situation, the hemostatic system is in balance and well regulated by procoagulant 
and anticoagulant factors, as shown in $gure 2A. If one of the factors in the system is not 
working properly, the hemostatic system may be disturbed leading to a risk of bleeding 
on the one hand ($gure 2B), or thrombosis on the other hand.
DIAGNOSIS OF DISTURBANCES OF THE HEMOSTATIC 
SYSTEM
!e diagnosis of bleeding disorders can be challenging. Bleeding symptoms are common 
in the general population and conventional laboratory assays lack sensitivity and 
speci$city, especially for some bleeding disorders such as disorders of $brinolysis. !e 
prothrombin time (PT) and activated partial thromboplastin time (APTT) assays show 
quite some variation in factor activity level responsiveness, and mild factor de$ciencies 
may be missed by these screening assays.19, 20 Novel diagnostic strategies such as global 
hemostasis assays and genome diagnostics are potentially valuable for the diagnosis of 
bleeding disorders.
Clinical work-up
!e majority of patients with an increased bleeding tendency present to the general 
practitioner. !ere is a risk of overanalyzing patients, as menorrhagia, epistaxis and 
bruising are frequently reported in the general population as well.2 A&er referral to a 
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specialist, patients generally undergo a stepwise diagnostic procedure starting with 
an extensive bleeding history using a bleeding assessment tool (BAT). Several BATs 
have been developed, of which the ISTH (International Society of !rombosis and 
Haemostasis) BAT is currently the most established for adult patients.21, 22 In addition to 
the BAT score, family history and use of medication like non-steroidal anti-in/ammatory 
drugs, anticoagulants and supplements are important aspects of the anamnesis. 
FIGURE 3. 
Flowdiagram of diagnostic process for a bleeding tendency in the Radboud university medical 
center.
BAT <4 for men
BAT <6 for women





BAT ≥4 for men
BAT ≥6 for women








Bleeding of unknown cause
Con#rmation assaysPlatelet function assaysCon#rmation assays
A B
Green = positive diagnostic test, Red = negative diagnostic test. A. Flow diagram of patients referred for a 
bleeding tendency with a normal BAT score. B. Flow diagram of patients with an abnormal BAT score. 
Screening assays consist of a whole blood count, aPTT, PT, PFA, "brinogen level, VWF ristocetin cofactor 
activity, VWF antigen level, VWF collagen binding activity, FVIII activity level, FXIII (qualitative assay) and 
α2-antiplasmin activity level. Con"rmation assays depend on the abnormalities in the screening assays and 
consists of speci"c coagulation factor activity levels or platelet function assays. If the medical history or the 
family history are suggestive of a speci"c bleeding disorder, deviations from this schedule can occur after 
discussion in a multidisciplinary meeting including hematologists, pediatric hematologists and laboratory 
specialists. For example, if a patient presents with a history of delayed bleeding after invasive procedures and 
bleeding in areas of high "brinolytic activity (e.g. epistaxis, menorrhagia) or a family history of a disorder of 






!e following step is a laboratory work up to detect abnormalities in primary and 
secondary hemostasis and $brinolysis. Many Hemophilia Treatment Centers (HTCs) use 
a diagnostic algorithm. Figure 3 shows the current diagnostic strategy at the Radboud 
University Medical Center, aiming to give as many patients as possible a de$nite diagnosis, 
including the diagnosis of mild coagulation factor de$ciencies. If screening assays such 
as the platelet function analyzer (PFA), PT and APTT are abnormal, it is essential to 
perform con$rmation assays to establish a $nal diagnosis. !ese assays include individual 
coagulation factor activity levels in case of prolonged PT and APTT, platelet function 
assays, VWF activity and antigen levels and $brinolysis assays.23, 24 In general, only 1 in 
3 patients referred for a bleeding tendency receive a $nal diagnosis.25 For a part of these 
cases, this may be due to a lack of sensitive and speci$c laboratory assays. !erefore, 
con$rmation assays are also required in case of high BAT scores with no abnormalities 
in screening assays. In addition, a proportion of the patients referred with a bleeding 
tendency might not have a congenital bleeding disorder, but bleeding due to the use of 
medication or other causes such as uterus atony causing postpartum hemorrhage.26, 27 In a 
study conducted by our HTC it was reported that patients referred for bleeding with a high 
bleeding score only for the ISTH BAT items surgery and postpartum hemorrhage o&en 
do not receive a $nal diagnosis for their bleeding tendency at the end of the diagnostic 
trajectory.25 Overall, the results of these conventional diagnostics are unsatisfactory, as 
every assay analyses only one piece of the hemostatic system. !e intertwining of the 
many hemostatic factors and translation to the clinical impact in a patient is missing.
Global hemostasis assays
A single assay to assess the complex system of hemostasis with its many interacting 
pathways, would be very useful. For this purpose, several global hemostasis assays are 
being developed. Firstly, thrombin generation assays measure the overall tendency of a 
plasma sample to form thrombin a&er initiation of coagulation. !e thrombin generation 
curve re/ects initiation, propagation and termination. !e speci$c contribution of each 
coagulation factor or inhibitor depends on the reaction conditions that are used in the 
assay.28 In a clinical setting, thrombin generation assays are mainly used in hemophilia 
in patients with inhibitors who require bypassing agents.29 In addition to thrombin 
generation, two assays have been developed measuring thrombin generation and 
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plasmin generation in a single test system.30, 31 One of these, the Nijmegen Hemostasis 
Assay (NHA) was developed at the Radboud University Medical Center.31 !e NHA 
has been previously used in an international cohort of patients with rare coagulation 
factor de$ciencies, showing distinct thrombin generation and plasmin generation curves 
for each coagulation factor de$ciency.32 Secondly, plasma turbidity assays allow the 
determination of clot formation, as aggregation of $brin $bers results in an increased 
turbidity. Only the overall $brin formation and solubilization is measured, making 
this type of assay not suitable to detect combined coagulation disorders with opposing 
e%ects.33 !romboelastography and thromboelastometry assess viscoelastic changes in 
whole blood or plasma and provide a fast bedside monitoring of the complete hemostatic 
system. However, there is a discrepancy of the results of these assays with standard 
laboratory values.34 !ese assays are currently mainly used in critical care medicine. In 
addition, a problem of all of the above mentioned assays is a lack of global validation. 
Every laboratory uses di%erent reagents or slightly di%erent methods for these assays, 
making it di'cult to extrapolate the results.
Genome diagnostics 
Besides measuring the hemostatic balance via global hemostasis assays, genome 
diagnostics are promising tools in addition to the conventional laboratory diagnostics. 
Direct diagnostics of one speci$c gene with Sanger sequencing has been used for 
several decades for con$rmation of a suspected diagnosis in case of a clear clinical and/
or laboratory phenotype. However, Sanger sequencing is costly and time consuming.24 
Next generation sequencing (NGS) techniques o%er the possibility to investigate a large 
number of genes at the same time. Available techniques are targeted NGS, whole exome 
sequencing (WES) and whole genome sequencing (WGS). For targeted NGS, a platform 
needs to be developed with relevant genes known to be involved in hemostasis. Targeted 
NGS needs some time-investment, but is an easy and relatively cheap technique. !e 
results in patients with bleeding disorders are promising, with a panel showing 100% 
concordance with Sanger sequencing and the detection of multiple novel pathogenic 
variants in hemostasis genes.35 A disadvantage is the di'culty of adding new genes 
a&er the platform has been developed. In WES, all exons are ampli$ed and sequenced. 
!e exome is the coding part of the genome, making up about 1% of the genome and 





the diagnostic /ow for inherited bleeding disorders in some hospitals, and the diagnostic 
yield appears to be the highest in patients with platelet disorders.37 WGS generates the 
most complete overview of genetic variants of an individual. A disadvantage is the 
enormous amount of information generated with this technique, of which the clinical 
consequences are not completely clear at this moment. Application of a panel of known 
genes, analyzed by WGS, has already proven its value in a research setting of patients with 
a bleeding tendency or thrombosis.38 
When a variant is found, it is classi$ed from class 1 (not pathogenic) to class 5 
(de$nitely pathogenic), according to the classi$cation shown in table 1.39 !e classi$cation 
is based on in silico prediction programs evaluating the type of variant (i.e. missense, 
nonsense, frameshi&), whether the variant is in a functional domain, the predicted 
e%ect of this variant to protein formation, and whether the variant has been previously 
described in humans or animals. !e bleeding phenotype of a patient depends on both the 
genotype as well as environmental factors such as the use of medication, comorbidities 
and in/ammation status. !erefore, genome diagnostics can never generate a complete 
overview of the patients’ coagulation status, and should always be used and interpreted 
in combination with functional laboratory assays such as global hemostasis assays and 
individual factor activity levels.40
TABLE 1. 
Classi"cation of variants found using NGS techniques.
Class 1 Not pathogenic
Class 2 Probably not pathogenic
Class 3 Variant of unknown signi"cance
Class 4 Probably pathogenic
Class 5 Pathogenic




Prevalence of Rare Bleeding Disorders
Bleeding disorders can be either inherited or acquired. !is thesis focusses on inherited 
bleeding disorders. Research of inherited bleeding disorders traditionally focused on 
hemophilia due to the clinical impact of severe bleeding and the relatively high incidence 
of 1:10.000 live births for hemophilia A and 1:60.000 for hemophilia B.41 Rare Bleeding 
Disorders (RBDs) consist of rare coagulation factor de$ciencies (RCDs) and disorders of 
$brinolysis. !e prevalence of disorders of $brinolysis is not known, as they have only 
been described in case reports and case series. RCDs refer to de$ciencies of $brinogen, 
prothrombin (FII), FV, FV&FVIII, FVII, FX, FXI, and FXIII. In contrast to X-linked 
hemophilia, RCDs are generally inherited as autosomal recessive disorders, except for 
dys$brinogenemia and some cases of FXI de$ciency which can be autosomal dominant. 
!e prevalences of RCDs for homozygosity or compound heterozygosity are shown in 
table 2, and vary from 1:500.000 to 1:2.000.000.41-43 !ey are signi$cantly more prevalent 
in population groups with a high rate of consanguinity.42, 44 Up till now, clinical practice 
only focuses on patients with severe coagulation de$ciencies (homozygous or compound 
heterozygous patients). However, mild coagulation factor de$ciencies can also lead to a 
bleeding tendency and are far more prevalent in the population. Due to their autosomal 
recessive inheritance, in general RBDs are equally present in males and females. However, 
real-life data about sex di%erences in bleeding disorders other than hemophilia is missing. 
Interestingly, there is a di%erence in naturally challenging events between men and women 
that can predispose to bleeding, like menstruation and giving birth. !e study of patients 
with a RBD has gained a lot of interest over the past decade, and a European registry 
for RCD patients has been established.45 !e clinical presentation of RBDs is diverse, 
ranging from asymptomatic to severe spontaneous bleeding.46 !e reported correlation 
between factor activity level and degree of bleeding varies from strong and predictable 
(for $brinogen, FX and FXIII) to very weak for FXI de$ciency.7 Overall, life-threatening 
bleeding episodes such as cerebral bleeding and spontaneous hemorrhages in muscles 
and joints appear to occur less frequently when compared to hemophilia.44 However, 
the large variability between the individual RBDs makes it impossible to consider these 






Prevalences of rare coagulation factor de"ciencies.41, 43





Factor II Prothrombin de"ciency 1:2.000.000
Factor V Factor V de"ciency 1:1.000.000
Factor V & VIII Combined FV & FVIII de"ciency 1:1-2.000.000
Factor VII Factor VII de"ciency 1:500.000
Factor X Factor X de"ciency 1:1.000.000
Factor XI Factor XI de"ciency 1:1.000.000
Hemophilia C
Factor XIII Factor XIII de"ciency 1:1-2.000.000
Clinical characteristics of Rare Bleeding Disorders
Patients with congenital a$brinogenemia su%er from a lifelong severe bleeding tendency. 
Bleeding can occur in all tissues and o&en presents in newborns with umbilical cord 
bleeding. In addition, patients with a$brinogenemia are susceptible to spontaneous 
splenic rupture, poor wound healing and the development of bone cysts.47, 48 Intracranial 
hemorrhage is the leading cause of death.47 Women usually require replacement therapy 
during pregnancy to prevent miscarriage. In addition, patients are at risk for development 
of arterial and venous thromboembolic complications.49 Hypo$brinogenemic patients 
are usually less symptomatic.47 Patients with dys$brinogenemia can be asymptomatic, 
have a bleeding tendency or a tendency towards thrombosis.49 A $brinogen activity level 
of >1.1 g/L should be enough to remain asymptomatic.7
Severe FII de$ciency leads to a marked bleeding tendency, whereas heterozygotes 
are usually asymptomatic. However, excessive bleeding a&er invasive procedures can be 
observed in heterozygotes.50 !e minimal factor activity level to remain asymptomatic is 
currently unknown. In addition, patients with dysprothrombinemia have been described, 
who have a low FII activity but normal FII antigen levels. !ese patients may not have a 
bleeding tendency but an increased risk of thrombosis.51
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Most patients with a FV de$ciency have only a mild to moderate bleeding tendency, 
even in case of severe FV de$ciency. !e minimal factor activity level to remain 
asymptomatic is 12%.7 Residual platelet FV may play a role in the mild bleeding phenotype 
and clinical heterogeneity of patients with a FV de$ciency.52 In addition, patients with FV 
de$ciency have low levels of TFPI due to the normal binding of TFPI to FV. !ese low 
TFPI levels greatly reduce the minimal FV levels to obtain normal thrombin generation 
and thus restrict bleeding episodes.53 Mucosal bleeding and cutaneous bleeding are the 
most common symptoms of patients with a FV de$ciency.42
Patients with a combined FV and FVIII de$ciency do not have a more severe bleeding 
tendency than individuals with either a FV or a FVIII de$ciency.54 !e bleeding tendency 
is usually mild to moderate, with mainly cutaneous bleeding, mucosal bleeding and 
bleeding a&er surgery, tooth extractions and trauma. However, more severe symptoms 
such as hemarthrosis and muscle bleeding can be observed.42, 54 Recently, it was discovered 
that a low FV is bene$cial in these patients, and ameliorates the bleeding tendency, caused 
by low TFPI levels. When adding FV to the plasma of these patients, thrombin generation 
paradoxically reduced, caused by a TFPI-dependent anticoagulant e%ect.55 
!e clinical manifestation of FVII de$ciency is heterogeneous, and there is a weak 
correlation between the baseline activity level of FVII and the bleeding tendency.7 !e 
bleeding phenotype is highly variable, with hematomas and hemarthrosis, but also 
epistaxis, easy bruising and heavy menstrual bleeding in females. Intracranial bleeding 
has also been described, especially in children.47, 49 !e minimal factor activity level to 
remain free from bleeding is around 25%.7
Severe bleeding is common in patients with FX de$ciency with factor activity levels 
below 10%, and includes umbilical cord bleeding, intracranial bleeding, joint and 
muscle bleeding, mucosal bleeding and excessive bleeding a&er surgery or trauma.42, 56 
Heterozygous individuals can have a bleeding tendency as well.56
FXI de$ciency is the mildest of the RCDs, with bruising, epistaxis and menorrhagia 
as the most common manifestations.49 In some patients with severe FXI de$ciency, a 
combined FXI de$ciency and von Willebrand disease has been reported, leading to a 
more severe bleeding tendency.57 However, this has only been found in one report and no 
underlying (genetic) association has been found. !is could be a coincidental $nd, given 
the high prevalence of VWD in the normal population. Although patients with a severe 





as well. Bleeding occurs mainly in areas with high $brinolytic activity, i.e. mucosal 
bleeding and bleeding a&er trauma or invasive procedures.42, 49 !e $brinolytic bleeding 
pattern may be partly caused by low thrombin generation leading to lower activation 
of TAFI. In addition, a thrombin-independent mechanism leading to TAFI resistance 
appears to be present in these patients. !is is clinically relevant, as the ISTH BAT of 
patients with FXI de$ciency correlates with both thrombin-induced TAFI activation and 
TAFI resistance.58
Patients with severe FXIII de$ciency o&en present with umbilical cord bleeding. 
!e lifelong bleeding tendency is severe, and intracranial hemorrhage is common. In 
addition, patients may experience impaired wound healing, and women may experience 
spontaneous miscarriages due to detachment of the placenta.42, 47, 59, 60 Heterozygotes may 
present with a bleeding tendency as well.47
FV Amsterdam is caused by a gain-of-function mutation in the FV gene leading 
to an aberrant FV that has an increased a'nity for TFPI, prolonging the half-life and 
concentration of TFPI, resulting in severely reduced thrombin generation and a bleeding 
tendency.61 
Pathophysiological conditions of $brinolysis with an increased risk of bleeding are a 
decreased inhibition of $brinolysis due to de$ciency of one of the main inhibitors (α2-
AP and PAI-1) or an increase in plasminogen activation due to excess tPA or uPA. !e 
abundant presence of uPA can be caused by increased expression of uPA in platelets, 
known as Quebec platelet disorder.62 !e bleeding phenotype of patients with $brinolytic 
disorders is characterized by delayed bleeding a&er trauma, surgery and dental procedures. 
Bleeding in areas of high $brinolytic activity is also common, such as menorrhagia and 
epistaxis.62
Management of rare bleeding disorders
!e treatment of patients with RBDs is mainly based on expert opinion rather than 
evidence-based guidelines. Long-term prophylaxis is o&en not necessary. However, 
patients with severe de$ciencies of $brinogen, FII, FVII, FX or FXIII may require primary 
prophylaxis to avoid severe spontaneous bleeding.63 Many treatment products that are 
used are nonspeci$c, such as plasma, prothrombin complex concentrate and tranexamic 
acid (TA), as speci$c factor concentrates are not available for all RBDs. Mucosal bleeding 
is o&en managed with the use of TA. For more severe bleeding and prophylaxis for 
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invasive procedures, speci$c factor concentrates are available for $brinogen de$ciency, 
FVII de$ciency, FX de$ciency, FXI de$ciency and FXIII de$ciency. In FII de$ciency, 
prothrombin complex concentrate can be used, whereas for patients with FV de$ciency 
plasma is the only available treatment.64 !e treatment of disorders of $brinolysis consists 
of TA.62 At this moment, monitoring of treatment is another challenge, due to the lack of 
e%ective laboratory assays. 
AIM AND OUTLINE OF THE THESIS
In the Netherlands, there is no information about patients with RBDs, their clinical 
characteristics, natural course of the bleeding disorder and treatment. At an international 
level, the only information available comes from a limited European registry.7 !erefore, 
additional information on RBDs is necessary to gain insight in these disorders, which is 
the main goal of this thesis. !e currently available diagnostic assays are not adequate, 
and better diagnostics are required to eventually diagnose more patients with a speci$c 
bleeding disorder and realize personalized based treatment. !e main goal of this thesis 
is to improve the knowledge on clinical characteristics, diagnostics and management of 
patients with rare bleeding disorders. For this purpose, the Rare Bleeding Disorders in 
the Netherlands (RBiN) study was initiated, mapping the Dutch RBD patient population 
for the $rst time. !e use of a global hemostasis assay, directed functional laboratory tests 
and the combination with genome diagnostics can generate a more accurate overview 
of the hemostatic system in the individual patient. !e research described in this thesis 
is a step towards better knowledge of RBDs and novel diagnostic strategies that can be 
used in future research to improve the treatment of each patient on a personalized basis. 
Extension of these data at an international level is necessary to gain sustainable results.
Chapter 2 unravels the complex diagnostics of patients with disorders of $brinolysis. It 
gives an overview of their bleeding symptoms and treatment options for these disorders. In 
addition, recommendations for clinical practice are given. Chapter 3 describes the clinical 
implication of the simultaneous measurement of thrombin and plasmin generation in the 
assessment of patients with a plasminogen de$ciency or PAI-1 de$ciency. In Chapter 4, 
whole exome sequencing with a panel of genes known to be involved in hemostasis and 
thrombosis is described in patients with platelet abnormalities as well as in patients with 





chapter 5, the RBiN study is described. !is chapter focusses on the clinical characteristics 
of the study patients, the use of bleeding assessment tools and the validation of previously 
determined threshold factor activity levels to remain free from bleeding. In Chapter 6, 
data from the RBiN study are combined with data from the von Willebrand Disease in 
the Netherlands (WiN) study and the !rombocytopathy in the Netherlands (TiN) study. 
As all of these disorders are inherited autosomal, they occur in both men and women. 
Sex di%erences in these patient populations are described. Chapter 7 describes the 
complicated course of 4 pregnancies in two women with congenital a$brinogenemia, and 
gives new insight for the treatment of this rare bleeding disorder during pregnancy and 
labor. Finally, in Chapter 8, the main $ndings of this thesis are discussed. !is chapter 
also provides future perspectives and recommendations for clinical practice.
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Hyper$brinolytic bleeding can be caused by a de$ciency of one of the inhibitors of 
$brinolysis (plasminogen activator inhibitor type 1 (PAI-1) or α2-antiplasmin (α2-
AP), or an excess of one of the activators of $brinolysis: tissue type plasminogen 
activator or urokinase type plasminogen activator. !is review focuses on the clinical 
implications of these disorders. !e bleeding phenotype of $brinolytic disorders 
is characterized by delayed bleeding a&er trauma, surgery and dental procedures. 
Bleeding in areas of high $brinolytic activity is also common, such as menorrhagia 
and epistaxis. Patients with α2-AP de$ciency present with the most severe bleeding 
episodes. Recently, it was discovered that hyper$brinolytic disorders are associated 
with a high rate of obstetric complications such as miscarriage and preterm birth, 
especially in PAI-1 de$cient patients. Hyper$brinolytic disorders are probably 
underdiagnosed due to lack of knowledge and lack of accurate diagnostic tests. A 
substantial part of the large group of patients diagnosed as ‘bleeding of unknown 
origin’ could actually have a hyper$brinolytic disorder. In case of a high index of 
suspicion, i.e. due to a positive family history, recurrent bleeding or uncommon 
type of bleeding such as an intramedullary hematoma, further testing should not be 
withheld because of normal results of standard hemostatic screening assays. Timely 
diagnosis is important because these disorders can generally be treated well with 
anti$brinolytic agents.
Keywords: alpha2-antiplasmin, $brinolysis, hemorrhagic disorders, obstetric labor 
complications, plasminogen activator inhibitor 1
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Primary hemostasis, secondary hemostasis and the $brinolytic system are the three main 
components of blood coagulation. !ese complex processes are integrated to serve a major 
common goal to stop unwanted bleeding and to prevent unnecessary clot formation. !is 
review focuses on the $brinolytic process, particularly on the hemorrhagic diathesis 
which occurs when the $brinolytic pathway is accelerated. In general, $brinolysis is the 
process of $brin clot solubilization. !is process is accurately regulated by activators, 
inhibitors and cofactors to maintain a delicate balance. An overview of this balance is 
illustrated in $gure 1. !e key component of $brinolysis is plasmin, a serine protease 
that degrades $brin. !e zymogen plasminogen is the pro-enzyme for plasmin and can 
be converted by tissue type plasminogen activator (tPA) or urokinase type plasminogen 
activator (uPA). tPA is synthesized and secreted primarily by endothelial cells, and its 
release is regulated by multiple stimuli including thrombin.1-3 In the absence of $brin, 
tPA is a very weak activator of plasminogen, however its catalytic e'ciency is greatly 
enhanced in the presence of $brin. In this situation $brin stimulates its own degradation.3 
uPA can e%ectively activate plasminogen both in presence and absence of $brin, but has 
much lower a'nity for $brin as compared to tPA.1,3 Once formed, plasmin cleaves $brin, 
generating $brin degradation products (FDP).1 Inhibitors, on the other hand, are present 
to balance the $brinolytic homeostasis. !rombin activatable $brinolysis inhibitor 
(TAFI) attenuates plasmin generation a&er being activated by thrombin, plasmin or 
thrombomodulin bound thrombin. TAFI removes the carboxy-terminal lysine residues 
from $brin, resulting in a decreased plasmin generation and stabilization of $brin 
containing thrombi.1,3 Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of 
tPA and uPA. Inhibitors of plasmin are α2-antiplasmin (α2-AP) and α2-macroglobulin 
(α2-M). !e main physiological plasmin inhibitor is α2-AP. In the situation when 
plasmin is formed in excess in respect to α2-AP, plasmin is neutralized by α2-M.2 Figure 
2 illustrates the interplay between activators and inhibitors of $brinolysis in vivo upon 
formation of a $brin clot a&er damage of the endothelium. Pathophysiological conditions 
of $brinolysis with an increased risk of bleeding disorders are a decreased inhibition of 
$brinolysis due to de$ciency of one of the main inhibitors (α2-AP and PAI-1) or an 
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increase in plasminogen activation due to excess tPA or uPA. !e abundant presence of 













Red arrows indicate inhibition, green arrows indicate stimulation. PAI-1, plasminogen activator inhibitor 
type 1; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; α2-AP, α2-
antiplasmin; FDP, "brin degradation products; TAFI, thrombin-activatable "brinolysis inhibitor
De$ciency of TAFI would theoretically lead to hyper$brinolysis due to decreased 
inhibition of the $brinolytic pathway, but has never been described in literature. TAFI-
de$cient mice did not show a bleeding tendency.4 On the contrary, high levels of TAFI have 
been described in patients with a bleeding tendency.5 However, since TAFI is activated by 
thrombin, coagulation disorders leading to decreased formation of thrombin can cause 
decreased activation of TAFI thus leading to hyper$brinolysis. It is suggested that this 
contributes to the bleeding phenotype in patients with a coagulation factor de$ciency as 
in hemophilia or in factor XI de$ciency.6,7 
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tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; PAI-1, plasminogen 
activator inhibitor type 1; α2-AP, α2-antiplasmin; TAFI, thrombin-activatable "brinolysis inhibitor
Diagnosis of a hyper$brinolytic bleeding tendency is challenged by the lack of currently 
available and validated laboratory tests. A di'culty in the development of a $brinolysis 
screening assay is the low baseline $brinolytic capacity due to the presence of $brinolysis 
inhibitors in plasma. !is can be partially resolved by acidi$cation of the plasma shi&ing 
the plasma to a more $brinolytic nature (less PAI-1 dependent).8 One of the most frequently 
used laboratory screening assays is the euglobulin clot lysis time (ECLT), recording the 
time till visual lysis of the euglobulin fraction in a tube. It is usually shortened in cases of 
increased $brinolysis. However, due to a lack of global validation, a normal euglobulin 
clot lysis time does not exclude hyper$brinolysis. !romboelastography (TEG) and 
rotation thromboelastometry (ROTEM) assess viscoelastic changes a&er re-calci$cation 
and addition of coagulation activators to citrated whole blood. !ey are mainly used as 
point-of-care coagulation tests in massive blood loss at the emergency department or in 
the operating room. However, their reproducibility is poor and they require specialized 
equipment.9 Plasma turbidity assays measure changes in optical density a&er the initiation 
of coagulation. !ey are sensitive for plasma levels of all $brinolytic proteins except for 
tPA, as tPA is added to induce lysis.10 Prolonged plasma clot lysis times measured by this 
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method are associated with hypo$brinolysis and have been shown to increase the risk 
of venous and arterial thrombosis. Shortened clot lysis times, on the other hand, may 
re/ect various hemorrhagic states induced by hyper$brinolysis.9,10 !e global $brinolytic 
capacity in whole blood is another assay of $brinolysis. An advantage of this method 
is that no $brinolysis activators are added. !is assay is sensitive for abnormalities in 
t-PA activity, PAI-1 activity, $brinogen and TAFI activity.9,11 Global assays may be helpful 
in the future, however they are not available for clinical use at the moment. TAFI, α2-
AP, PAI-1, tPA and uPA can all be measured in blood using con$rmation assays and 
allow quanti$cation of antigen and activity levels, but these assays are not available in 
every laboratory and there is no consensus about the cut o% level to de$ne de$ciencies. 
Treatment of hemorrhagic diatheses due to hyper$brinolysis occurs with anti$brinolytic 
agents such as tranexamic acid or ε-aminocaproic acid. !ese are lysine analogues that 
block the lysine-binding sites of plasminogen, inhibiting binding of plasminogen to 
$brin leading to decreased plasminogen activation.12 In this review, we will discuss the 
main disorders of $brinolysis causing a bleeding tendency and their associated clinical 
implications, laboratory diagnosis and treatment. 
METHODOLOGY
A systematic search was undertaken in PubMed and EMBASE for relevant articles from 
the past until August 22nd 2017. Except for English articles some other languages (e.g. 
Dutch, French and German) were also included. !e used search terms are shown in the 
supporting information. Articles describing at least one clinical symptom of at least one 
patient with a hemorrhagic disorder of $brinolysis were included in the analysis calculating 
the prevalences of clinical symptoms. Two authors (J.S. and M.N.) independently 
screened articles for relevance. Discrepancies were resolved through consensus with a 
third author (S.S.). References of identi$ed articles were crosschecked for other relevant 
articles. !e search strategy identi$ed 1397 articles. A&er removal of duplicates, 1101 
articles were screened for eligibility based on title and abstract. !e study /ow diagram is 
shown in $gure 3. !e kappa agreement for study selection was 0.98, indicating excellent 
agreement between the investigators. A total of 77 articles were identi$ed accounting 
for a total of 181 relevant cases with information on the clinical symptoms. Of these 
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cases, 14 patients were homozygous for α2-antiplasmin de$ciency and 104 heterozygous 
carriers. !irty-six patients had a PAI-1 de$ciency, 23 Quebec platelet disorder and 4 tPA 
excess. Patients with a primary TAFI de$ciency were not found. Prevalences of clinical 
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α2-antiplasmin (α2-AP) is the main physiological inhibitor of plasmin.2 !e de$ciency 
can lead to the abundant presence of plasmin and therefore induce hyper$brinolysis 
and bleeding. α2-AP is a member of the serpin family of enzyme inhibitors, and it is 
synthesized in the liver.13 !e gene for α2-AP is located on chromosome 17.14 !e $rst 
case of α2-AP de$ciency was published in 1978 in a patient with posttraumatic as well as 
spontaneous bleeding. !e de$ciency was then named Miyasoto disease a&er the patient’s 
surname. By studying the family, it was noted that this disorder was most likely inherited 
autosomal recessive.15 !e prevalence of α2-AP de$ciency is unknown, but it is very rare. 
Clinical manifestations 
An overview of bleeding symptoms in patients with a homozygous α2-AP de$ciency can 
be found in $gure 4.15-30 !ese numbers were extracted from 14 cases. A homozygous 
de$ciency usually leads to serious bleeding symptoms, mostly post-trauma and post-
surgery or a&er dental extractions. A few of the included patients in $gure 4A did not have 
a hemostatic challenge, therefore the prevalence of 43% post-surgery bleeding is likely 
an underestimate, as well as the percentages for post-trauma and post dental extraction 
bleeding. Only 3 adult females have been described with a homozygous α2-AP de$ciency. 
!erefore, the prevalence of menorrhagia could not be calculated. However, two of 
these three women experienced menorrhagia so it appears to be a relevant issue.17,24,29 
Interestingly, multiple patients have been described with intramedullary hematomas, an 
uncommon type of bleeding.21,22 
A total of 104 individuals with a heterozygous α2-AP de$ciency were found. !ese 
individuals had either bleeding symptoms or are family members of a known homozygous 
patient. 17,19,20,24,26-29,31-45 Sixty-six of 104 heterozygous individuals were asymptomatic. 
!e number of symptomatic heterozygous individuals is likely an overestimate caused 
by publication bias. Interestingly, severe bleeding tendencies such as gastro-intestinal 
bleeding and umbilical cord bleeding have also been described in individuals with a 
heterozygous α2-AP de$ciency.31,38 !e most common bleeding symptoms in individuals 
with a heterozygous α2-AP de$ciency were post-surgery and post-traumatic. Although 
the occurrence of menorrhagia and postpartum bleeding could not be calculated, since 
CHAPTER 2
Hemorrhagic disorders of "brinolysis: a clinical review
39
2
many articles do not describe sexes, these symptoms appear to occur quite o&en as 
well.34,36,38,40,42 All of the heterozygous individuals had α2-AP levels of around 50%. A 
study in patients with acquired α2-AP de$ciency showed that clinical hyper$brinolysis 
only occurred at plasma levels of α2-AP below 60%.46. It is unknown whether women 
with a heterozygous α2-AP de$ciency experience high rates of obstetric complications, 
as almost no adult females and pregnancies have been described. !ere are some reports 
with relevant obstetric bleeding complications in both a homozygous and 2 heterozygous 
women, leading to miscarriage and preterm delivery.29,34,38 In summary, homozygous 
α2-AP de$ciency is associated with a severe bleeding tendency and possibly a high rate 
of female-speci$c bleeding problems. Bleeding manifestations in individuals with a 
heterozygous α2-AP de$ciency are less o&en described in literature, however they do 
occur. 
Diagnosis & treatment 
Ignorance about α2-AP de$ciency might lead to underestimation of the diagnosis. !is 
can be aggravated by the lack of abnormalities in screening assays. !e euglobulin clot 
lysis time is usually shortened but can be normal in both carriers and homozygous 
patients.15,17-20,23,25,26,31,33,37,38. A reason for this low sensitivity for α2-AP de$ciency can be 
the lack of enrichment of α2-AP in the euglobulin fraction a&er acidi$cation of plasma.47 
When a de$ciency is suspected based on a shortened clot lysis time and/or suspicious 
history, directed α2-AP con$rmation assays should be performed. A de$ciency can be 
either quantitative (type I), causing a coincidental decrease in α2-AP activity and antigen, 
or qualitative (type II) causing low activity levels with normal or only slightly decreased 
antigen concentrations.12 !e treatment of bleeding episodes consists of anti$brinolytic 
agents. Anti$brinolytic agents can also be used as prophylaxis before invasive 
procedures.12,13 !e use of fresh frozen plasma (FFP) has also been described, however 
the variable activity of α2-AP in FFP and the possible adverse event of introducing 
dilutional coagulopathy due to volume overload make this a less attractive option.12,13,35 
Currently, in many countries FFP is being replaced by omniplasma, however omniplasma 
has lower α2-AP levels and shorter ROTEM lysis times with a reduction of more than 
50% when compared to FFP. !erefore, the use of omniplasma is not recommended 
in the treatment of α2-AP de$ciency.48 Desmopressin acetate may induce secretion of 
plasminogen activator and should therefore be avoided.35




Prevalence of bleeding symptoms in patients with (A) homozygous α2-antiplasmin de"ciency, 
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Symptoms other than post-traumatic and post-surgery were only scored if occurring spontaneously. 
PAI-1, plasminogen activator inhibitor type 1. *Of women >12 years of age. **Of patients who had 
dental extractions. ***Of patients who had a serious accident. ****Of patients who experienced deep 
cut(s).15-30,52-55,57-75,82
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Plasminogen activator inhibitor type 1 de"ciency
Background 
Plasminogen activator inhibitor type 1 (PAI-1) is the principal inhibitor of tPA and uPA.2 
Like α2-AP, PAI-1 is a member of the serpin family.2 A variety of cells synthesize PAI-1, 
including hepatocytes, adipocytes and endothelial cells.49 !e PAI-1 gene is located on 
chromosome 7, and its expression can be induced by several factors such as insulin.50 
Although the principal function of PAI-1 is inhibition of $brinolysis, it has other 
functions in in/ammation as an acute phase protein. In contrast to low PAI-1 levels, high 
PAI-1 levels are associated with atherosclerosis and coronary artery disease, metabolic 
syndrome, $brosis and poor prognoses in several cancer types.51 When evaluating a 
patient for PAI-1 de$ciency, both antigen and activity levels should be analyzed, as the 
de$ciency can be both qualitative or quantitative. !e $rst case of a bleeding disorder due 
to a qualitative PAI-1 de$ciency was described by Schleef et al. in 1989, followed by the 
$rst reported quantitative de$ciency in 1991.52,53 It is an autosomal recessive disorder.54 
!e prevalence of PAI-1 de$ciency is not known as it has only been described in case 
reports. However, two studies show that the incidence of PAI-1 activity <1.0 U mL-1 and 
<2.0 U mL-1 in healthy populations was as high as 10-13% and 21%, respectively.55,56 
!ese data suggest that many individuals with low PAI-1 activity are asymptomatic. !e 
prevalence of a bleeding disorder caused by PAI-1 de$ciency is low. However, accurate 
diagnosis is hampered by a lack of accuracy of the currently available activity assays in 
the lowest range.50
Clinical manifestations 
!e bleeding tendency of patients with a PAI-1 de$ciency is shown in 
$gure 4B.30,52-55,57-75 A total of 36 patients with a PAI-1 de$ciency have been described, 
including both qualitative and quantitative de$ciencies. Most patients experienced post-
trauma and post-surgery bleeding. Two cases could not be included in the analysis of 
this review, because aside from their PAI-1 de$ciency, they also had another disorder 
that could explain their speci$c bleeding symptoms, and both of the articles did not 
report any other symptom.76,77 When only taking into account the 17 women ≥12 years 
of age that have been described, 9 of them experienced menorrhagia making this a 
common symptom. Obstetric complications appear to occur o&en in females with a 
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PAI-1 de$ciency. !e reason for this is not entirely clear, although animal studies have 
suggested that PAI-1 and the accompanying proteolytic process play a role in degradation 
of the follicular wall during ovulation, as well as in fertilization, embryo implantation, 
embryogenesis and angiogenesis .54,78 A total of 17 described pregnancies and outcomes 
were found. As shown in $gure 5 there is a high rate of miscarriage and preterm birth with 
only 24% of described pregnancies reaching term. Vaginal bleeding during pregnancy 
was common occurring in 54% as well as postpartum bleeding with a prevalence of 
27%. 54,65,67,69,70,73 !ese numbers might be an overestimation due to publication bias. 
However, in case of missing information about bleeding complications, pregnancies were 
considered as being normal to compensate for the possible overestimation bias. Family 
investigation revealed only symptoms in a minority of the heterozygous family members. 
58,59,63,66 However, Del Rosario et al described a heterozygous individual with severe 
bleeding symptoms including spontaneous hemarthrosis.79 In summary, homozygous 
PAI-1 de$ciency is associated with major bleeding problems and obstetric complications, 
whereas heterozygous PAI-1 de$ciency is usually asymptomatic. 
FIGURE 5. 
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Diagnosis & treatment 
!e actual diagnosis of a PAI-1 de$ciency is o&en delayed due to normal screening 
tests and impaired recognition of the disorder. !e currently available assays for PAI-1 
activity are not discriminative in the lowest range, as the normal limit of these assays 
ranges to zero.50 PAI-1 antigen levels are even more di'cult to interpret as these assays 
do not discriminate between complexed PAI-1 and free PAI-1. Furthermore, the diurnal 
variation of PAI-1, with highest levels in the early morning and lowest in the a&ernoon, can 
make accurate diagnosis more complicated.80 !e diagnosis of PAI-1 de$ciency is further 
complicated by the fact that the euglobulin clot lysis time is not always shortened despite 
the fact that PAI-1 is enriched in the euglobulin fraction.52,53,60,61,63,64,66,70,73 In addition, tPA 
activity can be high, however a normal value does not exclude the diagnosis.52,58,61,63,71,72 
Treatment of PAI-1 de$ciency consists of anti$brinolytics. !ey can be used as treatment 
for an acute bleeding, as a preventive measure before an invasive procedure and for 
limiting the amount of menstrual blood loss or epistaxis.50,59,70
Urokinase type plasminogen activator excess
Background 
!e Quebec platelet disorder (QPD) is the only described disorder with hyper$brinolysis 
caused by excess of urokinase type plasminogen activator (uPA). It is caused by a 
tandem duplication of a 78-kb genomic segment that includes the PLAU gene leading to 
overexpression of uPA. It is an autosomal dominant disorder with a high penetrance.81 
Most known cases have been traced to a single family from French ancestry in Quebec, 
Canada.82 !e hyper$brinolysis is caused by increased expression and storage of uPA in 
platelets.83 !e genetic defect causes increased transcription of the PLAU allele during 
megakaryocyte di%erentiation located on chromosome 10.84 !e $rst case was described 
in 1984, although at the time, bleeding was thought to be caused by a qualitative platelet 
factor V de$ciency. !erefore the disorder was $rst called factor V Quebec.85 !e 
prevalence of the disorder worldwide is unknown, however in Canada it is estimated at 
1:655.000 and in Quebec 1:220.000.86 




!e bleeding history of the QPD family has been described in detail by McKay et al.82 
Twenty-three patients with the disorder were described (see $gure 4C for their bleeding 
symptoms). As in the other $brinolytic disorders, bleeding a&er dental extractions, 
surgery and trauma were frequently reported. A total of 9 pregnancies were described, 
none of which ended in miscarriage. None of the patients reported antenatal bleeding, 
however 2 women needed transfusion a&er giving birth. As in PAI-1 de$ciency, some 
patients reported impaired wound healing, which was associated with lower platelet 
counts. 82 One separate case of QPD from Pakistan was not included in the review, because 
the diagnosis was only based on reduced aggregation with epinephrine. Although o&en 
seen in QPD, this is not considered speci$c for this disorder.87
Diagnosis & treatment 
As this disorder is autosomal dominant with a high penetrance, the family history will 
be positive most of the time and raise a suspicion in case of bleeding. !e disorder is 
characterized by increased platelet content of uPA, which is released upon platelet 
activation. In a resting condition, uPA in plasma is normal or only moderately increased.81 
!e disorder can be accompanied by an unexplained mild thrombocytopenia.85,88 
Screening assays for coagulation are usually normal, although factor V can be mildly 
de$cient. Platelet factor V is reduced.85 Functional platelet tests o&en reveal a characteristic 
pattern of absent aggregation with epinephrine and a reduced platelet aggregation with 
ADP and collagen probably due to the overexpression of uPA and subsequent activation 
of plasminogen in platelets. Plasmin then can degrade von Willebrand factor, factor 
V and $brinogen.81,88 Whole-blood clot lysis time is normal, and urinary uPA is not 
increased.89,90 As the genetic defect has been unraveled and other diagnostics are variable 
and complicated, it is now recommended to perform a PCR assay for the QPD mutation 
when diagnosis is suspected.91 Patients with bleeding complications should be treated 
with anti$brinolytic therapy. !e administration of platelets does not reduce bleeding.88,90 
Tissue type plasminogen activator excess
As previously mentioned, patients with a congenital PAI-1 de$ciency may have high 
levels of tPA activity with most of the time normal tPA antigen levels.52,58,61,63,71,72 A total 
of 4 cases have been described with high levels of plasminogen activator and a bleeding 
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tendency92-94. !ese patients had symptoms of excessive bleeding a&er trauma and surgery, 
and in some cases also spontaneous hematomas or easy bruising. Family members of a 
patient with an excess of tPA had high tPA levels and shortened euglobulin clot lysis time, 
without any bleeding symptoms.93 One of the patients underwent liver transplantation for 
cirrhosis and was thereby cured from his bleeding disorder.94 In addition, an abstract by 
Hampton et al. described a family of 12 members who showed elevated plasma activator 
levels, of which 9 had a history of excessive bleeding.95 As few of the above-mentioned 
cases of tPA excess were diagnosed before the discovery of PAI-1 de$ciency in 1989, 
these cases can be misdiagnosed. However, 2 cases had normal PAI-1 activity and antigen 
level. 93,94 Given the sparse number of cases, it is currently unclear whether this can be 
considered a separate entity within the bleeding disorders. For diagnosis we recommend 
the use of an activity assay rather than an antigen assay, as currently available antigen 
assays do not only measure the free form but also complexes between tPA and PAI-1.
Acquired disorders of "brinolysis
Acquired disorders of $brinolysis are an important cause of bleeding and mortality. In 
acute promyelocytic leukemia (APL), a de$ciency of α2-AP, TAFI or excess of uPA can 
contribute to the bleeding tendency.46,96,97 Fibrinolysis can be further increased in these 
patients due to high levels of annexin A2 expression on APL cells, leading to increased 
production of plasmin.98 In cirrhosis, high levels of tPA as well as de$ciency of α2-
AP and TAFI have been described.99 However, this may be rebalanced by a decline in 
anti$brinolytic factors, and typical hyper$brinolytic bleeding in cirrhotic patients is 
rare.100 In addition, acquired α2-AP de$ciency has been described in a variety of diseases 
including amyloidosis, gastric cancer, prostatic cancer, adenocarcinomas and nephrotic 
syndrome (due to renal loss). 46,99,101-103 Trauma is also associated with high $brinolytic 
activity, and a higher $brinolytic activity correlates with a poor clinical outcome in 
these patients.104 In addition, there are also iatrogenic causes of hyper$brinolysis. 
Cardiopulmonary bypass provokes a state of hyper$brinolysis caused by rapid thrombin 
generation and high circulating levels of epinephrine, bradykinin and vasopressin. 105 
!rombolysis, increasingly used for ischemic stroke and other indications, is also 
an important cause of iatrogenic hyper$brinolysis. Risk factors for postthrombolytic 
bleeding include advanced age, female gender and low body weight. For patients with a 
high risk of major bleeding, weight-adjusted doses and catheter directed therapy should 
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be considered to reduce the risk.106 Postthrombolytic bleeding can be converted using 
reversal agents, especially in the case of intracranial bleeding <24h a&er thrombolysis 
or ongoing coagulopathy demonstrated by hypo$brinogenemia. Possible reversal 
agents include cryoprecipitate, recombinant factor VIIa, FFP or anti$brinolytic agents. 
Other options may be considered in speci$c patient groups, e.g. prothrombin complex 
concentrate in patients on vitamin K antagonists.107 !eoretically, omniplasma and 
$brinogen concentrate are options for conversion as well, however they have not been 
described in literature for this indication.
Fibrinolysis in bleeding of unknown cause
!ere is a substantial number of patients with a bleeding tendency and positive family 
history for bleeding complications without a de$nite diagnosis a&er performing all 
available screening tests and conformational tests. Conceivably, there will be a subset 
of patients with a hyper$brinolytic disorder amongst them. In addition, several studies 
have demonstrated an altered $brinolytic balance in patients with a bleeding tendency 
of unknown cause. In a study of 270 patients with bleeding of unknown cause, patients 
had higher tPA activity levels and lower levels of tPA-PAI-1 complexes and lower PAI-1 
levels, indicating a possible underlying hyper$brinolytic disorder.5 In a cohort of patients 
undergoing a cardiac surgery, postoperative blood loss was associated with lower pre-
operative levels of PAI-1 and lower post-operative tPA-PAI-1 levels.108 On the other hand, 
a study evaluating $brinolysis in patients with a mild-to-moderate bleeding tendency 
of unknown cause showed no di%erences in PAI-1 levels between patients and healthy 
controls. In addition, low PAI-1 activity levels are common in a normal population and 
there is no signi$cant di%erence between PAI-1 activity levels in patients with a bleeding 
tendency compared to blood donors and healthy controls.5,56 
CONCLUSIONS
Although the prevalence of hyper$brinolytic disorders as a cause of bleeding described in 
literature is quite low, the bleeding tendency is usually characterized by a pattern of delayed 
bleeding upon trauma or surgery and mucocutaneous bleeding such as menorrhagia 
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and epistaxis. However, a clinical di%erentiation with other bleeding disorders such as 
platelet disorders or von Willebrand disease can be di'cult, as they frequently present 
with mucocutaneous bleeding as well. Bleeding complications caused by $brinolytic 
disorders can be very severe and can lead to increased morbidity and mortality if not 
treated adequately with anti$brinolytic therapy. 
In general, the group of $brinolytic disorders can be divided into patients with 
excess of stimulators of $brinolysis and patients with a de$ciency of inhibitors. !e most 
severe clinical phenotype is caused by α2-AP de$ciency. Noteworthy, PAI-1 de$ciency 
is accompanied by obstetric complications by a yet unexplained underlying mechanism. 
Concerning the other $brinolytic disorders, the occurrence of obstetric complications is 
yet unknown and therefore an interesting subject for future research.
Due to the lack of recognition of $brinolytic disorders and the di'culties in assessing 
the right diagnosis, the prevalence of these disorders is probably higher than described 
thus far. An accurate diagnosis is severely hampered by the absence of a sensitive and 
validated test of $brinolysis. !is accounts for the PAI-1 antigen and activity level, but 
also for the euglobulin clot lysis time. Normal results of these tests do not rule out a 
hyper$brinolytic disorder. Furthermore, these current $brinolytic assays can only be 
undertaken in specialized laboratories. Global assays may overcome this problem as, 
in general, these assays are more sensitive and able to measure several pathways in just 
one test. Examples are assays that measure plasmin generation or plasma-based turbidity 
assays.109,110 A disadvantage is that these assays are not widely available. Moreover, next 
generation sequencing techniques of genes involving the whole spectrum of coagulation 
may attribute to the unraveling of suspected $brinolytic disorders. 
Fibrinolytic assays in patients with bleeding of unknown cause show inconclusive 
results. Overall, an imbalance in the $brinolytic system could be the explanation of a 
bleeding tendency more o&en than currently anticipated, and more research in this 
$eld would be bene$cial. Finally, without a proper and accurate diagnosis, bleeding 
complications cannot be treated with targeted therapy, leading to unnecessary use of 
inappropriate blood products and expensive factor concentrates. We suggest to develop 
or validate new diagnostic tools to better monitor $brinolysis in order to facilitate the 
use of adequate therapy upon bleeding due to malfunctioning of the $brinolytic cascade.
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Recommendations for clinical practice:
• Disorders of $brinolysis should not be routinely tested in patients with a 
bleeding tendency, since they are rare and laboratory diagnostics unreliable
• Fibrinolysis assays should be undertaken in a specialized laboratory when 
there is a high index of suspicion, raised by:
 0 recurrent abnormal bleeding, mainly delayed bleeding post trauma/
surgery and mucocutaneous bleeding
 0 positive family history of an established hyper$brinolytic disorder
 0 co-occurrence with reproductive failure
 0 unusual bleeding sites, e.g. intramedullary hematomas, umbilical cord 
bleeding
• In the future, diagnostics may be improved by the implementation of 
thrombin and plasmin generation assays and genetic tests using next 
generation sequencing
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Introduction: De$ciencies of plasminogen and plasminogen activator inhibitor 
type 1 (PAI-1) are rare disorders of $brinolysis. Current laboratory assays for 
analysis of activity of plasminogen and PAI-1 do not provide an accurate correlation 
with clinical phenotype. 
Methods: !e Nijmegen Hemostasis Assay (NHA) was used to simultaneously 
measure thrombin and plasmin generation in $ve patients with plasminogen 
de$ciency (PLGD) and ten patients with complete PAI-1 de$ciency. Parameters 
analysed included: lag-time ratio, thrombin peak time ratio, thrombin peak height, 
thrombin potential (AUC), $brin lysis time, plasmin peak height and plasmin 
potential. Parameters were expressed as a percentage compared to a reference value 
of $&y-three healthy normal controls. 
Results: Patients with PLGD demonstrated a short lag time and thrombin peak 
time, with normal thrombin peak height but an increased AUC. Plasmin generation 
was able to be detected in only one (23% plasminogen activity) of the $ve PLGD 
patients.  All ten PAI-1 de$cient patients demonstrated a short lag and thrombin 
peak time, low thrombin peak height with normal AUC. Plasmin generation 
revealed an increased plasmin peak and plasmin potential; interestingly, there was 
a large variation between individual patients despite all patients having the same 
homozygous defect.
Conclusion: Patients with either PLGD or PAI-1 de$ciency show distinct 
abnormalities in plasmin and thrombin generation in the NHA. !e di%erences 
observed in the propagation phase of thrombin generation may be explained by 
plasmin generation. !ese results suggest that disorders of $brinolysis also in/uence 
coagulation and a global assay measuring both activities may better correlate with 
clinical outcome.
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Plasminogen and plasminogen activator inhibitor type 1 (PAI-1) are proteins of the 
$brinolytic pathway.1 Plasminogen is a zymogen activated by tissue-type plasminogen 
activator enzymes to produce plasmin, the central enzyme in $brinolytic pathway that 
dissolves $brin networks. PLGD results in the development of woody pseudomembranes 
on mucosal surfaces. Although ligneous conjunctivitis is a characteristic manifestation 
of PLGD, involvement of the gingiva, oral cavity, tracheobronchial tree, middle ear, 
gastrointestinal and urogenital tracts, and central nervous system are described.2-7 
there are two sub-types of PLGD: type 1 is a quantitative de$ciency and type 2 a 
qualitative de$ciency. Patients with type 1 PLGD clinically present with development 
of pseudomembranes.2 Despite the central role of plasmin in $brinolysis, PLGD is not 
primarily associated with thrombotic disease.8-10 
PAI-1 downregulates $brinolysis through inhibition of tissue-type plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA). Homozygous PAI-1 
de$ciency is associated with increased $brinolysis resulting in a moderate clinical 
bleeding phenotype with haemorrhage associated with injury, surgery or invasive 
procedures especially in areas with increased $brinolysis. Reported clinical manifestations 
include abnormal epistaxis, oral bleeding with injury or dental extractions, hematoma 
formation, maenorrhagia, haemorrhagic ovarian cysts, haemorrhage in pregnancy, 
intracranial bleeding with injury, etc. 11-15 An association with delayed wound healing has 
also been described.15 Heterozygous PAI-1 de$ciency is not associated with abnormal 
bleeding, even a&er haemostatic challenge.12 PAI-1 levels exhibit a diurnal variation and 
are therefore usually measured in the morning in a fasting state. !e diagnosis of PAI-1 
de$ciency is challenging as current PAI-1 activity assays include “zero” within the normal 
range and therefore do not discriminate between normal and de$cient individuals; a 
PAI-1 antigenic assay is available. !e diagnosis of a dysproteinemic PAI-1 de$ciency 
(abnormal PAI-1 activity with detectable PAI-1 antigen) cannot currently be reliably 
diagnosed due to limitations in the PAI-1 activity assay. PAI-1 de$ciency is only reliably 
diagnosed in the absence of a circulating antigen.16 
For both PLGD and PAI-1 de$ciencies, the ability to correlate the results of 
commonly available activity and antigenic assays to clinical symptoms is limited. !e 
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NHA is a global haemostatic assay that simultaneously measures thrombin and plasmin 
generation in a single well.17 !e impetus to develop the NHA was based upon the need 
to evaluate overall haemostatic potential in patients utilizing }rinolytic therapy (e.g. 
t-PA, urokinase) where concomitant administration of anticoagulants is required.18 !e 
simultaneous measurement of thrombin and plasmin generation in one assay has limited 
to no reported cases of the rare $brinolytic states of PLGD and complete PAI-1 de$ciency 
respectively. 19,20 
!e NHA was used to evaluate simultaneous thrombin and plasmin generation in $ve 
patients with PLGD and ten patients with complete PAI-1 de$ciency who carry the same 
homozygous frame-shi& mutation. In addition, the results of the NHA were evaluated for 
correlation to phenotypic expression of these two rare $brinolytic de$ciencies. Overall, 
it was hypothesized that plasmin generation would be decreased or absent in PLGD 
and enhanced in PAI-1 de$ciency, and that thrombin generation would be abnormal in 
individuals with increased plasmin generation. 
MATERIALS AND METHODS
Patients
Patients were enrolled at the Indiana Hemophilia and !rombosis Center (IN, USA). 
!e cohorts evaluated included $ve patients with PLGD and ten patients with PAI-
1 de$ciency. Both groups are described in detail in the section ‘Results – clinical and 
laboratory phenotype’. 
IRB approval and consent were obtained according to GCP. !e following data 
variables were collected on each subject: genotype, clinical phenotype; in the PLGD 
patients, the plasminogen activity and antigen levels were collected from medical 
records. Blood was collected with the subject at rest in the seated position by atraumatic 
peripheral venipuncture technique with minimal applied stasis into BD Vacutainer 3.2% 
bu%ered sodium citrate siliconized blood collection tubes (Becton-Dickinson, Franklin 
Lakes, NJ), a&er collection of the initial 1 mL of blood into a discard tube. Specimens 
were centrifuged for 15 minutes at 4 °C and 2500×g, and the plasma supernatant was 
then centrifuged for an additional 15 minutes at the same settings to remove residual 
platelets. Plasma found to be icteric or lipemic was excluded from analysis in assays that 
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measure optical density or /uorescence intensity. Platelet-poor plasma (PPP) samples 
were aliquoted into 1.5 mL copolymer polypropylene long-term freezer storage tubes 
with O-ring screw caps (USA Scienti$c, Ocala, FL) and stored at -70 °C until shipment 
or analysis. Plasma samples for the NHA were sent on dry ice to the Radboud University 
Medical Center, Nijmegen, the Netherlands. Plasma samples were defrosted only 
once. Simultaneous thrombin and plasmin generation curves were performed in the 
Radboudumc, Nijmegen !e Netherlands.
Plasminogen and PAI-1 assays
A documented rare frameshi& mutation (c.699_700dupTA) in the SERPINE1 gene results 
in complete de$ciency of PAI-1 activity and antigen.21 !e ten enrolled PAI-1 de$cient 
patients are documented to be homozygous for this mutation. !is mutation results in 
undetectable PAI-1 antigen and activity levels.12 !erefore PAI-1 activity/antigen levels 
were not assayed. Plasminogen activity levels were measured by chromogenic assay 
(HemosIL Plasminogen), and plasminogen antigen levels by a nephelometric assay.
FIGURE 1. 
The Nijmegen Hemostasis Assay.
(1) lag-time, the time at which thrombin formation is initiated; (2) thrombin peak time, that is the time when 
thrombin production reaches maximal velocity; (3) thrombin peak height, the maximal velocity of thrombin 
generation; (4) the area under the curve (AUC, relates to the thrombin potential); 5) plasmin peak height, 
the maximal velocity of plasmin production and; (6) "brin lysis time (FLT), the time between the initiation of 
thrombin generation and the time plasmin generation reaches maximal velocity; (7) plasmin potential, area 
under the curve that represents the total amount of plasmin generated




!e Nijmegen Hemostasis Assay (NHA) evaluates haemostasis through simultaneous 
measurement of thrombin generation (TG) and plasmin generation (PG) as a function 
of coagulation and $brinolysis respectively. !rombin generation is initiated with a low 
tissue factor concentration, and plasmin generation initiated by t-PA which is dependent 
on $brin formation. In normal pooled plasma, the delay in plasmin generation is 
dependent on !rombin-Activatable Fibrinolysis Activator. A complete description 
of the assay and its validation procedure has been published previously.17 !e NHA is 
characterized by seven parameters as shown in $gure 1. To perform the NHA, 80 µL of 
patient plasma was mixed with 2 µL crude cephalin (Roche, Basel, Switzerland), 2 µL 
tissue factor (Innovin®, Healthcare Diagnostics, Marburg, Germany, $nal concentration 
corresponding to approximately 0.3 pM), 4 µL /uorescent thrombin speci$c substrate 
Bz-β-Ala-Gly-Arg-7-amino-4-methylcoumarin ($nal concentration 833 µM) and 2 
µL /uorescent plasmin speci$c substrate (Cbz-L-phenylalanyl-L-arginyl)-rhodamine-
morpholinourea ($nal concentration 33 µM). !rombin and plasmin substrates are 
from Chiralix (Nijmegen, Netherlands) and dissolved in Tris Bu%ered Saline (TBS, 50 
mM Tris, 150 mM NaCl bu%er pH 7.4). !e NHA was started with 18 µL TBS bu%er 
containing tPA (Actilyse®, Boehringer Ingelheim, Ingelheim am Rhein, Germany, $nal 
concentration 193 IU/mL) and 4 µL CaCl
2
 to a $nal concentration of 16.7 mM (from 
Merck, Darmstadt, Germany), resulting in a total volume of 120 µL. Fluorescence was 
measured alternately every 30 seconds for 70 min in a 37 oC thermostated /uorometer 
(Fluostar Optima Fluorometer, BMG Labtechnologies, O%enburg, Germany). Pre-
warmed black polystyrene Fluotrac microtiter plates (Greiner Bio-One, Monroe, North 
Carolina, USA) were used. !e thrombin-speci$c substrate was excited at 355 nm and 
measured at an emission wavelength of 460 nm. !e plasmin-speci$c substrate was 
excited at 485 nm and measured at an emission wavelength of 520 nm. !rombin and 
plasmin proteolytic activities were calculated by comparing the arbitrary /uorescence 
values to known amounts from a calibration curve prepared with human α-thrombin 
and human plasmin respectively. !e calibration curve demonstrated linear substrate 
cleavage throughout the reaction and the $rst derivative of the calibration curve was used 
to convert the /uorescence tracing to thrombin and plasmin concentrations respectively. 
!e $rst derivative was calculated from the /uorescent cumulative signal and all 
parameters of the NHA were determined by a Microso& Excel macro programmed in 
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Microso& Visual Basic (version 11.1.1 [Microso& Corporation]) as described elsewhere.17 
!e one di%erence between the current NHA compared to that described previously, is 
improved characteristics of the plasmin substrate. !e new plasmin substrate contains one 
peptide chain, and therefore overcomes the previous observation of increased plasmin 
generation a&er complete clot lysis noted in the rhodamine-based plasmin substrate with 
two peptide chains. For each run of the NHA, a control plasma was included for quality 
assurance. !e control plasma is a pooled plasma of equal amounts of platelet-free blood 
plasma from 10 healthy donors aged 18-70 years, with representing males and females 
equally; females were not on oral contraceptives or pregnant. NHA results are speci$ed 
as a percentage compared to a normal level, derived by the mean of 53 normal controls. 
For all results, the mean of two measurements was taken. 
Statistical analysis
Values are reported as medians. Statistical analysis was performed using IBM SPSS 
Statistics 22. !rombin and plasmin generation parameters were analysed using the 
Mann-Whitney U test by comparison to a reference (mean values for 2 runs of 53 normal 
controls). !e Spearman Correlation was used to correlate the laboratory phenotype 
with the results of the NHA. All p-values are two-sided. P-values lower than 0.05 were 
considered statistically signi$cant.





Genotype information for PLGD patients is presented in table 1. !e ten PAI-1 de$cient 
patients were homozygous for the mutation: c.699_700dupTA.12 
Clinical and laboratory phenotype
Five patients including 3 females (6, 7, 49 years) and 2 males (10, 37 years) with 
plasminogen de$ciency were evaluated. (table 1) Patients with PLGD had plasminogen 
activity levels ranging from 5 IU/dL to 23 IU/dL (normal level >51 IU/dL). Plasminogen 
antigen levels ranged from 12 mg/L to 64 mg/L (normal level >90 mg/L) consistent with 
type 1 de$ciency. None of the PLGD patients experienced a thrombotic or haemorrhagic 
event. All patients had experienced ligneous conjunctivitis, and two patients had ligneous 
gingivitis as well. Samples were obtained without exposure to exogenous therapy. 
!e PAI-1 de$cient patients had absent PAI-1 activity and antigen levels, inferred by a 
known genetic null mutation. Of the ten patients evaluated there were 7 females (ages 16-
37 years), and 3 males (ages 16-35 years). (table 2) PAI-1 de$cient patients experienced 
bleeding manifestations of varying severity. Maenorrhagia was most prevalent, occurring 
in the majority of females (5 of 7); other symptoms included major bleeding such as 
intracranial haemorrhage a&er trauma, other bleeding events associated with injury, 
trauma or invasive procedures, antenatal and postpartum bleeding in gravid females, 
haemorrhagic rupture of ovarian cyst, and minor mucocutaneous bleeding. Patients 
with at least one severe bleeding manifestation such as haemarthrosis, central nervous 
system bleeding, gastro-intestinal bleeding or umbilical cord bleeding where considered 
major bleeders, and those with only mucocutaneous bleeding were categorized as minor 
bleeders as in table 2. All of the patients are currently utilizing on-demand treatment 
with oral anti$brinolytics, either tranexamic acid or ε-aminocaproic acid; samples were 
obtained without use of exogenous therapy for a period of time su'cient to assure results 
representing only the de$ciency state.
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Thrombin (A/C) and plasmin (B/D) generation in plasma of patients with plasminogen 
de"ciency (A/B) and plasminogen activator inhibitor type 1 de"ciency (C/D).
NP, normal pooled plasma.
Thrombin and plasmin generation
!rombin and plasmin generation curves measured simultaneously in a single reaction 
in PLGD patients are shown in $gure 2A and 2B. Results of the NHA parameters of 
individual patients as well as patient characteristics are shown in table 1. PLGD patients 
demonstrated a short initiation with a median lag-time of 38% (p<0.001, IQR 38-57%) 
and thrombin peak time of 59% (p<0.001, IQR 48-78%) as compared to the reference 
group of healthy controls. Propagation was relatively normal with a thrombin peak height 
of 87% (IQR 65-113%) with slightly enhanced AUC of 139% (p<0.001, IQR 109-159%). 
No measurable plasmin generation was observed in PLGD patients, except for patient 4, 
whose baseline plasminogen activity level was 23%.
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Figure 2C and 2D show the thrombin and plasmin generation curves of patients with 
PAI-1 de$ciency. !e NHA corresponding parameters and patient characteristics are 
listed in table 2. When compared to healthy controls, the initiation showed a median 
lag-time of 57% (p<0.001, IQR 47-66%), and thrombin peak time of 77% (p<0.001, IQR 
68-88%); thrombin peak height was low with a median of 67% (p<0.001, IQR 62-80%), 
with a normal AUC of 106% (IQR 86-124%), a normal $brin lysis time (median 104%, 
IQR 80-111%) with high plasmin peak height and plasmin potential (median with IQR 
254%, 193-298% and 232%, 182-267%, respectively, both p<0.001). 
!e NHA results in PLGD and PAI-1 de$cient patients as compared to the reference 
group of healthy controls are displayed in $gure 3.
Correlation with laboratory phenotype
!ere was no strong correlation between the parameters of the NHA and plasminogen 
activity and antigen levels. A moderate correlation of 0.60 (p=0.28) was found between 
thrombin potential expressed as AUC and plasminogen activity. !ere were moderate 
negative correlations between plasminogen antigen levels and thrombin peak height and 
AUC of -0.62 (p=0.27) and -0.60 (p=0.29), respectively. As PAI-1 de$cient patients had 
undetectable PAI-1 activity and antigen, no correlation calculations were performed for 
the NHA parameters in this population.
Correlation with clinical phenotype
!e clinical manifestations of PLGD patients were not clearly associated with plasminogen 
activity level (range 7-23%). Patients with lower plasminogen antigen levels trended 
towards multiple site involvement as compared to patients with a higher antigen levels; 
due to the small sample size, no conclusive interpretations can be drawn. !ere were no 
signi$cant di%erences in the NHA parameters between di%erent PLGD patients. 
When comparing the three patients with PAI-1 de$ciency categorized with major 
bleeding events to the 7 patients with minor bleeding, no di%erences were observed in 
lag-time ratio, thrombin peak time ratio, thrombin peak height and $brin lysis time 
ratio. !ere were trends towards lower AUC (median 86% vs 114%), lower plasmin peak 
height (median 143% vs 294%) and lower plasmin potential (median 135% vs 234%) in 
the major versus minor bleeding event group respectively. !ese di%erences were not 
statistically signi$cant.
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Results of Nijmegen hemostasis assay parameters in patients with a plasminogen activator 
inhibitor type 1 de"ciency and plasminogen de"ciency, compared to the reference group (dotted 
line).
Median of the patient group is shown by the solid line.




We report the analysis of haemostatic balance as determined in the NHA in two ultra-rare 
$brinolytic de$ciency states, PLGD and PAI-1; the NHA results were used in an initial 
e%ort to evaluate an association with clinical phenotype. Type 1 PLGD patients do not 
have an increased risk of thrombosis despite the pivotal role of $brinolytic enzymes in 
limiting excessive $brin formation. In contrast, a de$ciency of the $brinolytic inhibitor, 
PAI-1, results in a pronounced increase in $brinolysis with resultant haemorrhagic 
manifestations. !e NHA results illustrate virtually absent plasmin generation in PLGD 
patients and high, yet variable, plasmin generation in PAI-1 de$cient patients. 
!ere was no measurable plasmin generation in PLGD patients, except in patient 4. 
Patient 4 was homozygous for the Lys38Glu (formerly known as K19E) mutation, which 
is associated with higher plasminogen plasma levels and a milder clinical course when 
compared with other plasminogen gene variations.3 Consistent with reports of patients 
with the Lys38Glu mutation, patient 4 demonstrated the highest plasminogen levels. Of 
interest in the PLDG patients overall, was an observed increased thrombin potential 
with normal thrombin peak height. !eoretically, PLGD patients could develop denser 
$brin structure due to the absence of plasmin, which could lead to changes in thrombin 
inactivation by inhibitors such as antithrombin (AT) or $brin, possibly contributing to a 
normal thrombin peak height but prolonged thrombin generation curve, and a relatively 
high AUC. It would therefore be interesting to perform plasma turbidity assays in these 
PLGD patients, to gain increased data on clot density.22 In contrast, two prior reports 
suggested a normal or low thrombin potential in PLGD.19,20 !ese prior studies utilized 
a commercial depleted product as the plasminogen de$cient plasma; therefore these 
results may not be equivalent to samples obtained from patients with a documented 
de$ciency state as used in our report. None of the PLGD patients who particpated in this 
analysis experienced a thrombosis; the clinical picture is not intuitively consistent with 
the observed increased thrombin potential with normal thrombin peak height. !erefore, 
it would be interesting to perform plasma turbidity assays in these patients, to gain more 
information on clot density or the level of !rombin-Antithrombin levels as we expect 
that D-dimer levels are absent. 
In PAI-1 de$cient patients, low thrombin peak height with normal AUC was 
observed. !ese results can be explained by accelerated $brin clearance in these patients, 
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as previously seen in patients with a$brinogenemia.23 !e absence of $brin results in an 
increase of free thrombin, as a lesser amount of thrombin is bound to available $brin; this 
leads to increased thrombin inactivation by antithrombin and other thrombin inhibitors, 
thus explaining the lower thrombin peak height. However, as $brin is a sink for thrombin, 
the absence of $brin leads to prolonged thrombin generation, illustrated by a normal 
AUC despite low thrombin peak height. On the other hand, PAI-1 de$cient patients 
demonstrated extremely high values of plasmin peak height and plasmin potential, 
consistent with accelerated $brinolysis. !ere was signi$cant variation between individual 
patients, as shown in $gure 1D. !e observed high variability in plasmin generation curves 
of PAI-1 de$cient patients is interesting given their unifying genetic mutation overlying 
a fairly uniform genetic background (Old Order Amish); this observation might provide 
a basis to understand the clinical phenotypic heterogeneity of bleeding in these patients 
and warrants further investigation. Similarly, the fact that all evaluated PAI-1 de$cient 
patients with no detectable PAI-1 activity or antigen had a marked di%erence in plasmin 
generation, highlights the issues of weak correlation between genotype, clinical and 
laboratory phenotype. It remains challenging to conduct further research to ascertain 
the correlation between the clinical and laboratory phenotype in an ultra-rare bleeding 
disorder such as PAI-1 de$ciency. 
For both PLGD and PAI-1 de$ciency, there was a short thrombin lag-time and time to 
thrombin peak observed in the NHA. !e PAI-1 de$cient population exhibited very high 
plasmin generation values. As plasmin, aside from dissolving $brin, also functions as an 
activator of a variety of proteins, it is possible that the large amount of generated plasmin 
in these patients activates coagulation factors leading to accelerated thrombin formation. 
It has been established that $brin architecture has an e%ect on thrombin generation.24 
However, as this e%ect was also seen in PLGD patients in absence of plasmin generation, 
the short initiation times could also be caused by preanalytical variability such as sample 
processing, transportation and storage, and as such should be interpreted with caution. 
!ese $ndings need con$rmation in further studies. Our group also reported reduced 
thrombin lag-times in other rare bleeding disorders a%ecting $brinolysis including 
a$brinogenemia and FXIII de$ciencies.23 !ese results are comparable to results of 
others, who reported shortened lag time with a$brinogenemia and with FXIII de$ciency 
as well.25,26 !e latter group argued that thrombin generation is supported by the action 
of altered $brin caused by FXIII de$ciency, similar to the e%ect of Glycin-Prolin-
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Arginin-Prolin (GPRP), although our results did not show these e%ects with GPRP 
titrations.17 GPRP inhibits $brinogen polymerization by direct binding to the $brinogen 
polymerization sites and modifying the glutamine residues in the α- and γ-chains of 
$brinogen. GPRP has been shown to inhibit ADP-induced platelet aggregation, and 
inhibits $brin proto$bril lateral aggregation and thereby promotes TG in normal plasma. 
!e novel results reported here suggest that enhanced thrombin generation may also be 
due to altered $brin structure. An explanation for shortened lag time in a patient with 
PLGD may result due to timely contraction of the clot, leading to less $brin surface to 
which thrombin may bind, leading to relatively higher thrombin plasma concentrations 
and shortened lag times. 
In the case of shortened lag times in patients with absent PAI-1, the higher plasmin 
levels generated and increased $brinolysis may result in partial activation of coagulation 
proteins. For instance, plasmin in/uences coagulation by (in)activation of factor VII, 
factor VIII, factor IX, factor X and factor XII. It has also been demonstrated that FVa is 
degraded by plasmin, although inactivation was preceded by a brief phase of activation.27-32 
!e cumulative list of potential coagulation proteins cleaved by plasmin may result in a 
shortened lag time. 
!is study has a few limitations. Due to limited plasma availability, additional 
laboratory tests such as coagulation screening assays, euglobulin clot lysis assays and 
other coagulation factor levels could not be performed. Secondly, although simultaneous 
measurement of thrombin and plasmin generation aims to mimic the in vivo milieu, 
other in/uences contributing to haemostasis cannot be accounted for in such assays, 
e.g. endothelium, platelets and leucocytes. Although coagulation and $brinolysis are 
o&en considered as two consecutive processes, in vivo they can occur simultaneously. In 
the NHA, where thrombin and plasmin are triggered simultaneously, tPA can activate 
plasminogen a&er $brin has been formed.33 !erefore, this is partly a sequential process 
and there may be in vivo e%ects that cannot be measured in vitro. Lastly, the small patient 
sample size prohibits an in-depth analysis of signi$cance for phenotype and genotype 
correlations. 
Despite these limitations, this report is the $rst study to investigate simultaneous 
measurement of thrombin and plasmin generation in two ultra-rare $brinolytic 
pathway de$ciencies, PLGD and PAI-1 de$ciency. Both patient cohorts represent well 
characterized $brinolytic disorders. Patients with PLGD and PAI-1 de$ciency showed 
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distinct patterns of thrombin and plasmin generation. !ere was a clear di%erence 
between the two de$ciencies in the propagation of coagulation, potentially explained by 
the di%erence in plasmin generation. Large international multicentre clinical studies that 
incorporate rare coagulation disorders such as these will increase our understanding of 
their overall haemostatic balance.
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Introduction: Bleeding assessment tools and laboratory phenotyping o&en remain 
inconclusive in patients with a haemorrhagic diathesis. 
Aim: To describe the phenotype and genetic pro$le of patients with a bleeding 
tendency.
Methods: Whole exome sequencing (WES) was incorporated in the routine 
diagnostic pathway of patients with thrombocytopenia (n=17), platelet function 
disorders (n=19) and an unexplained bleeding tendency (n=51). A panel of 126 
OMIM (online Mendelian Inheritance in Man) genes involved in thrombosis and 
haemostasis was conducted, and if negative, further exome-wide analysis was 
performed if informed consent given. 
Results: Eighteen variants were detected in 15 patients from a total of 87 patients 
(17%). Causative variants were observed in MYH9 (2 cases), SLFN14, P2RY12 and 
GP9. In addition, one case was considered solved due to combined carriership of 
F7 and F13A1 variants and one with combined carriership of F2, F8 and VWF, 
all variants related to secondary haemostasis protein aberrations. Two variants of 
uncertain signi$cance (VUS) were found in two primary haemostasis genes; GFI1B 
and VWF. Eight patients were carriers of autosomal recessive disorders. Exome-wide 
analysis was performed in 54 cases and identi$ed three variants in candidate genes. 
Conclusion: Based on our $ndings we conclude that performing WES at the end of 
the diagnostic trajectory can be of additive value to explain the complete bleeding 
phenotype in patients without a de$nite diagnosis a&er conventional laboratory 
tests. Discovery of combinations of (novel) genes that predispose to bleeding will 
increase the diagnostic yield in patients with an unexplained bleeding diathesis. 
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!e current diagnostic strategy of patients with a haemorrhagic diathesis by bleeding 
assessment tools (BAT) and laboratory phenotyping is o&en inconclusive, time consuming 
and expensive. Patients are heterogeneous in their clinical presentation, age, sex and 
family history. !e majority of patients with an increased bleeding tendency present 
to the general practitioner. Here, the decision has to be made whether a true bleeding 
tendency exists, knowing that maenorrhagia, epistaxis and easy bruising are frequently 
reported in the general population as well.1 Consequently, there is an increased risk of 
overanalysing patients and generating false-positive laboratory results.2
As the haemostatic system is complex, disturbances can occur in either primary 
haemostasis, secondary haemostasis, $brinolysis or a combination of these. Current 
screening and con$rmatory laboratory tests lack su'cient speci$city and sensitivity. 
Only in a limited number of patients, single gene analysis yields a clear diagnosis. 
Consequently, many patients remain without a de$nitive diagnosis.3 !erefore, improved 
diagnostic approaches are needed to establish a more personalized based treatment and 
limit bleeding complications.
Novel strategies, such as proteomics, metabolomics and genomics are slowly 
incorporated into clinical practice.4-6 Continued next generation sequencing (NGS) 
e%orts have already signi$cantly improved our understanding of the pathobiology in 
other diseases such as acute myeloid leukaemia and changed treatment towards more 
individualized therapy.7 Routine diagnostic whole exome sequencing (WES) in our 
genetic department has shown to be an e%ective tool to elucidate the genetic defect 
underlying many di%erent types of heterogeneous disorders and we hypothesize that 
such an approach would also bene$t the diagnostics of bleeding disorders.8-11 Several 
research groups have introduced the use of NGS approaches in patients with a bleeding 
diathesis.12-17 !us far, only one research group incorporated WES in their routine 
diagnostic work up.13 In 2016 we implemented WES in the diagnostic pathway of patients 
with thrombocytopenia, platelet function abnormalities or an unexplained bleeding 
tendency a&er accomplishing the standard laboratory assays at the Radboud university 
medical center with the main goal to better understand the clinical phenotype. !e results 
of the $rst interim analysis are presented here.





Patients with a suspected bleeding diathesis were analysed using the Tosetto BAT score 
and standard diagnostic tests covering coagulation, platelet function and $brinolysis.18 
!ese included Platelet Function Analysis (PFA), activated partial thromboplastin 
time (APTT), prothrombin time (PT), $brinogen, FVIII levels, von Willebrand Factor 
(vWF) activity and antigen, collagen binding capacity, α2-antiplasmin, FXIII levels, 
platelet aggregation assays, plasminogen activator inhibitor type 1 (PAI-1) activity and 
antigen, tissue plasminogen activator (TPA) and euglobulin clot lysis time. A&er these 
conventional diagnostic assays, the patients were distributed into three separate groups 
either due to an increased BAT without any laboratory abnormalities or with abnormal 
platelet count or function without a de$nite diagnosis. Eighty-seven patients diagnosed 
with thrombocytopenia (de$ned as a platelet count <150x109/L with or without a platelet 
function abnormalities, group A), a platelet function abnormality (de$ned as abnormal 
platelet aggregation and normal platelet count, group B) or a bleeding diathesis of 
unknown origin (group C) were subjected to WES between January 1st 2016 and January 
1st 2018. Patients were counselled by clinical geneticists and informed consent was 
obtained for ‘bleeding disorder gene panel only’ or ‘gene panel and exome-wide analysis’ 
according to the declaration of Helsinki and in accordance with the local Institutional 
Review Board. Patients with a clearly de$ned diagnosis a&er conventional laboratory 
diagnostics underwent single gene analysis, they did not undergo WES and were therefore 
not taken along in this analysis. In case a variant was found by WES in a coagulation gene, 
this speci$c coagulation factor level was quanti$ed a&er WES results. 
Exome sequencing
Genomic DNA was isolated from whole blood. Exonic enrichment (Agilent Technologies, 
USA) and sequencing (Illumina Hiseq) generating reads to a median coverage of >75x 
was performed at Bejing Genome Institute Europe, Denmark. Sequenced reads were 
mapped to the hg19 reference genome using the mapping algorithm from BWA (version 
0.5.9-r16) and called by the GATK uni$ed genotyper (version 3.2-2).19,20 All variants 
were annotated using an in-house pipeline for exome analysis containing variant and 
CHAPTER 4
Whole exome sequencing in the diagnostic work up of patients with a bleeding diathesis
85
4
gene speci$c information.21 For the gene panel analysis, a bioinformatic in silico $lter 
was applied to select for variants a%ecting known thrombosis and haemostasis genes. 
Variants were $ltered for non-synonymous variants with population frequencies ≤1% in 
our in-house database (>15000 exomes), and subsequently evaluated for their possible 
pathogenicity and phenotypic overlap with earlier described cases. All detected and 
reported variants were of high quality (GATK quality by depth >500) or were con$rmed 
by standard Sanger sequencing in case of low quality variant calls. In exome-wide 
analysis all variants for coding were $ltered, non-synonymous variants with population 
frequencies of ≤1% in-house and ≤5% homozygous occurrences reported in ExAC for 
autosomal recessive candidates, and allele counts of ≤10x in-house, or ≤20x in ExAC for 
autosomal dominant candidates.22 
Variant interpretation and classi"cation
All identi$ed genetic variants were judged by a variant calling team on their possible 
pathogenicity based on practice guidelines of the Association for Clinical Genetic Science, 
and the standards and guidelines of the American College of Medical Genetics and 
Genomics.23,24 !e variant calling team consists of clinical genetical laboratory specialists. 
Results were discussed in monthly multidisciplinary meetings with (paediatric) 
haematologists, laboratory specialists and geneticists to assess $nal diagnosis. We 
reported class 5 (pathogenic), class 4 (likely pathogenic), or class 3 (variant of uncertain 
signi$cance, VUS) variants. Class 3 variants were only reported if the a%ected gene 
corresponded to an autosomal dominant or X-linked dominant bleeding disorder. Patients 
with reported variants were counselled to perform further analyses of their families by 
co-segregation or de novo analysis if autosomal dominant inheritance was suspected, or 
carrier status analysis of parents and siblings in cases of recessive inheritance. Since new 
genes are being discovered continuously, the gene panel is updated every 3-6 months a&er 
detailed discussion by our multidisciplinary team. !e originally de$ned 85 gene panel 
was extended in two steps to 126 Online Mendelian Inheritance in Man (OMIM) genes 
associated with haemorrhagic or thrombotic disorders (table 1).25 If a causative variant 
(class 4/5) was found in the panel, open exome analysis was not performed.




Haemostasis/thrombosis gene panel. 
A2M* CTLA4* FERMT3 ITGA2B PLAU SRC*
ABCG5 CYCS FGA ITGB3 PLG STIM1
ABCG8 DGKE* FGB JAK2* PRKACG STXBP2
ACTN1 DIAPH1* FGG KLKB1 PROC TALDO1*
ACVRL1** DNASE1* FLI1 KNG1* PROS1 TBXA2R
ADAMTS13* DTNBP1 FLNA KRAS* PROZ TBXAS1
ANKRD26 ENG** GATA1 LMAN1 PTGS1 THBD
ANO6 ETV6 GFI1B LYST PTPN11* THPO
AP3B1 F10 GGCX LZTR1* PTPN22* TREX1*
BLOC1S3 F11 GP1BA MASTL RAB27A TUBB1*
BLOC1S6 F12 GP1BB MCFD2 RAF1* VIPAS39
BRAF* F13A1 GP6 MECOM* RASGRP2 VKORC1
C3* F13B GP9 MPL RBM8A VPS33B
CALR F2 HABP2 MTHFR RIT1* VWF 
CBL* F2RL3* HOXA11 MYH9 RUNX1 WAS
CD46* F5 HPS1 NBEA* SERPINC1 WIPF1
CFB* F7 HPS3 NBEAL2 SERPIND1
CFH* F8 HPS4 NRAS* SERPINE1  
CFHR1* F9 HPS5 P2RX1 SERPINF2  
CFHR3* FCGR2A* HPS6 P2RY12 SLFN14*
CFI* FCGR2B* HRG PLA2G4A* SOS1*
COL3A1 FCGR2C* ITGA2 PLAT SOS2*
Genes involved in Mendelian inherited haemostatic and thrombotic disorders were selected 
(megakaryopoiesis, coagulation factors, "brinolysis, platelet function and formation, thrombosis, blood 
vessel integrity).* Added at "rst revision. ** added at second revision.
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Basic patient characteristics and WES results
Eighteen variants were found with the gene panel in 15 of 87 patients (17%). All variants 
that were discovered are shown in table 2. Mean age at WES inclusion was 41 years, with 
82% female patients. Overall results and work/ow are shown in $gure 1. 
Seventeen patients were categorized in group A. !is group had the highest incidence 
of pathogenic causative variants with 4 of the 17 cases solved (24%). Two patients had a 
heterozygous MYH9 variant causing an autosomal dominant MYH9 associated bleeding 
disorder. One patient had a heterozygous SLFN14 variant causing autosomal dominant 
platelet secretion defects.26 In addition, one patient had a homozygous GP9 variant 
causing autosomal recessive Bernard-Soulier syndrome. A VUS was identi$ed in GFI1B 
corresponding to autosomal dominant gray platelet syndrome, and a carriership in FGG 
corresponding to autosomal recessive a$brinogenemia.27
Group B consisted of 19 patients, in whom one causative variant was found (5%): a 
homozygous P2RY12 variant leading to an autosomal recessive impairment of platelet 
response to ADP.28 One heterozygous VUS was found in VWF and furthermore a VUS 
in MASTL was classi$ed as likely non-pathogenic (class 2) based on segregation analysis.
Fi&y-one patients were categorized as group C. In this group, one patient carried a 
heterozygous F7 variant and a heterozygous F13A1 variant. Another patient had combined 
carriership of F2, F8 and VWF variants (all heterozygous). !e found variants in these 
2 patients (4%) were considered to play a major role in the explanation of the bleeding 
phenotypes. Five carrierships of autosomal recessive disorders were found in GP1BA 
(corresponding to Bernard-Soulier syndrome) MPL (corresponding to myelo$brosis, 
thrombocythemia or thrombocytopenia), F2, F5 and F11. Two heterozygous VUSes in 
one patient in NBEAL2 were not considered causative as segregation analysis showed that 
these variants were on the same allele (and thus not compound heterozygous), while gray 
platelet syndrome is an autosomal recessive disorder. 
Exome-wide analysis was performed in 54 of the 80 unsolved cases. !is includes 
patients without causative variants in the panel or only a VUS, and carriers of autosomal 
recessive disorders. Exome-wide analysis identi$ed three VUSes in candidate genes 
(6%), currently under further analysis to de$ne causality. In 2 cases (4%) there was an 
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unsolicited $nding: one heterozygous variant in the RET (multiple endocrine neoplasia) 
gene and one heterozygous variant in the FH (hereditary leiomyomatosis and renal cell 
cancer) gene. 
TABLE 2. 
Reported variants detected by gene panel analysis using WES.
Patient Gene Transcript Variant* Class AF gnomAD
1 MYH9 NM_002473.4 c.287C>T p.Ser96Leu 5[41-46] 0
2 MYH9 NM_002473.4 c.3493C>T p.Arg1165Cys 5[15, 47-50] 0
3 SLFN14 NM_001129820.1 c.657A>C p.Lys219Asn 5[26] 0
4 GP9 NM_000174.3 c.182A>G p.Asn61Ser ** 5[51-53] 0.052%
5 P2RY12 NM_022788.4 c.772C>A p.Pro258Thr ** 5[54-56] 0.0032%
6 F7 NM_000131.4 c.1061C>T p.Ala354Val 4[57, 58] 0.057%
6 F13A1 NM_000129.3 c.949G>T p.Val317Phe 4[59] 0.00041%
7 F2 NM_000506.3 c.260A>G p.Tyr87Cys 5[60] 0.00081%
7 F8 NM_000132.3 c.2150G>T p.Arg717Leu *** 5[61-64] 0
7 VWF NM_000552.3 c.2561G>A p.Arg854Gln 5[65-68] 0.34%
8 GFI1B NM_004188.6 c.521C>A p.Thr174Asn 3 0.012%
9 VWF NM_000552.3 c.695C>T p.Ser232Leu 3 0.0012%
10 FGG NM_021870.2 c.323C>G p.Ala108Gly 4[29, 69-73] 0.20%
11 GP1BA NM_000173.5 c.275del p.Leu92fs 5[74-79] 0
12 MPL NM_005373.2 c.305G>C p.Arg201Pro 5[80] 0.038%
13 F2 NM_000506.3 c.260A>G p.Tyr87Cys 5[60] 0.00081%
14 F5 NM_000130.4 c.6526A>T p.Lys2176 Stop 5[81, 82] 0
15 F11 NM_000128.3 c.403G>T p.Glu135 Stop 5[83-87] 0.088%
In blue patients from case descriptions 1-4. * variant nomenclature according to HGVS guidelines (https://
varnomen.hgvs.org/); ** homozygous; *** patient is female. Allele frequencies in the gnomAD database 
(http://gnomad.broadinstitute.org) are listed.
CHAPTER 4























 4 Causative mutations 
 1 VUS 
 1 carriership 
 11 negative
 1 Causative mutation 
 1 VUS 
 0 carriership 
 17 negative
 2 Causative mutations 
 0 VUS 
 5 carriership 
 44 negative
 3 candidate genes51 negative
BAT + screening tests + 
conventional laboratory testing +
informed consent
All included cases were subjected to gene panel WES analysis. Causal pathogenic variants (class 4/5) were 
observed in seven cases (9%). Variants of unknown signi"cance were observed in one case in group A and 
one in group B (2%). Carriership of class 4/5 heterozygous variants associated with autosomal recessive 
disease was observed in six cases.
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Genotype translation to clinical practice
!e additional bene$t of performing WES to the diagnostic work up is illustrated by the 
following $ve case descriptions, highlighted in blue in table 2 and $gure 1:
In the $rst case (table 2, patient 11), a class 5 variant in GP1BA was identi$ed in a 
four year old boy with a bleeding tendency. His paediatric bleeding score was 3, due to 
rebleeding a&er tonsillectomy for which two re-operations were necessary. Besides these 
surgical interventions, he had no other haemostatic challenges so far. His mother has a 
bleeding tendency with a BAT score of 6, and he has a sister with a paediatric bleeding 
score of 1 (based on easy bruising). His father is unknown. !e child had low-normal 
VWF levels with a ristocetin cofactor activity of 33%, VWF antigen of 43% and FVIII 
activity of 59% but no causative variants in the VWF gene. His blood group was O+. !e 
PFA showed a prolonged epinephrine (186 sec, cut o%: <170) and ADP (162 sec, cut o%: 
<120) response. Whole blood platelet aggregometry showed normal platelet aggregation 
with ADP, collagen, arachidonic acid and adrenalin. Other haemostatic screening assays 
($brinogen, FVIII, FIX, FXI, FXII, PT and APTT) were normal. Hence, the bleeding 
phenotype of this child might be explained by the combination of low vWD parameters 
together with the heterozygous pathogenic GP1BA variant, leading to an inadequate 
primary haemostasis.
Secondly, a 76 year old woman (table 2, patient 7) with a bleeding score of 14 was 
referred for WES. Her bleeding tendency consisted of easy bruising, prolonged bleeding 
from minor wounds, bleeding a&er tooth extraction requiring resuturing, bleeding 
a&er surgery, maenorrhagia, postpartum haemorrhage and spontaneous haemarthrosis 
requiring puncture. She has a son and a cousin with mild haemophilia A, and another 
cousin with a combination of mild haemophilia A, von Willebrand disease type 2N and 
hyper$brinolysis. Coagulation screening assays (PFA, FVIII, FXIII, whole blood platelet 
aggregometry, VWF, PT, APTT, $brinogen PAI-1 activity and antigen, TPA, euglobulin 
clot lysis time and α2-antiplasmin) were normal, including a FVIII chromogenic assay of 
98% and FVIII activity of 130%, von Willebrand factor antigen 151%, ristocetin cofactor 
activity 149% and collagen binding assay of >100% . Analysis of the gene panel showed 
heterozygous variants in F2, F8 and vWF. On subsequent analysis, the factor II level 
was 63%. In this case, a combination of heterozygous variants in secondary haemostasis 
might have caused the abnormal bleeding tendency, whereby the individual haemostatic 
levels are in/uenced by age.
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In the third case, 2 heterozygous class 4 variants were found in F7 and F13A in an 18 
year old female with a bleeding tendency (table 2, patient 6). Her bleeding score was 10, 
consisting of maenorrhagia with blood transfusions and hormonal therapy, easy bruising, 
bleeding of gums and bleeding a&er extraction of wisdom teeth for which an additional 
procedure was necessary. !e family history was negative for a bleeding diathesis. Initial 
laboratory investigation including a qualitative FXIII measurement and PT as well as 
other haemostatic screening assays (FVIII, PFA, VWF, PAI-1 activity and antigen, 
TPA, euglobulin clot lysis time, α2-antiplasmin, PT, APTT and $brinogen) revealed no 
abnormalities. A&er identi$cation of the two heterozygous variants, the F7 level was 
determined to be 52% and the FXIII level 58%. As both FVII and FXIII play a dominant 
role in the coagulation pathway by generating the $rst burst thrombin and optimizing 
$brin clot stability, heterozygosity for both de$ciencies can generate a relatively severe 
bleeding tendency upon interventions.
!e fourth case describes a four year old girl with a thrombocytopenia of <1x109/L 
(table 2, patient 10). Her bleeding tendency consisted of epistaxis and easy bruising. 
!e family history was negative. Haemostatic screening assays (FVIII, VWF, PT, APTT 
and $brinogen) were normal, whereas PFA could not be determined because of the 
thrombocytopenia. In this patient, a heterozygous FGG variant was found. Although this 
is only a carriership with normal $brinogen levels, this variant has been described earlier 
in a patient with a thrombocytopenia.29
Finally, a 58 year-old woman was referred with a bleeding score of 8, consisting of 
easy bruising, prolonged bleeding from minor wounds, maenorrhagia and bleeding a&er 
caesarean section requiring blood transfusion (not incorporated in table 2). Haemostatic 
screening assays (FVIII, PFA, whole blood aggregometry, VWF, PAI-1 activity and 
antigen, TPA, euglobulin clot lysis time, α2-antiplasmin, PT, APTT and $brinogen) 
were normal. She also had arthropathy since the age of 40. One of her sisters had a 
bleeding tendency and arthropathy as well, in combination with an aortic aneurysm. Her 
father and uncle had an aortic dissection. !e family was previously tested for Ehlers-
Danlos syndrome with negative results. !e gene panel was negative, but open exome 
analysis revealed a heterozygous class 3 FBN1 variant. Variants in the FBN1 gene cause 
autosomal dominant Marfan syndrome. !e identi$ed variant (c.694C>T p.Arg232Cys) 
creates an extra cysteine in the transforming TB domain, making it strongly suspicious 
to be pathogenic. Segregation analysis showed that the sister with a bleeding tendency, 
arthropathy and aortic aneurysm carries the same variant.




!e value of WES is demonstrated by the detection of rare causative variants that are 
not found by conventional laboratory diagnostics.7,17 !e main goal of our study was to 
evaluate the additional value of WES to the standard diagnostic work up in patients with 
an increased bleeding tendency, to unravel the clinical phenotype. By introducing WES 
a&er conventional laboratory assays, 18 variants were found in 15 patients of a total of 
87 patients with an unexplained clinical haemostatic phenotype (17%). Interestingly, 10 
of these 18 variants were categorized as causative variants, yielding a de$nite diagnosis. 
Four autosomal recessive variants and one X-linked variant were found in two patients. 
Combinations of these variants may explain their clinical phenotype as all variants are 
related to genes involved in secondary hemostasis. In current clinical practice, there are 
no guidelines and no consensus how to treat patients with an increased bleeding tendency 
without a de$nite diagnosis or combinations of carriership in autosomal recessive genes, 
and consequently treatment is o&en based on the physician’s expert opinion. 
In the $rst highlighted case, a variant was found related to autosomal recessive Bernard 
Soulier disease, leading to carriership for this disorder. !e combination of this variant 
with low vWD parameters is highly suspected to have impaired primary haemostasis 
despite normal results on platelet aggregation. Current platelet function assays, as the 
LTA and whole blood aggregation, have a high speci$city but only moderate sensitivity 
in detecting inherited platelet function disorders.30,31 In this patient, a personalised 
treatment algorithm should focus on optimizing the adherence of platelets to the vessel 
wall and consist of desmopressin (DDAVP) or the transfusion of platelets. !e second 
case demonstrated an increased bleeding tendency in an older woman with a combination 
of pathogenic variants in F2, F8 and VWF with normal coagulation assays and normal 
vWD parameters. vWF and FVIII levels increase during adulthood, however it is debated 
whether this translates into a decreased bleeding phenotype, as elderly patients with vWD 
disease still have increased bleeding a&er surgery or trauma.32,33 Consequently, normal 
vWF and FVIII levels at an older age can mimic a physiological situation. !e third case 
described a patient with two heterozygous F7 and F13A variants and reduced levels of the 
corresponding factors, which can be easily missed in the standard haemostatic laboratory 
screening. However, a combination of low-normal Factor VII and factor XIII levels can 
predispose patients to inadequate thrombin generation and $brin clot formation during 
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events where there is an increased haemostatic demand, such as in the menstrual period 
or during surgery.34,35 In the fourth case, the found variant in FGG does not appear to be 
related to the thrombocytopenia at $rst sight. However, this variant has been described 
previously in a patient with hypo$brinogenemia, and a thrombocytopenia as well.29 !is 
is a very interesting $nding because in theory, this variant can cause an increased binding 
of $brinogen to the GPIIbIIIa receptor, which can cause small platelet aggregates and 
subsequent thrombocytopenia due to platelet consumption.
Interestingly, in the last case, a variant was found in the FBN1 gene, involved in 
Marfan syndrome. !e clinical phenotype of the patient consisted of increased bleeding, 
arthropathy and an incidental aortic aneurysm in several family members all carrying 
this variant. Whether her bleeding tendency is linked to this variant is still under debate, 
however an altered connective tissue and collagen structure of the vessel wall has been 
described in patients with easy bruising and postpartum bleeding complications.36,37
A limitation of WES is that only coding regions of the DNA are being explored 
and current practice is still time consuming. Whole genome sequencing (WGS) is an 
interesting alternative.14 However, both WES and WGS generate an enormous amount of 
information including polymorphisms and haplotypes of which the clinical signi$cance 
is currently unclear. !eir clinical usefulness will increase when results of NGS techniques 
are incorporated in diagnostic algorithms.
In this study we chose to include only class 3 variants corresponding to autosomal 
dominant bleeding disorders as they are potentially pathogenic, whereas a class 3 variant 
corresponding to an autosomal recessive disorder can cause carriership at most, with 
unknown signi$cance. A limitation of our study is the small number of patients that 
were analysed. In addition, our study re/ects the diagnostic work up retrospectively 
and does not have a prospective design. A prospective extension study is planned with 
incorporation of WES in the diagnostic work up with the addition of performing family 
based segregation analysis.
We emphasize the additive bene$t of implementing WES in the diagnostic work 
up of patients with an increased bleeding phenotype without a de$nite diagnosis a&er 
performing conventional laboratory assays. A pitfall of these latter assays is that they 
determine a limited part of the primary or secondary haemostasis and do not re/ect the 
total haemostatic system. NGS techniques are a valuable tool to assist in evaluating the 
haemostasis balance as a whole. We pose that combinations of mild abnormalities in 
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one haemostatic process (for example the primary haemostasis) or di%erent processes 
(primary, secondary haemostasis and/or $brinolysis) can lead to an increased bleeding 
tendency which is not detected by current conventional laboratory assays. However, 
besides implementation of NGS techniques, functional haemostatic assays need to be 
improved. Currently, /ow cytometry-based platelet function diagnostic tests are being 
developed and global haemostatic assays are implemented in clinical practice.38-40 
CONCLUSION
Based on the results of this diagnostic approach presented here and recently published 
genetic studies in bleeding disorders, we propose to include NGS techniques in the 
diagnostic work up for unexplained bleeding disorders.13 We advise to discuss the 
results in a multidisciplinary team including haematologists, laboratory specialists and 
geneticists. Discovery of combinations of (novel) genes that predispose to bleeding will 
increase the diagnostic yield in patients with an unexplained bleeding diathesis. To accept 
NGS techniques in the standard diagnostic work up of patients with bleeding tendency, 
prospective studies with larger patient numbers and cost-bene$t analyses are needed.
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Introduction: Patients with hereditary rare bleeding disorders (RBDs) present 
with diverse hemorrhagic symptoms. Correlation between factor activity levels and 
clinical bleeding severity is poor for most RBDs. !reshold factor activity levels have 
been previously described in relation to bleeding severity, but have not yet been 
validated.
Methods: !e Rare Bleeding Disorders in the Netherlands (RBiN) study is a 
nationwide cross-sectional study of patients registered in all 6 Dutch Haemophilia 
Treatment Centers with a known RBD who are aged 1-99 years. Bleeding scores 
were determined, and laboratory and clinical data were extracted from patient $les.
Results: In all, 263 patients were included, of whom 202 (77%) attended the study 
visit. !e median International Society of !rombosis and Haemostasis (ISTH) 
bleeding assessment tool (BAT) score was 9. Correlations between baseline factor 
activity levels and ISTH BAT scores were strong for de$ciencies in factor II (FII) 
(r=-0.792) and FX (r=-0.838) and were moderate for de$ciencies of $brinogen 
(r=-0.683), FV (r=-0.623), FVII (r=-0.516), FXIII (r=-0.516), and α2-antiplasmin 
(r=-0.594). !ere was no correlation for FXI de$ciency (r=-0.218). !e RBD BAT 
identi$ed more women (94% versus 83%)  and children (100% versus 71%) with an 
RBD than the ISTH BAT. Importantly, 48% of patients had more severe bleeding 
than predicted for their baseline factor activity level. In addition, 34% of patients 
were predicted to be asymptomatic, but they actually had grade II (31%) or III (3%) 
bleeding.
Conclusions: Bleeding severity in patients with RBDs is more pronounced than 
previously anticipated. !e previously determined threshold factor activity levels to 
ensure no (spontaneous) bleeding in patients with a RBD are inaccurate. !is trial 
was registered at www.clinicaltrials.gov as #NCT03347591.
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Rare bleeding disorders (RBDs) refer to hereditary de$ciencies of $brinogen, prothrombin 
(factor II, [FII]), FV, FV&FVIII, FVII, FX, FXI, and FXIII as well as disorders of 
$brinolysis. RBDs are generally inherited as autosomal recessive disorders, except for 
dys$brinogenemia and some cases of FXI de$ciency, which can be autosomal dominant. 
!e prevalences of RBDs for homozygosity or compound heterozygosity vary from 
1:500.000 to 1:2.000.000.1 !ey are signi$cantly more prevalent in population groups 
with a high rate of consanguinity.1,2 
!e clinical presentation of RBDs is diverse, ranging from asymptomatic to severe 
spontaneous bleeding.3 !e reported correlation between the factor activity level and 
degree of bleeding varies from strong and predictable (for de$ciencies of $brinogen, 
FV+FVIII, FX and FXIII) to no correlation for FXI de$ciency as reported in a multicenter 
cohort study (EN-RBD) among 489 patients.4 Overall, life-threatening bleeding episodes 
such as cerebral bleeding and spontaneous hemorrhages in muscles and joints appear to 
occur less frequently when compared with hemophilia.2 However, the large variability 
between the individual RBDs makes it impossible to consider these disorders only as a 
group.
Hemorrhagic disorders of $brinolysis mainly consist of plasminogen activator 
inhibitor type 1 (PAI-1) de$ciency and α2-antiplasmin (α2-AP) de$ciency. !e bleeding 
phenotype of patients with $brinolytic disorders is characterized by delayed bleeding a&er 
trauma, surgery, and dental procedures.5 Bleeding in areas of high $brinolytic activity 
is also common, such as menorrhagia and epistaxis.5 Another category of RBDs is FV 
Amsterdam. !is bleeding disorder is caused by a pathogenic gain-of-function variant in 
the FV gene leading to an aberrant FV that binds Tissue Factor Pathway Inhibitor (TFPI), 
prolonging the half-life and concentration of TFPI, which results in severely reduced 
thrombin generation and a bleeding tendency.6
Peyvandi et al. described the minimal factor levels needed to remain asymptomatic 
for RBDs, showing a large variety between di%erent coagulation factor de$ciencies. 
Although heterozygous patients are usually considered not to have a bleeding disorder, 
factor activity levels needed to remain symptomatic vary from 12 IU/dL for FV de$ciency 
up to 56 IU/dL for FX de$ciency.4 !ese threshold levels are o&en used in clinical practice; 
however, they have not been validated in a separate patient population.7
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Bleeding assessment tools (BATs) have been used since 1982 for the quanti$cation 
of a bleeding tendency.8 Since then, several BATs were developed for the assessment and 
quanti$cation of bleeding symptoms and diagnosis of bleeding disorders, including the 
International Society of !rombosis and Haemostasis (ISTH) BAT in 2010.9-11 However, 
these BATs originally focused on patients with von Willebrand disease (VWD). !e ISTH 
BAT score has also been validated in carriers of hemophilia, but few RBD patients have 
been evaluated with these tools.12 In addition, BATs are known to be of limited diagnostic 
value for patients with mild bleeding disorders.13 In 2016, Palla et al. published a novel 
BAT score for patients with RBDs.14 !e most important di%erences between the ISTH 
BAT and the RBD BAT are (1) the RBD-BAT has separated the individual surgical items 
as tonsillectomy, minor surgery and major surgery instead of categorizing these as one 
item, (2) the RBD BAT includes subtraction points in case of no bleeding a&er hemostatic 
challenges, and (3) the calculation of the score in the RBD BAT corrects for sex and 
age and uses subtraction points for speci$c hemostatic items. !e RBD BAT score is a 
potentially interesting diagnostic tool, but it has not yet been validated in a separate RBD 
patient cohort.
Given the low prevalence of RBDs, systemically collected data on these disorders 
are scarce.15 Over the past years, several registries in Europe and the United States have 
been developed for patients with an RBD.16,17 However, data derived from registries is still 
limited and is mostly absent for disorders of $brinolysis.
!e aims of this study are to describe the Dutch RBD patient population for the 
$rst time and to determine the usability of the ISTH BAT and RBD BAT for this patient 
population. In addition, we aim to validate the previously determined threshold factor 
activity levels. Because the Dutch patient population was not included in the EN-RBD 
study, this study can be used to validate the results from the EN-RBD study in a separate 
RBD cohort.4,14





A nationwide cross-sectional study was conducted among patients with a hereditary RBD 
in the Netherlands: the Rare Bleeding Disorders in the Netherlands (RBiN) study. All 
known patients with a RBD including in a Dutch Hemophilia Treatment Center (HTC), 
including those with $brinolytic disorders, were invited to participate in this study. 
Patients were recruited from all 6 Dutch HTCs: Expertise center for Hemophilia and 
Related Disorders (Leiden University Medical Centre & HAGA Hospital, !e Hague), 
Haemophilia Treatment Center Nijmegen – Eindhoven – Maastricht (HTC NEM: 
Radboud University Medical Centre, Maxima Medical Centre and Maastricht University 
Medical Center), Amsterdam University Medical Centers, University Medical Centre 
Groningen, van Creveldkliniek (University Medical Centre Utrecht), and Erasmus 
Medical Centre Rotterdam. Patients were included from October 2017 till November 
2019. !is study was approved by the Medical Ethical Committee of Arnhem – Nijmegen. 
All patients (and/or parents in the case of minors) provided written informed consent in 
accordance with the declaration of Helsinki.
Patient inclusion
!is study included patients aged 1 year or older. Patients with a congenital coagulation 
factor de$ciency were invited to participate if the speci$c coagulation factor activity level 
was below the lower limit of normal, or if there was a proven pathogenic heterozygous, 
compound heterozygous or homozygous variant in the gene encoding for a RBD factor 
de$ciency. Patients were diagnosed because of a bleeding tendency, family investigation, 
or abnormal laboratory values upon screening (eg, before surgery). HTC NEM is 
the only Dutch HTC that tests for PAI-1 de$ciency and hyper$brinolysis. To avoid 
overdiagnostics and false-positive results, laboratory tests for diagnosing a PAI-1 
de$ciency or hyper$brinolysis are performed only in case of an ISTH BAT ≥10, a positive 
family history of a $brinolysis disorder, or in patients with a typical $brinolytic bleeding 
pattern (ie, delayed bleeding a&er interventions and/or co-occurrence with obstetric 
failure).5,18 Patients with a PAI-1 de$ciency were eligible for inclusion if the PAI-1 activity 
level was below the detection limit and the PAI-1 antigen level was below the lower limit 
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of normal (reference range, 3.4-39 ng/ml). Patients with hyper$brinolysis were eligible if 
the euglobulin clot lysis time ratio before and a&er application of a tourniquet was ≥5.8 
(reference range 1.2-5.7, locally validated assay).
Assessment methods
Participating patients were asked to come to their HTC for a study visit, during which the 
ISTH BAT and RBD BAT were conducted and blood was drawn for laboratory testing.10,14 
!e number of patients identi$ed by the ISTH BAT and RBD BAT for the individual 
coagulation factor de$ciency was calculated by dividing the number of patients with a 
positive score on the speci$c BAT by the number of included patients for the total group 
and for children, women, and men separately. !e cuto% value for a positive or abnormal 
ISTH BAT score was ≥4 in adult men, ≥6 in adult women and ≥3 in children.10,19 
!e cuto% value for a positive or abnormal RBD BAT was ≥1.5 for men, women and 
children.14 All participating patients were interviewed about their clinical symptoms by 
1 investigator (J.L.S) to conduct the BATs and to avoid inconsistencies. Patients were 
divided into clinical bleeding severity categories (asymptomatic and grade 1, 2, or 3 
bleeding) based on previous research on RBD patients by Peyvandi et al. in the EN-RBD 
study.4 !is bleeding severity scale uses the most severe bleeding a patient has ever had. 
Category I refers to provoked bleeding episodes; category II refers to spontaneous minor 
bleeding episodes (eg, bruising); and category III refers to spontaneous major bleeding 
episodes (eg, cerebral bleeds or hemarthrosis). To determine whether the threshold levels 
to remain asymptomatic or free from grade 1, 2, or 3 bleeding are correct and may be 
used in clinical practice, patients were classi$ed as “correct” if they had no more severe 
bleeding than expected considering their baseline factor activity level. If they experienced 
more severe bleeding than predicted, they were classi$ed as “incorrect”. Data regarding 
the patients’ medical history, baseline factor activity levels, treatment plan, and use of 
other medications were extracted from electronic patient $les. Factor measurements 
were performed locally using 1-stage clotting assay. In addition, participants were asked 
to complete an extensive self-administered questionnaire that contained questions 
on their bleeding disorder, quality of life, and social aspects. !e results of laboratory 
measurements in the central laboratory and the results of the questionnaires will be 
analyzed separately.




Statistical analysis was performed using IBM SPSS Statistics 25. Values are reported 
as medians with interquartile range (IQR). Pearson’s correlation was used to correlate 
the ISTH BAT scores with the RBD BAT scores and to correlate the ISTH BAT with 
baseline factor activity levels. !e strength of the correlations was described using the 
following classi$cation: no correlation (0-0.29), weak correlation (0.30-0.59), moderate 
correlation (0.50-0.69), strong correlation (0.70-0.89) or very strong correlation (0.90-
1.0). McNemar’s test was used to compare the percentage of patients identi$ed by the 




A total of 263 patients were included from October 2017 to November 2019. Patient 
characteristics are provided in table 1. !e median age at time of inclusion was 38.5 
years (range, 1-87 years). Overall, 49% of included patients were adult women, 29% were 
adult men, and were 22% children between age 1 and 18 years. Bleeding scores were 
available for 202 patients (77%). !e genotype was known in 26% of patients. All patients 
with factor activity levels in the normal range had genetically con$rmed heterozygous 
pathogenic variants. Disorders of $brinolysis were relatively common, accounting for 
21% of included patients. Eight percent of patients were receiving prophylactic treatment, 
mainly those with an FXIII de$ciency or $brinogen de$ciency.
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Bleeding scores – ISTH BAT
!e overall median ISTH BAT score of the total group (n=202) was 9 (IQR, 5-15). 
!e median ISTH BAT score for adult female patients was 11 (IQR, 6.5-15.5), and for 
pediatric patients, the median score was 5 (IQR ,1-7). !e individual ISTH BAT scores 
per RBD are shown in $gure 1. !ere were large di%erences in the BAT scores for each 
RBD. !e highest median scores were seen in patients with FV and FXIII de$ciencies. 
Because scores were available for only two patients with FV Amsterdam (16 and 19), 
these are not shown in $gure 1. !e presence of speci$c bleeding symptoms in the ISTH 
BAT score per RBD are shown in $gure 2. !e number of patients with each symptom for 
the separate RBDs is shown in supplemental table 1. A symptom was scored as present 
if the patient had a score of 1 or more on the ISTH BAT for this item. Overall, the most 
common symptom was menorrhagia, occurring in 77% of all included women age 14 
years or older (n=119). All female patients with PAI-1 de$ciency (n=12), hyper$brinolysis 
(n=13), FXIII de$ciency (n=2) or combined FV+VIII de$ciency (n=1) had menorrhagia. 
Other prevalent symptoms were bleeding a&er surgery (76%), tooth extractions (65%), 
and postpartum hemorrhage (51%). !e least common symptoms were gastrointestinal 
bleeding (7%) and cerebral bleeding (7%), the latter mainly occurred in patients with an 
FXIII de$ciency (42%) or an FII de$ciency (15%). Muscle hematomas and hemarthrosis 
were also seen less o&en, except in patients with an FXIII de$ciency (58% and 50%, 
respectively).
Correlation between baseline coagulation factor activity level and ISTH 
BAT score
Figure 3 shows the correlation between baseline coagulation factor activity levels and the 
ISTH BAT score for each RBD. A strong correlation between baseline coagulation factor 
activity level and the ISTH BAT score was found for FII de$ciency (r=-0.792, p=.001) 
and FX de$ciency (r=-0.838, p=.162). A moderate correlation was found for $brinogen 
de$ciency (r=-0.583, p=0.001), FV de$ciency (r=-0.697, p<0.001), FVII de$ciency (r=-
0.515, p<0.01), FXIII de$ciency (r=-0.516, p=0.086), and α2-antiplasmin de$ciency (r=-
0.592, p=0.01). !ere was no correlation for FXI de$ciency (r=-0.218, p=0.238). PAI-1 
de$ciency and hyper$brinolysis were not quanti$able, so correlations could not be made 
for these disorders.
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ISTH BAT scores of patients included in the RBiN study. 
Black horizontal lines are medians
FIGURE 2. 
Percentage of patients with di&erent types of bleeding symptoms. 
A symptom was scored as being present if the patient had an ISTH BAT score on the item of ≥1. * patients 
who underwent a tooth extraction respectively surgery, ** adult female patients, ***female patients who 
underwent labor.




Correlation between baseline factor activity levels and ISTH BAT scores with linear regression 
lines. 
Panels show de"ciencies in (A) "brinogen de"ciency, (B) FII, (C) FV, (D) FVII, (E) FX, (F) FXI, (G) FXIII, and (H) 
a2-AP.
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Correlation and comparison of the ISTH BAT and RBD BAT.
(A) Correlation between ISTH BAT score and RBD BAT scores with linear regression line. (B) Comparison of 
the percentage of identi"ed patients (all patients, children younger than 18 years old, adult women aged 18 
years or older, and adult men aged 18 years or older) by the ISTH BAT and RBD BAT. *statistically signi"cant 
di&erence.
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Bleeding scores – RBD BAT
!e median RBD BAT score for the total group (n=202) was 3.36 (IQR, 2.00-4.895), for 
adult female adult patients, 3.98 (IQR, 2.60-5.265) and for pediatric patients, 3.30 (IQR, 
2.79-4.10). !e individual RBD BAT scores per RBD are shown in supplemental $gure 1. 
Figure 4A shows the correlation between the ISTH BAT and RBD BAT scores. !ere was 
a correlation of 0.692 between the 2 BATs (p<.001). !e sensitivities for both bleeding 
scores are shown in $gure 4B for the entire RBD group and separately for children, 
women, and men. No di%erence could be found between the RBD BAT vs the ISTH BAT 
(84% vs 80%, p=.291).However, the RBD BAT was able to identify more women (94% vs 
83%, p<.01) and children (100% vs 71%, p<.01), whereas the ISTH BAT identi$ed more 
men (79% vs 57%, p<.01). !e correlations between baseline coagulation factor activity 
levels and the RBD BAT were less pronounced than the correlations with the ISTH BAT 
(supplemental $gure 2).
Bleeding severity grade and validation of threshold factor activity levels
!e distribution of bleeding severity per RBD is shown in $gure 5A. In total, 16 patients 
(8%) were classi$ed as asymptomatic. Grades 1, 2, and 3 bleeding were noted in 26 
(13%), 122 (60%) and 38 (19%) patients respectively. Patients with FXIII de$ciency had 
the highest proportion of grade III bleedings (75%). !ere was a correlation between 
the ISTH BAT and the bleeding severity grade, but there was a wide spread in all of 
the bleeding categories except for the asymptomatic patients (supplemental $gure 3). 
Figure 5B shows the predicted bleeding grade of a patient calculated from his or her 
individual factor activity level results, using previously determined threshold levels per 
RBD.4 Overall, 48% of patients had more severe bleeding than predicted, based on their 
baseline factor activity level. Over the whole group, 34% of patients were predicted to 
be asymptomatic, but they actually had grade 2 (31%) or 3 (3%) bleeding (not shown in 
$gure 5B). !e greatest discrepancies were observed for FV de$ciency (57% incorrect), 
FVII de$ciency (57% incorrect), and FXI de$ciency (59% incorrect).
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(A) Clinical bleeding severity of patients with an RBD. (B) Patients with more severe bleeding then expected, 
taking into account previously determined baseline factor activity levels.




!e RBiN study is the $rst study in which clinical data of Dutch RBD patients are 
described. In all, the study population had 263 patients with a wide variety of baseline 
factor activity levels and included both homozygous and heterozygous patients. !e 
bleeding severity revealed that the Dutch RBD population showed a more severe bleeding 
pattern than the previously described European RBD population.4,20 More importantly, 
these RBiN patients o&en showed more severe bleeding than was predicted for their 
baseline factor activity levels.
!ere was considerable heterogeneity in the bleeding phenotype between di%erent 
RBDs. !is can be explained by the speci$c bleeding phenotype of the RBD as well as the 
heterogeneous population included in this study, which ranged from young children to 
adults and from severe homozygous de$ciencies to mild heterozygous de$ciencies. !e 
large variety in clinical phenotype within 1 RBD can be explained by the poor correlation 
between baseline factor activity levels and bleeding phenotype. For clinical practice, 
it remains important to always consider the speci$c disorder of an individual patient. 
In general, the ISTH BAT score of patients with an RBD was mainly dominated by the 
following types of bleeding: bleeding a&er surgery, a&er tooth extractions, a&er labor, 
and with menorrhagia. !is is o&en described as a relatively mild bleeding phenotype 
when compared with hemophilia.2 Because clinical studies of hereditary bleeding 
disorders historically have focused on patients with hemophilia, knowledge on female-
speci$c bleeding is less developed and may be underestimated. !e high occurrence of 
menorrhagia (77% of the female patients age older than 14 years) found in this study is 
similar to that in women with VWD (73%) but higher than in carriers of hemophilia A 
(50%-64%).12,21-23 Fi&y-one percent of women in this study who underwent labor had a 
postpartum hemorrhage (PPH). As shown in $gure 2, PPH was especially common in 
patients with FXI de$ciency (70%; n=10), hyper$brinolysis (70%; n=8), FVII de$ciency 
(63%; n=8) and FV+VIII de$ciency (100%; n=1). None of the women with FXIII 
de$ciency in this study had experienced labor, so the prevalence of PPH could not be 
calculated for this RBD. In women with VWD and carriers of hemophilia, deliveries 
are complicated with PPH in 34%.24 More recently, slightly lower prevalences of PPH in 
carriers of hemophilia have been reported (24%-30%).12,23 However, the results observed 
in this study are di'cult to interpret, because PPH was de$ned by the speci$c ISTH BAT 
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item, not by actual blood loss in the electronic medical record because these data were 
not available. Nevertheless, the number of women scoring on this individual item is high, 
and alertness on this topic is warranted.
!e highest median ISTH BAT scores were found in patients with FV de$ciency (16), 
FXIII de$ciency (15), PAI-1 de$ciency (12), and hyper$brinolysis (12). Although it was 
expected for patients with FXIII de$ciency, their ISTH BAT scores may be underestimated 
because 86% of patients with a FXIII de$ciency were receiving prophylaxis.25 !e high 
number of patients with FXIII de$ciency who experienced grade 3 bleeding can be 
explained by the fact that most of these patients had a baseline factor activity level of 0. 
!e higher BAT scores in FV de$ciency, known to be a mild bleeding disorder, might be 
explained by the relatively low baseline factor activity levels of the included patients in 
this study (table 1).4 !e absence of a speci$c FV concentration to ensure prophylactic 
treatment for these patients may further increase their BAT scores. In addition, platelet 
FV levels were not available, so possibly patients in this study had relatively low FV in 
their platelets as well.26 !e mild bleeding phenotype of FV de$ciency is thought to be 
(partly) caused by the low TFPI levels in these patients because TFPI binds to FV.27 !e 
hypothesis regarding the in/uence of TFPI levels on the bleeding tendency is reinforced 
by two patients in this study with FV Amsterdam. With normal FV activity levels, they 
had very high TFPI levels, resulting in ISTH BAT scores of 16 and 19. Possibly, patients 
with FV de$ciency in this study had relatively normal levels or activity of TFPI, which 
would cause the higher bleeding tendency. TFPI levels will be measured in the speci$c 
RBiN population (results are outside of the scope of this study). !e high ISTH BAT scores 
in patients with a PAI-1 de$ciency and hyper$brinolysis are possibly an overestimation 
because of an inclusion bias; people with low ISTH BAT scores and without another 
speci$c indication of a $brinolytic disorder did not undergo laboratory testing for these 
disorders. !e relatively high number of patients with a $brinolysis disorder (23 with 
α2-antiplasmin de$ciency, 14 with a PAI-1 de$ciency, and 14 with hyper$brinolysis) and 
their high median ISTH BAT scores (7, 12, and 12, respectively) illustrate the importance 
of performing additional assays for $brinolysis to diagnose these disorders. In addition, it 
is noteworthy that all patients with PAI-1 de$ciency or hyper$brinolysis and the majority 
of patients with α2-AP de$ciency had at least grade 2 bleeding, meaning they experienced 
spontaneous bleeding and not only a&er interventions.
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For all RBDs, the absence of a good correlation between coagulation factor activity 
levels and clinical phenotype indicates that there are other essential variables contributing 
to the clinical bleeding phenotype. In previous studies, a strong correlation between 
coagulation factor activity level and clinical phenotype was found for de$ciencies of 
$brinogen, FV+FVIII, FX, and FXIII.4 In this study, the strongest correlations were 
found in patients with FII or FX de$ciencies. Only a small number of patients with an FX 
de$ciency were included in the RBiN study, which may explain the lack of a signi$cant 
correlation between coagulation factor activity level and clinical phenotype. !e fact that 
only a moderate correlation was found for $brinogen de$ciency in this study suggests 
that the initial correlation found for this de$ciency may not be as strong as previously 
reported. !e lack of an association for FXI de$ciency is consistent with the study 
byPeyvandi et al.4 Most likely, the balance of all coagulant and anticoagulant factors will 
determine the bleeding severity. !is study is the $rst to describe a correlation between 
α2-AP and bleeding severity and showed a moderate correlation. Global hemostasis assays 
such as thrombin generation, could contribute to the determination of an individualized 
bleeding phenotype. !is is an interesting topic for further research.
!e patients in this study had a more severe bleeding phenotype than patients in 
previous European studies.4,20 !e patient population in this study possibly had more 
severe factor de$ciencies compared with patients in those studies. Another explanation 
might be that the methodologies of the studies was di%erent: all of the patients in 
the RBiN study were all interviewed by the investigator, but the EN-RBD study used 
electronical medical records to assess bleeding severity. !e previously determined factor 
activity levels to remain free from di%erent bleeding severity grades were incorrect in 
48% of the patients included in this study. !is can be partly explained by the higher 
number of patients in this study su%ering from grade 2 or 3 bleeding compared with 
the EN-RBD study, which determined the threshold levels.4 !e only RBD with a 
good prediction of bleeding severity in this study was FXIII de$ciency, with only 8% 
of patients having bleeding more severe than predicted. However, because patients with 
FXIII de$ciency in this study almost exclusively had very low factor activity levels, more 
data are necessary on heterozygous patients to determine whether the threshold levels 
are accurate. Overall, these results highlight the importance of obtaining a complete 
overview of an individual patients’ coagulation status. Given the fact that for most RBDs, 
correlations between factor activity levels and clinical bleeding severity are not strong, it 
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is probably impossible to obtain better threshold levels than the ones used at the moment. 
Although these threshold levels to remain free from bleeding are o&en used in clinical 
practice, they should be interpreted with caution and not seen as de$nite cut o% levels 
for an individual patient with a bleeding tendency, which was also shown by the wide 
con$dence intervals in the original study.4 Caution is especially warranted concerning 
patients with FV de$ciency, FVII, and FXI de$ciencies.
!e number of RBD patients identi$ed by the RBD BAT was higher than for the ISTH 
BAT for women and children, and the ISTH BAT identi$ed more men. !e RBD BAT 
corrects for age and sex in the questionnaire, but the ISTH BAT does not correct for age; 
it does, however, correct for sex by a lower cuto% value for men than for women. !ese 
results suggest that a correction for age in the RBD BAT helps diagnose RBDs in the 
pediatric RBD patient population. !e correction for sex seems to be better in the RBD 
BAT for women, but there is an underestimation of the RBD BAT in men. !erefore, 
the correction factor appears to be inaccurate in the male patient population. !ese 
corrections for gender and age can be useful for the diagnosing other bleeding disorders 
as well. To conclude that the RBD BAT is a better diagnostic tool, it will be necessary to 
use a healthy control group as a negative control in future studies.
A limitation of this study is the small number of patients per bleeding disorder, 
which is inherent in research on rare disorders at a nationwide level. In the future, it 
would be bene$cial to cooperate at an international level, which would help enlarge the 
patient group. In addition, there may be local di%erences per HTC in the diagnostics of 
RBDs. However, the inclusion of all diagnosed patients was done to give an overview 
as complete as possible, and because all patients were diagnosed in an HTC, they were 
diagnosed by experts in the $eld. Despite the limited number of patients per RBD in 
our study population, our study has several signi$cant implications. For the $rst time, 
patients with a $brinolytic disorder were included, and they had high bleeding scores. 
Another of our study’s strong points is that it reports real-life data. In addition, although 
most studies only include symptomatic patients as they have been diagnosed because of 
a bleeding phenotype, this study also included known heterozygous family members as 
well as patients diagnosed as a result of abnormalities on coagulation screening before 
surgery. However, as in all studies on patients with bleeding disorders, there is still likely 
to be an underestimation of the number of asymptomatic patients, because they are less 
likely to be diagnosed with a bleeding disorder.
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In conclusion, the RBiN study reports real life data and con$rmed the heterogenous 
bleeding tendency of patients with RBDs. Overall, correlations between baseline factor 
activity levels and clinical bleeding severity are poor, which is illustrative of RBDs. 
Bleeding was more severe in this patient population than the previously described 
European RBD population. !is di%erence persisted even when taking into account only 
patients with rare coagulation factor de$ciencies, because disorders of $brinolysis were 
not included in the previous study. !reshold levels to remain free from bleeding may not 
be reliable in this patient population and should be interpreted with caution.
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SUPPLEMENTAL FIGURE 2. 
Correlation between baseline factor activity levels and RBD BAT scores with linear regression 
lines. 
Panels show de"ciencies in (A) "brinogen de"ciency, (B) FII, (C) FV, (D) FVII, (E) FX, (F) FXI, (G) FXIII, and (H) 
a2-AP.
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SUPPLEMENTAL FIGURE 1. 
RBD BAT scores of patients included in the RBiN study.
Black lines are medians.
SUPPLEMENTAL FIGURE 3. 
Correlation between the ISTH BAT and bleeding severity scale.
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Background: In recent years, more awareness is raised about sex-speci$c dilemmas 
in inherited bleeding disorders. However, no large studies have been performed to 
assess di%erences in diagnosis, bleeding phenotype and management of men and 
women with bleeding disorders. !erefore, we investigated sex di%erences in a large 
cohort of well-de$ned patients with autosomal inherited bleeding disorders (von 
Willebrand disease (VWD), rare bleeding disorders (RBDs) and congenital platelet 
defects (CPDs)).
Methods: We included patients from three nationwide cross-sectional studies on 
VWD, RBDs and CPDs in the Netherlands, respectively the WiN, RBiN and TiN 
study. In all studies a bleeding score (BS) was obtained, and patients $lled in an 
extensive questionnaire on the management and burden of their disorder.
Findings: We included 1092 patients (834 VWD; 196 RBD; 62 CPD), of whom 
665 (60.9%) were women. Women were more o&en referred because of a bleeding 
diathesis than men (47.9% vs 36.6%, p=0.002). Age of $rst bleeding was similar 
between men and women, respectively 8.9 ±13.6 (mean ±sd) years and 10.6 ±11.3 
years (p=0.075). However, the diagnostic delay, which was de$ned as time from $rst 
bleeding to diagnosis, was longer in women (11.6 ±16.4 years) than men (7.7 ±16.6 
years, p=0.002). Similar results were found when patients referred for bleeding were 
analyzed separately. Of women aging 12 years or older, 469 (77.1%) had received 
treatment because of sex-speci$c bleeding.
Interpretation: Women with autosomal inherited bleeding disorders are more o&en 
referred for bleeding, have a longer diagnostic delay, and o&en require treatment 
because of sex-speci$c bleeding.
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Evidence before this study
• In recent years, more awareness is raised about sex-speci$c dilemmas in inherited 
bleeding disorders. 
• Heavy menstrual bleeding is o&en a presenting symptom of a bleeding disorder.
• We have previously reported that 81% of all women with von Willebrand disease 
experienced menorrhagia, whereas over 50% of women experienced bleeding 
complications a&er childbirth or pregnancy loss. 
Added value of this study
• !is is the $rst study to investigate sex di%erences in a large cohort of well-de$ned 
patients with di%erent types of autosomal inherited bleeding disorders. 
• Women are more o&en referred to the hospital because of bleeding episodes, and 
more o&en require treatment because of sex-speci$c bleeding compared to men. 
• Although the age of $rst bleeding was similar between men and women with 
autosomal inherited bleeding disorders, the diagnostic delay was on average 6 years 
longer in women.
Implications of all the available evidence
• !ere are important di%erences in presentation, diagnosis and management of men 
and women with autosomal inherited bleeding disorders.
• When the diagnosis of a bleeding disorder is delayed, women are at risk for not 
receiving appropriate treatment in case of bleeding or prophylaxis for surgery, dental 
procedures or during child delivery.
• Physicians should be more aware of bleeding disorders in women who present 
with a personal bleeding diathesis, and should investigate them earlier for bleeding 
disorders.
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Most studies on hereditary bleeding disorders have historically focused on hemophilia A 
and B, both X-linked disorders mainly a%ecting men. !e vast majority of other bleeding 
disorders are autosomal inherited, and therefore sex di%erences may have an important 
impact on diagnosis, clinical characteristics and management of patients.
Autosomal inherited bleeding disorders predominantly consist of patients with von 
Willebrand disease (VWD), followed by patients with a rare hereditary bleeding disorder 
(RBD) which encompass a heterogeneous group of rare coagulation factor de$ciencies 
and disorders of the $brinolytic system. Lastly, hereditary platelet disorders (CPDs) are 
autosomal inherited bleeding disorders of primary hemostasis, a%ecting both men and 
women.
VWD, the most common inherited bleeding disorder, is characterized by 
mucocutaneous bleeding such as heavy menstrual bleeding (HMB), epistaxis and 
gum bleeds.1 VWD is divided into three types, based on the quantitative or qualitative 
defect of von Willebrand factor (VWF).1 Type 1 VWD, which accounts for 70-80% of 
VWD patients, is characterized by quantitatively reduced VWF levels.2 Type 2 VWD, 
which a%ects about 20% of VWD patients, is characterized by an abnormal function of 
VWF. Type 3 VWD, the most severe form of VWD, a%ecting less than 5% of patients, is 
characterized by the absence of VWF.1, 3 Type 1 and 2 VWD usually have an autosomal 
dominant inheritance pattern, whereas type 3 VWD is an autosomal recessive disorder.
RBDs are most o&en inherited as autosomal recessive disorders, except for 
dys$brinogenemia and some cases of FXI de$ciency, which are inherited autosomal 
dominant.4 Rare coagulation factor de$ciencies refer to de$ciencies of $brinogen, factor 
(F) II, FV, combined FV&FVIII, FVII, FX, FXI and FXIII. Patients with a rare coagulation 
factor de$ciency have a diverse clinical presentation. In addition, there is a poor correlation 
between factor activity levels and bleeding phenotype.5 Disorders of $brinolysis consist of 
de$ciencies of plasminogen activator inhibitor type 1 or α2-antiplasmin, or unspeci$ed 
hyper$brinolysis. !e bleeding phenotype of patients with a disorder of $brinolysis is 
characterized by delayed bleeding a&er trauma and interventions and bleeding in tissues 
with high $brinolytic activity, such as HMB and epistaxis.6
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CPDs are disorders of primary hemostasis caused by defects in adhesion, activation, 
secretion, or aggregation of platelets.7 Patients typically present with mucocutaneous 
bleeds or persistent bleeding following a hemostatic challenge such as dental extraction, 
invasive procedures or childbirth.8
Although the autosomal inheritance pattern of these bleeding disorders should lead 
to an equal distribution amongst men and women, di%erences in prevalence have been 
reported.1, 9, 10 Moreover, increasingly more awareness is raised in recent years about 
sex-speci$c problems in patients with inherited bleeding disorders due to menstruation 
and delivery as physiologic hemostatic challenges in women.11, 12 To our knowledge, 
no comprehensive studies have been conducted yet to investigate sex di%erences in 
symptoms, diagnosis and management of patients with autosomal inherited bleeding 
disorders.
!erefore, we investigated sex-speci$c di%erences in clinical phenotype, diagnosis 
and management of men and women with autosomal inherited bleeding disorders in a 
large cohort of well-de$ned patients with VWD, RBDs and CPDs from three nationwide 
cross-sectional studies in the Netherlands.
METHODS
Nationwide studies on VWD, RBD and CPD patients
For this study, we included patients from three nationwide cross-sectional studies on VWD, 
RBDs and CPDs in the Netherlands, respectively the Willebrand in Netherlands (WiN) 
study, Rare Bleeding disorders in Netherlands (RBiN) study, and !rombocytopathy in 
the Netherlands (TiN) study. !e WiN study was performed between 2007 and 2009 
and included 834 VWD patients.13, 14 !e RBiN study was performed between 2017 and 
2019 and included 263 patients with RBDs.15 !e TiN study was performed between 2016 
and 2018 and included 62 patients with con$rmed CPDs.16 !ese three studies included 
patients from all Hemophilia Treatment Centers in the Netherlands. All studies were 
performed according to the Declaration of Helsinki and approved by the Medical Ethical 
Committees of all participating centers. All participants signed informed consent. !is 
manuscript was written in adherence to the STROBE guidelines.
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!e inclusion criteria for the WiN study were hemorrhagic symptoms or a family history 
of VWD, and historically lowest VWF antigen level (VWF:Ag) and/or VWF activity 
(VWF:Ab) and/or VWF collagen binding activity (VWF:CB) ≤ 0.30 IU/mL and/or 
factor VIII activity (FVIII:C) ≤ 0.40 IU/mL (for type 2N VWD).13, 17, 18 Type 1 VWD was 
categorized as VWF:Ab/VWF:Ag ratio >0.6, whereas type 2 VWD was categorized as 
VWF:Ab/VWF:Ag ratio ≤0.6.3 Type 3 VWD was de$ned as VWF activity and antigen 
levels ≤0.05 IU/mL and VWF propeptide ≤0.05 U/mL.3 !e inclusion criteria for the 
RBiN study were a coagulation factor level below the lower limit of normal, and/or a 
proven heterozygous, compound heterozygous or homozygous mutation for the rare 
coagulation factor de$ciencies and α2-antiplasmin de$ciency. Patients with a PAI-1 
de$ciency were eligible for inclusion if the PAI-1 activity was below the detection limit 
of the assay and the PAI-1 antigen level was below the lower limit of normal (reference 
range 3.4-39 ng/ml). Patients with hyper$brinolysis were eligible if the euglobulin clot 
lysis ratio before and a&er application of a tourniquet was ≥5.8 (reference range 1.2-5.7, 
locally validated assay). From the TiN study, we included patients with a con$rmed CPD: 
Bernard Soulier Syndrome, Glanzmann thrombasthenia, Adenosine diphosphate (ADP) 
pathway defect, !romboxane A2 (TxA2) pathway defect and dense granule de$ciency.16
Assessment methods
At inclusion in the studies, patients $lled in an extensive questionnaire containing 
questions on age of $rst bleeding and treatment, reason for referral, age of diagnosis 
and bleeding requiring hemostatic treatment in the year prior to inclusion in the study. 
Additionally, in the WiN study a self-administered Tosetto bleeding score (BS) was 
obtained, whereas in the RBiN and TIN studies the ISTH-BAT was obtained by the 
investigator.15, 19, 20 We have previously shown that the self-administered BS obtained in the 
WiN study was comparable to the investigator obtained BS.14 Lastly, blood samples were 
drawn to measure relevant coagulation factor levels in a central laboratory for each of the 
studies.13, 15, 18, 21, 22 Laboratory measurements have been described in detail previously.13-16




Diagnostic delay was de$ned as age of diagnosis minus age of $rst bleeding. To make a 
better comparison between men and women, sex-speci$c bleeding was excluded from 
BS. In VWD, BS without sex-speci$c bleeding was de$ned as total BS minus the BS item 
for HMB, postpartum hemorrhage (PPH) and circumcision. In patients with RBDs and 
CPDs, BS without sex-speci$c bleeding was de$ned as the ISTH-BAT minus BS items 
for HMB, PPH, ovulation bleeding and bleeding during circumcision.19 !ese de$nitions 
di%er due to the fact that in the Tosetto BS, ovulation bleeding is not an individual item.
[20] To determine the proportion of women experiencing HMB, only women ≥12 years 
of age were taken into account. For PPH, only women who had at least one delivery were 
taken into account. Both these symptoms were scored as ‘present’ in case the speci$c BS 
item was scored ≥1. For the current bleeding phenotype, the patients reported bleeding 
requiring treatment in the year prior to inclusion in the study in the questionnaires. 
Lastly, type 2 and type 3 VWD, RBDs with factor activity below 0.10 IU/mL, Glanzmann 
thrombasthenia and Bernard Soulier Syndrome were de$ned as severe bleeding disorders.
Statistical analysis
Continuous data are presented as mean ±standard deviation, whereas categorical data 
are presented as frequency and proportion (%). Normality of data was assessed visually. 
Missing data were not imputed.
An independent t-test was used to investigate a di%erence in continuous variables 
between two groups, whereas ANOVA test was used to investigate a di%erence between 
three groups or more. Continuous data were adjusted for relevant confounders using 
linear regression analysis. Di%erence in diagnostic delay between men and women was 
adjusted for type of disease and BS without sex-speci$c bleeding. Outcomes of linear 
regression analyses are presented as unstandardized β and 95% con$dence interval (CI). 
Categorical data were compared between two or more groups using a chi-square test. 
!ese outcomes were adjusted for type of disease and BS without sex-speci$c bleeding 
using logistic regression analysis. Outcomes of logistic regression analyses are presented 
as odds ratio (OR) and 95% CI. 
Time to $rst bleeding, time to diagnosis and time from $rst bleeding until diagnosis 
were compared between men and women with Kaplan-Meier Curves. Based on the event-
curves, we used the log-rank test to compare the time to $rst bleeding between men 
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and women, whereas the Breslow test was used to compare time to diagnosis and time 
from $rst bleeding until diagnosis between men and women. A p-value below 0.05 was 
considered to be statistically signi$cant. All analyses were performed with SPSS version 
25 (IBM Corp., Armonk, NY, USA).
Role of funding source
!e funders did not have any role in design of the study, in data collection, in statistical 
analysis, in the interpretation of data or in writing of the manuscript. !e authors were 
fully responsible for all aspects of this research.
RESULTS
We included 1092 patients with VWD (n=834), RBDs (n=196) and CPDs (n=62) in this 
study, of whom 665 (60.9%) were women (table 1). Men were slightly younger at inclusion 
in the studies compared to women, respectively 37.1 years ±21.8 vs 41.2 years ±18.2 
(p=0.002, table 1). !e baseline characteristics of the total population are presented in 
table 1, whereas the characteristics for each disorder including laboratory measurements 
are presented in supplemental table 1.
TABLE 1. 






Age at inclusion, years 37.1 ±21.8 41.2 ±18.9 0.002
Age "rst bleeding, years 8.9 ±13.6 10.6 ±11.3 0.075
Age at diagnosis, years 16.6 ±19.6 22.5 ±18.4 <0.001
Diagnostic delay, years 7.7 ±16.6 11.6 ±16.4 0.002
Referred for bleeding, n (%) 145/396 (36.6%) 296/618 (47.9%) 0.002
BS 9.7 ±6.9 11.6 ±7.2 <0.001
Abnormal BS 341 (84.2%) 495 (80.6%) 0.145
BS without sex-speci"c bleeding 9.6 ±6.9 8.8 ±6.0 0.036
Bleeding requiring treatment in year 
prior to inclusion, n (%)
153/399 (38.3%) 215/623 (34.5%) 0.213
Data are presented as mean ±standard deviation unless otherwise speci"ed. BS bleeding score. Abnormal BS 
is de"ned as ≥3 in children, ≥4 in males and ≥6 in females.




Of the 1014 patients in whom the reason for referral was known, the most common reason 
was a positive family history in 510 patients (50.3%), followed by a personal bleeding 
tendency in 441 patients (43.5%) and other reasons (mostly prolonged prothrombin time 
(PT), activated partial thromboplastin time (APTT) or platelet function analyzer (PFA) at 
pre-operative screening) in 63 patients (6.2%). Overall, women were more o&en referred 
because of bleeding symptoms than men, respectively 296 of 618 women (47.9%) vs 145 
of 396 men (36.6%) (p=0.002) ($gure 1). Men were more frequently referred because of a 
family history of bleeding disorders ($gure 1).
In 399 patients diagnosed with a severe bleeding disorder (i.e. type 2 and type 3 VWD, 
RBDs with factor activity below 0.10 IU/mL, Glanzmann thrombasthenia and Bernard 
Soulier Syndrome) of which 192 (48.1%) were men and 207 (51.9%) women, there was no 
di%erence in the reason for referral between men and women (p=0.215). 
FIGURE 1. 
Reason for referral in men and women with autosomal inherited bleeding disorders. 
*p<0.05 between men and women. VWD von Willebrand Disease, RCD Rare coagulation factor de"ciencies, 
DF Disorders of "brinolysis, CPD congenital platelet defects.
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Age of "rst bleeding and diagnosis 
Overall, age of $rst bleeding was 8.9 ±13.6 years in men and 10.6 ±11.3 years in women 
(p=0.075), whereas age of diagnosis was 16.6 ±19.6 years in men, and 22.5 ±18.4 years in 
women (p<0.001, table 1). !erefore, the diagnostic delay (i.e. time from $rst bleeding 
until diagnosis) was markedly longer in women than in men, respectively 11.6 ±16.4 
years vs 7.7 ±16.6 years (p=0.002). !is di%erence persisted a&er adjustment for type 
of disease and BS minus sex-speci$c bleeding with a di%erence of β=3.6 (1.1; 6.1) years.
!e age of $rst bleeding was not di%erent between patients who were referred because 
of a positive family history and patients referred because of bleeding, respectively 8.7 
±11.9 years vs 10.2 ±11.8 years, p=0.108. Nevertheless, there was a major di%erence in age 
of diagnosis between patients referred because of a positive family history and patients 
referred because of bleeding, respectively 15.7 ±17.8 years vs 24.0 ±18.7 years, p<0.001. 
In patients referred for bleeding, age of $rst bleeding was similar between men and 
women ($gure 2A, p=0.179), which was on average 9.4 ±13.0 years in men and 10.7 ±11.1 
years in women (p=0.303). Nevertheless, men were at a much younger age diagnosed 
than women, especially in childhood ($gure 2B, p<0.001). !e average age of diagnosis 
was 19.4 ±20.0 years in men and 26.3 ±17.7 years in women (p=0.001). !e diagnostic 
delay in patients referred for bleeding was longer in women ($gure 2C, p=0.003). Half 
of all men referred for bleeding were diagnosed within 2.0 (0.8-3.2) years a&er their $rst 
bleeding, whereas in women this was a&er 14.0 (10.4-17.6) years ($gure 2C). !e average 
diagnostic delay was 9.1 ±17.5 years in men and 14.5 ±16.5 years in women (p=0.006). 
A&er adjustment for type of disease and BS minus sex-speci$c bleeding, the average 
diagnostic delay was still longer in women compared to men with a di%erence of β=5.8 
(1.9; 9.7) years. Even in patients with severe bleeding disorders referred for bleeding 
(n=134), the diagnostic delay was longer in women (10.0 ±15.4 years) than in men (4.3 
±14.7 years), p=0.048.
Bleeding during life time
!e BS, which gives an indication of the severity of bleeding episodes during life time, was 
lower in men (9.7 ±6.9) compared to women (11.6 ±7.2, p<0.001, $gure 3A). However, 
a&er exclusion of sex-speci$c bleeding, BS was higher in men than in women, respectively 
9.6 ±6.8 vs 8.8 ±6.0, p=0.036 ($gure 3B). A&er adjustment for age and type of disease, BS 
minus sex-speci$c bleeding was still higher in men compared to women with a di%erence 
of β=1.2 (0.4; 1.9) points.




(A) Time to "rst bleeding, (B) time to diagnosis and (C) diagnostic delay in patients referred for 
bleeding. 
Data presented as outcomes of Kaplan-Meier curves. (A) Log-rank test was used to compare the time to "rst 
bleeding between men and women, whereas Breslow test was used to compare (B) time to diagnosis and (C) 
time from "rst bleeding until diagnosis between men and women. No at risk numbers at risk.
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Bleeding phenotype of men and women with autosomal inherited bleeding disorders. 
(A) In the total population, BS was higher women than men, whereas (B) BS minus sex speci"c bleeding was 
higher in men than women. (C) No di&erence was found in percentage of patients with bleeding requiring 
treatment in the year prior to inclusion in the study between men and women. *p<0.05 between men and 
women. VWD von Willebrand Disease, RCD Rare coagulation factor de"ciencies, DF Disorders of "brinolysis, 
CPD congenital platelet defects.
Rare bleeding disorders: diagnostic strategies and clinical features
142
6
Current bleeding phenotype (bleeding symptoms in the year prior to 
inclusion)
Overall, 153 of 399 (38.3%) men and 215 of 623 (34.5%) women had a bleeding episode 
requiring hemostatic treatment in the year prior to inclusion in the study (p=0.213) ($gure 
3C). In adult patients, there was no di%erence in bleeding requiring treatment in the year 
prior to inclusion between men and women, respectively 112 (36.8%) vs 190 (35.1%) 
(p=0.616). In children (<18 years), boys seemed to have more o&en bleeding requiring 
treatment in the year prior to inclusion compared to girls, although not statistically 
signi$cant, respectively 41 boys (43.2%) vs 24 girls (29.6%) (p=0.064). A&er adjustment 
for age and type of disease, boys seemed to have almost a two times higher chance for 
bleeding requiring treatment in the year prior to inclusion in the study compared to girls: 
OR=1.9 (1.0; 3.6).
Sex-speci"c bleeding and management
HMB was the most common bleeding symptom in women with a prevalence of 81.7% 
(497 of 608 ) in women aging 12 years or older. Four hundred-thirty-six women (71.5%) 
had been treated because of HMB. Ninety-$ve women (16.7%) had undergone an 
endometrial ablation or curettage, whereas 66 (11.6%) had undergone a hysterectomy 
because of HMB. A comparable number of women had used desmopressin, factor 
concentrates or needed blood transfusion because of HMB, respectively 38 (6.7%), 34 
(6.0%) and 40 (7.0%) women. Lastly, 236 women (41.5%) had received iron supplements 
because of iron de$ciency due to HMB.
Of 409 women who had at least one delivery, 204 women (49.9%) reported to have 
had PPH and 180 (43.8%) had been treated because of PPH. A large proportion of women 
who had a delivery received a blood transfusion: 79 (20.4%). Additional uterotonic 
medication, factor concentrates and desmopressin were given in respectively 60 (15.5%), 
54 (14.0%) and 16 (4.1%) women with PPH. Four women had to undergo a hysterectomy 
and $ve women were treated with anti$brinolytics because of PPH.
Overall, of all women aging 12 years or older, 469 (77.1%) women had received 
treatment because of sex-speci$c bleeding, such as HMB and PPH.
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In this large combined nationwide study of patients with autosomal inherited bleedings 
disorders including VWD, RBD and CPD patients, we found major sex di%erences in 
the clinical phenotype of patients. Firstly, women were more o&en referred for bleeding, 
whereas men were referred more o&en because of a positive family history. Secondly, 
the diagnostic delay, de$ned as time between $rst bleeding and diagnosis of bleeding 
disorder, was longer in women than in men, irrespective of the type of bleeding disorder 
and severity of the bleeding phenotype. !irdly, due to sex-speci$c bleeding (HMB and 
PPH), women had a higher BS than men. However, when sex-speci$c bleeding symptoms 
were excluded, men had a more severe bleeding phenotype. In children, boys more o&en 
had a bleeding requiring treatment in the year prior to inclusion in the study than girls, 
whereas in adults there was no di%erence between men and women.
Remarkably, the diagnostic delay was longer in women with bleeding disorders than 
in men, independent of the type of bleeding disorder and severity of bleeding phenotype. 
!is is probably because women may have less o&en traumatic bleeding episodes at early 
childhood than men. Men may present more o&en with spontaneous or traumatic bleeding 
at a younger age, and since these bleeding are not physiologic, they may be investigated 
early to diagnose or to rule out an underlying bleeding disorder. In accordance, it has 
previously been shown in the WiN study that boys with VWD are overrepresented at 
childhood compared to girls with VWD (60% vs 40%), whereas in adults women are 
overrepresented (64% women vs 36% men).14, 23 A recent study in children with VWD 
also found that boys were diagnosed at a younger age and had their $rst bleed at a 
younger age than girls with VWD.24 !is study also found that boys with VWD more 
o&en had a bleeding and more treatment product use than girls with VWD.24 Similarly, 
in our current study, in the total group of autosomal inherited bleeding disorders, boys 
seemed to have an almost two times higher chance of bleeding requiring treatment in 
the year prior to inclusion than girls. !is is probably due to the fact that boys are more 
physically active and participate more o&en in sports with a higher chance of bleeding, 
as previously shown in VWD patients.25-27 Women on the other hand, may present more 
o&en with HMB as the $rst symptom of their bleeding disorder. Since oral contraceptive 
therapy is o&en used as initial and e%ective treatment to alleviate menstrual blood loss, 
this presenting symptom may not be recognized as a $rst sign of a bleeding disorder, and 
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therefore no laboratory investigation will be performed. About two decades ago, Ragni et 
al investigated 38 women with type 1 VWD and Kirtava et al investigated 75 type 1 VWD 
women, and found a diagnostic delay of respectively 4 and 16 years in their studies.28, 29 
In both studies, most women presented with HMB as $rst bleeding symptom.28, 29 Other 
studies have also shown that HMB is o&en a presenting symptom of a bleeding disorder.11, 
30, 31 In addition, physicians may consider the presence of a bleeding disorder more o&en 
in boys than girls, because hemophilia A and B, the most known bleeding disorders, 
mainly a%ect men. Another explanation for the longer diagnostic delay in women is that 
women with a mild bleeding phenotype are due to menstruation and delivery exposed to 
physiologic hemostatic challenges throughout life, and can therefore be diagnosed with 
a bleeding disorder. Men with a mild bleeding phenotype on the other hand, do not have 
physiologic hemostatic challenges, and may therefore never be diagnosed with a bleeding 
disorder. Notwithstanding, the diagnostic delay was on average about 6 years longer in 
women compared to men in our current study, irrespective of the type of disease and 
the severity of bleeding phenotype. Moreover, half of all men referred for bleeding were 
diagnosed within 2 years a&er their $rst bleeding, whereas in women this was a&er 14 
years. Future studies should investigate patients with bleeding disorders on an individual 
basis, to identify additional risk factors associated with the diagnostic delay. 
!is study indicates that there is much to win in diagnosing women with bleeding 
disorders earlier. When the diagnosis of a bleeding disorder is delayed, women are at risk 
for not receiving appropriate treatment in case of bleeding or prophylaxis for surgery, 
dental procedures or during child delivery. In addition, there may be a negative impact 
on quality of life due to absence at school or work and potentially missing out on social 
activities and sports.18, 32 !erefore, physicians should be more aware of bleeding disorders 
in women who present with a personal bleeding diathesis, and should investigate them 
earlier for bleeding disorders. We recommend general practitioners and gynecologists 
to ask about other bleeding symptoms and family history of bleeding symptoms and 
disorders in women presenting with HMB. A formal BS assessment may not be su'cient 
in such a setting, since in many BS items the points are scored based on whether patients 
have had treatment for a certain bleeding, and therefore in young women this may 
yield false negative BS results. !us, in such women easy bruising, recurrent epistaxis 
or prolonged bleeding a&er minor wounds may already be considered as clues for a 
possible bleeding disorder. In addition, it may be useful to screen family members of 
index patients to diagnose them earlier.
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Furthermore, women were more o&en referred because of a personal bleeding diathesis 
than men. !is is probably also because women have more physiological hemostatic 
challenges than men. !erefore, they have a higher chance of experiencing bleeding 
episodes, and higher chance for referral to diagnose or rule out a bleeding disorder. !is 
partly explains why in our study there were more women with generally milder bleeding 
disorders (type 1 VWD, mild rare coagulation factor de$ciencies, disorders of $brinolysis 
and CPDs), whereas the number of women and men with severe bleeding disorders (type 
2 and 3 VWD and severe rare coagulation factor de$ciencies) were comparable. Similarly, 
other large studies in patients with VWD and low VWF identi$ed more women than 
men.9, 10 Because these bleeding disorders have an autosomal inheritance pattern, it seems 
that a large proportion of men with bleeding disorders with a clinically mild bleeding 
phenotype are never diagnosed.
HMB was the most common symptom (82%) in women aged 12 years and above, and 
necessitating treatment in most of these women. In addition, half of all women with a 
delivery in the past in our study had a PPH. For VWD we have previously reported that 
81% of all women experienced menorrhagia (self-reported), whereas over 50% of women 
experienced bleeding complications a&er childbirth or pregnancy loss.12 A previous review 
on patients with RBDs found that more than 30% of women with RBDs experienced 
menorrhagia, whereas PPH incidence was uncommon in this population.4 In CPD, HMB 
was present in 61% of women, whereas PPH was present in 78% of women who had a 
delivery.33 Overall, these results indicate that sex-speci$c bleeding is an important issue 
in women with bleeding disorders, and o&en requires treatment.
!is is the $rst study to investigate sex di%erences in a large cohort of well-
de$ned patients with di%erent types of autosomal inherited bleeding disorders. We 
included patients from three nationwide studies in the Netherlands, which is therefore 
representative for all patients with these disorders in our country. Moreover, the methods 
of the three large included nationwide studies were very comparable, making the results 
suitable for combining them.
Nevertheless, there are some potential limitations. Firstly, data on age of diagnosis 
and age of $rst bleeding were self-reported. !erefore, this could lead to non-di%erential 
information bias and may cause a dilution of e%ect (i.e. loss of power). Since we found 
clear di%erences between men and women, this potential information bias seems 
negligible, and does not explain the objecti$ed di%erences between men and women. 
Secondly, we included more VWD patients than patients with other disorders. However, 
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this represents the prevalence of VWD compared to other bleeding disorders in the 
general population. Lastly, we acknowledge that future studies should investigate patients 
with bleeding disorders in an individual basis, to identify other factors associated with 
the diagnostic delay. 
To conclude, there are important di%erences in presentation, diagnosis and 
management of men and women with autosomal inherited bleeding disorders. Women 
are referred more o&en with bleeding episodes, the diagnostic delay is longer in women, 
and they o&en require treatment for sex-speci$c bleeding. It is of utmost importance that 
girls and women presenting with bleeding symptoms should be referred and investigated 
sooner for a bleeding disorder and to extend family investigation to women in case of an 
established bleeding disorder.
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Four pregnancies in women  




B.A.P. Laros - van Gorkom
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Congenital a$brinogenemia is associated with a high rate of obstetric complications
We report four pregnancies in two related patients with congenital 
a$brinogenemia
Both hemorrhagic and thrombotic complications can occur in patients with 
a$brinogenemia
Maintaining $brinogen levels ≥1.0 g/L during pregnancy and ≥1.5 g/L during 
labor may reduce the risk of fetal loss
ABSTRACT
Congenital a$brinogenemia is a rare autosomal recessive disorder associated with 
an increased risk of hemorrhage, thrombosis and obstetric complications. !is case 
series of four pregnancies in two related patients seeks to address the key clinical 
question of the necessary doses of $brinogen concentrate during pregnancy and 
puerperium. One pregnancy without the prophylactic use of $brinogen concentrate 
resulted in spontaneous abortion. !e second pregnancy was complicated by a 
subchorionic hematoma despite the prophylactic administration of $brinogen 
concentrate to maintain the plasma trough levels at ≥0.6 g/L. Labor was complicated 
by postpartum hemorrhage with a blood loss volume of 1480 cc. Two weeks later, 
the patient presented with postpartum thrombosis. !e other two pregnancies were 
uncomplicated with $brinogen trough levels ≥1.0 g/L during pregnancy and ≥1.5 
g/L during labor. !ese cases illustrate that during pregnancy, patients may bene$t 
from $brinogen trough levels ≥1.0 g/L. In addition, the increased risk of postpartum 
thrombosis with prolonged $brinogen supplementation warrants personalized 
postpartum advice that is guided by postpartum blood loss.
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Congenital $brinogen defects can be quantitative (a$brinogenemia or hypo$brinogenemia), 
qualitative (dys$brinogenemia), or a combination of both (hypodys$brinogenemia). 
Congenital a$brinogenemia (the complete absence of circulating $brinogen) is an 
autosomal recessive disorder with a prevalence of 1:1.000.000.1-3 !e disorder typically 
presents at birth with umbilical cord bleeding. Other types of frequently occurring 
bleeding are easy bruising, so& tissue bleeding, (spontaneous) muscle and joint bleeding, 
gastrointestinal bleeding, genitourinary bleeding and intracranial hemorrhage.1,3-5 
Interestingly, patients with a$brinogenemia may also have an increased risk of thrombosis 
because they form loosely packed and unstable thrombi with a tendency to embolize.1,2,5,6 
Obstetric complications, such as $rst-trimester pregnancy loss or antepartum and 
postpartum hemorrhage (o&en caused by placental abruption), are also common.4,6,7 
!ere are no universal guidelines on the optimal trough levels of $brinogen during each 
stage of pregnancy to prevent bleeding complications, and treatment is based on expert 
opinion. Although there is no consensus on the optimal values during pregnancy or in the 
peripartum period, it is suggested that the $brinogen level should be maintained at ≥0.5-
0.6 g/L during pregnancy and ≥1.0-1.5 g/L during labor.5,8 !e current Dutch national 
guidelines advise the maintenance of $brinogen levels at ≥0.6 g/L during pregnancy 
and ≥1.0 g/L during labor.9 We address the key clinical question of the optimal doses 
of $brinogen concentrate during pregnancy and puerperium, by presenting the clinical 
outcomes of four pregnancies in two related women with congenital a$brinogenemia. All 
patients provided written informed consent for publication of this case series.




!e $rst pregnancy occurred in a 27 year-old woman. She was diagnosed with 
a$brinogenemia at 7 years of age a&er a large hematoma formed on her buttocks and upper 
legs a&er playing on a seesaw, with a $brinogen level <0.3 g/L. She had a homozygous 
nonsense mutation resulting in a STOP codon in the FGA gene (c.1001G>A, p.Trp334*).10 
Both parents were carriers of the mutation and had no history of abnormal bleeding or 
thrombosis. !ere was no consanguinity in the family. She was treated with on-demand 
$brinogen concentrate from the time of diagnosis. During her $rst pregnancy, the patient 
planned a visit to the outpatient clinic to discuss her pregnancy. However, before the visit 
took place, she was admitted to the hospital at 13 weeks of pregnancy with subchorionic 
bleeding. She received 2 g (33 mg/kg) of $brinogen concentrate on admission followed 
by the continuous infusion of 4 g (67 mg/kg) of $brinogen every 24 hours. However, 3 
days a&er admission, ultrasound examination showed the loss of the fetal heartbeat, and 
a spontaneous miscarriage occurred. She had a dilation and curettage procedure in the 
operating room due to heavy blood loss. !e total blood loss volume was 1100 cc and she 
received two units of packed red blood cells. 
A year later, the patient became pregnant again, and prophylactic treatment with 
$brinogen concentrate was started immediately, maintaining a target $brinogen level ≥0.6 
g/L. She received 3 g (50 mg/kg) of $brinogen concentrate once every 4 days. Despite the 
prophylactic regimen, she experienced a subchorionic bleeding at 15 weeks of pregnancy 
with a $brinogen level of 0.7 g/L. Her target level of $brinogen was raised to ≥1.0 g/L; to 
achieve this level, she required 3 g of $brinogen concentrate every other day. At 29 + 1 
weeks, the patient was readmitted to the hospital because of a threatened abortion with 
symptomatic cervix shortening of 11 mm. She had abdominal pain and dark blood loss. 
Corticosteroids were given to stimulate fetal lung maturation. Her symptoms disappeared, 
and she was able to leave the hospital 3 days later. At 40 + 1 weeks, she went into labor and 
received 1 g (17 mg/kg) tranexamic acid and 2 g (33 mg/kg) of $brinogen concentrate 
to maintain a target level ≥1.0 g/L. Labor progressed uneventfully, and she vaginally 
delivered a healthy girl. However, a couple of hours later, a heavy bleeding occurred, and 
she received oxytocin, misoprostol, and tranexamic acid for postpartum hemorrhage. 
Her $brinogen level at that time was 1.0 g/L, and 2 g (33 mg/kg) of $brinogen concentrate 
was given to control the bleeding. !e total blood loss volume was 1480 cc, and she was 
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discharged 2 days later. She continued $brinogen concentrate infusions of 3 g (50 mg/kg) 
every 3 days until one week a&er labor and continued tranexamic acid (1 g (17 mg/kg) 
every 8 hours) because of mild vaginal blood loss. Two weeks postpartum, she presented 
at the hospital with a thrombosis of the gastrocnemius vein and thrombophlebitis of the 
long saphenous vein in her le& leg. Tranexamic acid treatment was stopped, and she was 
treated with acetylsalicylic acid for 6 weeks with good clinical results. 
FIGURE 1. 
(A) Timeline of described pregnancies. 
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Black = patient 1, white = patient 2, *in response to this, target "brinogen levels were raised to ≥1.0 g/l for 
both patients, (B) Family tree. Grey = uncon"rmed carrier.
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!e third pregnancy described in this series occurred in a 32 year-old second cousin of the 
previously described woman, only a few weeks apart from above mentioned pregnancy 
($gure 1A). She was diagnosed with a$brinogenemia at birth due to umbilical cord 
bleeding with a $brinogen level <0.2 g/L. She had the same homozygous mutation in the 
FGA gene. A simpli$ed family tree is shown in $gure 1B. !e genotypes, laboratory values 
and clinical phenotypes of the patients and family members are shown in table 1. !e 
couple was counseled, and the partner had a normal $brinogen level. In the initial stage 
of the $rst trimester, the target $brinogen level was maintained at ≥0.6 g/L. However, 
this level was raised to ≥1.0 g/L a&er her cousin’s complicating event with subchorionic 
bleeding at 15 weeks. !is target $brinogen level was reached by the administration of 3 g 
(44 mg/kg) of $brinogen concentrate every other day. During labor, the target $brinogen 
level was set at ≥1.5 g/L. She gave birth to a healthy daughter at 39 + 1 weeks by vaginal 
delivery a&er an uneventful pregnancy and labor. !e target $brinogen level was reached 
with one bolus of 3 g (44 mg/kg) of $brinogen concentrate at the time of maximal dilation. 
She did not receive tranexamic acid during labor or in the postpartum period.
Two years later, the second patient was pregnant again. Her initial target levels were 
≥0.6 g/L during the $rst 12 weeks of pregnancy and ≥1.0 g/L during the second and 
third trimesters. She received 2 g (29 mg/kg) of $brinogen concentrate every other day, 
which was raised to 3 g (44 mg/kg) every other day at 22 weeks to reach the target levels. 
At 11 weeks, she forgot to administer a dose of $brinogen concentrate. !is dose was 
administered one day later. However, she experienced vaginal bleeding the next day at 
a trough level of 1.15 g/L. Evaluation by vaginal ultrasound showed no abnormalities. 
Trough levels were maintained above 1.0 g/L with the administration of 3 g (44 mg/
kg) of $brinogen concentrate every other day, and the rest of the pregnancy progressed 
uneventfully. She gave birth to a healthy daughter at 39 + 3 weeks of pregnancy by vaginal 
delivery, with a $brinogen level ≥1.5 g/L during labor. Replacement therapy was stopped 
4 days postpartum in the absence of vaginal blood loss.
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Genotypes, laboratory values and clinical phenotypes of the patients and their family members. 













Clinical phenotype ISTH 
BAT
1 Homozygous >100 >200 0.25 0.20 Bruising, muscle bleeds, 
traumatic joint bleeds, 
miscarriage requiring red 
blood cell transfusion, 
postpartum hemorrhage
17
1.1 Heterozygous NA NA 2.0 1.9 None 0
1.2 Heterozygous NA NA 1.8 1.7 None, no miscarriages, 
three successful births 
without complications.
0
2 Homozygous 58 46 0.24 0.18 Umbilical stump bleeding 
at birth, bruising, prolonged 
wound healing, muscle 
bleeds, traumatic joint 
bleeds, RBC transfusion 
after skiing accident
17
2.1 Heterozygous 14 31 NA 2.77 None 0
2.2 Heterozygous 14 28 NA 2.40 Epistaxis, menorrhagia, 
one miscarriage, four 
successful births without 
complications
4
2.3 Homozygous 99 238 0.38 <0.5 Bruising, muscle bleeds, 








!ese cases illustrate the di'culties faced when treating women with congenital 
a$brinogenemia, who experience an increased risk of both hemorrhage and thrombosis 
during pregnancy and in the peripartum period. Large-scale studies on this topic do not 
exist, but most guidelines, including the Dutch national guidelines, currently advise the 
maintenance of $brinogen levels at ≥0.6 g/L during pregnancy to prevent fetal loss; this 
level is based on expert opinion and case reports.8,11-16 Interestingly, although the target 
level was reached during the second pregnancy, bleeding complications still occurred.
In the second patient, a $brinogen trough level was established and maintained at >1.0 
g/L, and no complications were reported during her two pregnancies. !e spontaneous 
vaginal bleeding observed a&er missing one dose of prophylactic $brinogen concentrate 
suggests that she might have had more complications if lower trough levels had been 
targeted.
In addition, women with a$brinogenemia and hypo$brinogenemia are at risk of 
thrombotic events during the puerperium, as observed in our $rst patient. !is risk 
may or may not be related to $brinogen replacement therapy.5,6,17 Although thrombotic 
events have been described in relation to high-dose $brinogen concentrate therapy, it 
is also possible that adequate $brinogen replacement in patients with a$brinogenemia 
decreases the prothrombotic risk by providing $brinogen as a ligand to trap increased 
levels of circulating thrombin and control the disrupted thrombin regulation.11 
Anti$brinolytic drugs can be used in patients with a$brinogenemia, but data are scarce 
and controversial.11,12 !e thrombotic event in our $rst patient may have been related 
to the combination of her a$brinogenemia and the use of $brinogen concentrate and 
tranexamic acid. !e main contributing factor remains uncertain. !erefore, the 
postpartum administration of $brinogen concentrate and anti$brinolytic agents should 
be used with caution and stopped as soon as possible. To optimize the treatment of 
pregnant women with a$brinogenemia, an individualized peri- and postpartum plan 
with documented target trough levels of $brinogen should be made. Prophylactic 
therapy should be adjusted based on the clinical phenotype. In the absence of an absolute 
indication, caesarian section is not recommended in these patients, as this procedure may 
increase the risk of postpartum thrombosis.12
CHAPTER 7
Four pregnancies in women with a"brinogenemia – are we underdosing "brinogen concentrate?
161
7
Based on our case series, we suggest maintaining plasma $brinogen concentrations 
at ≥1.0 g/L during pregnancy, starting immediately a&er the pregnancy is discovered, 
and at ≥1.5 g/L during labor. !e medical history of the patient and the family history 
can be used as guidance when creating a personalized treatment plan with preset trough 
levels, based on the occurrence of thrombotic or bleeding events. In the puerperium, 
the supplementation with $brinogen concentrate and the use of anti$brinolytic agents 
should be based on the amount of blood lost and stopped early to reduce the risk of 
thrombosis due to the postpartum period and immobilization.
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
In previous decades, clinical research in the $eld of congenital bleeding disorders has 
mainly focused on patients with hemophilia and von Willebrand disease. Important 
reasons are the relatively high prevalence of these bleeding disorders of around 1:10.000 
up to 1:100 for von Willebrand disease and 1:5.000 men for hemophilia (80% hemophilia 
A, 20% hemophilia B), and the severe bleeding phenotype leading to signi$cant morbidity 
(e.g. hemophilia arthropathy, neurological dysfunction due to intracerebral bleeding) 
and even mortality.1,2 At $rst, hemophilia was only a bleeding disorder of men, but in 
more recent years it was acknowledged that carriers of hemophilia can bleed as well, 
and this has consequences for their health, social life and wellbeing.3,4 !e acceptance 
that carriers can bleed has broadened the interest in congenital bleeding disorders with 
mild coagulation factor de$ciencies other than hemophilia. Although severe coagulation 
factor de$ciencies with factor activity levels <1% are very rare, the patient population 
with a mild coagulation factor de$ciency is larger. Up till now, no information on the 
epidemiology and clinical phenotype of these Rare Bleeding Disorders (RBDs) in the 
Netherlands is available. In this thesis, we focused on the clinical presentation of the 
Dutch RBD patient population and explored the use of novel hemostatic assays and 
genotyping to better assess the clinical phenotype of patients with RBDs. Finally, at the 
end of this general discussion, we provide expectations for the future of RBD patient care, 
and recommendations to apply our knowledge to clinical practice.
PREVALENCE OF RARE BLEEDING DISORDERS
!e prevalence of RBDs in the general population is estimated to be 1:500.000 up to 
1:2.000.000 for each individual coagulation factor de$ciency.5,6 However, although these 
severe coagulation factor de$ciencies are rare in the general population, heterozygosity 
for a pathogenic variant in a coagulation gene must be relatively common. If a disorder 
has a prevalence for homozygosity of 1:1.000.000 people, the prevalence of heterozygosity 
should be around 1:500 according to the Hardy Weinberg equation.7 !is means that for 
all RBDs together, 0,56% of the population should be heterozygous. In a population of 17 
million people in the Netherlands, this comes down to almost 100.000 subjects. As there 
CHAPTER 8
General discussion and future perspectives
167
8
are relatively few patients known with a heterozygous defect, it is likely that many subjects 
with factor levels of around 50% are asymptomatic or do not pursue medical attention. 
Mild disturbances of secondary hemostasis are o&en only revealed during invasive 
procedures or upon trauma. If these challenges do not occur, a mild bleeding disorder will 
not be exposed. Moreover, some diagnoses of mild de$ciencies may be missed by doctors 
due to a lack of knowledge and of accurate laboratory screening assays.8 In addition, 
women with mild bleeding disorders may experience heavy menstrual bleeding and/or 
postpartum hemorrhage as their only bleeding symptoms. As these types of bleeding are 
also common in the general population, a bleeding disorder is o&en not suspected and 
thus not tested.9,10 In addition, as heavy menstrual bleeding can o&en be treated well with 
contraceptives, further medical investigations may be withheld.9
Hemostasis is a balanced system, as shown in $gure 1A. A mild coagulation factor 
de$ciency can potentially be compensated by a mild de$ciency of an anticoagulant 
factor such as protein C. However, combined mild coagulation factor de$ciencies can 
potentially lead to a more severe bleeding tendency ($gure 1B). In chapter 4, several cases 
are shown of patients with carriership of an autosomal recessive bleeding disorder, and 
patients with combined defects in hemostasis that were initially missed by conventional 
diagnostics. One of these patients indeed had a normal PT and a normal qualitative FXIII 
assay, but heterozygous pathogenic variants in the F7 and F13 genes, with both factor 
activity levels around 50%. On the other hand, combined hemostatic defects on opposite 
sides (procoagulant - anticoagulant) can potentially compensate each other ($gure 1C). 
In clinical practice, the most notorious example of such a vulnerable balance is present 
in patients with liver failure, as the liver is the main producer of pro- and anticoagulant 
factors. At baseline no bleeding or thrombosis occurs, but this balance of hemostasis is 
easily disturbed leading to either severe hemorrhage or thrombosis.11 Mild coagulation 
factor de$ciencies and especially combined disorders of hemostasis leading to a disturbed 
hemostatic balance are easily missed with conventional diagnostics. Overall, the number 
of patients with a RBD is de$nitely higher than the number of known patients due to the 
di'cult diagnosis of bleeding disorders, especially for mild bleeding disorders.




(A) Hemostatic balance. (B) Disbalance caused by combined coagulation factor de"ciency and 
von Willebrand factor de"ciency, resulting in a higher risk of bleeding. (C) Hemostatic balance 













































General discussion and future perspectives
169
8
DIAGNOSIS OF RARE BLEEDING DISORDERS
Current hemostatic diagnostic tests
Current hemostatic assays that are available to diagnose a potential bleeding disorder 
include general clotting assays such as the platelet function analyzer (PFA), the 
prothrombin time (PT) and the activated partial thromboplastin time (aPTT). !e PFA 
has a limited sensitivity and speci$city for both vWD and platelet function disorders, 
and is not performed in every hemophilia treatment center (HTC).12 !e PT and aPTT 
show quite some variation in factor activity level responsiveness, and as such, mild 
factor de$ciencies may be missed.13,14 Only in case of severe factor de$ciencies, the test 
results will be prolonged, stimulating clinicians to undertake further hemostatic testing. 
However, isolated mild factor de$ciencies or combined mild de$ciencies in pro- and 
anticoagulant factors usually do not lead to abnormal results in these screening assays. 
As a consequence, patients with mild bleeding disorders are not diagnosed properly. 
Functional factor activity levels are only assessed in case of clearly prolonged screening 
test results and still represent only a part of the hemostatic balance of a patient. !ese 
screening tests are not sensitive for FXIII de$ciency, so it is necessary to always assess 
FXIII levels in case of a suspected bleeding tendency. However, many laboratories are 
not equipped with a quantitative FXIII activity, making it impossible to diagnose a mild 
FXII de$ciency.15 !e diagnosis of disorders of $brinolysis is especially challenging, 
as described in chapter 2 of this thesis. Normal results of speci$c assays such as the 
euglobulin clot lysis time do not rule out a disorder of $brinolysis. On the other hand, an 
activity level of plasminogen activator inhibitor type 1 (PAI-1) below the lower limit of 
detection, does not con$rm a PAI-1 de$ciency as this is also quite common in the normal 
population.16 In addition, only a minority of the specialized hemophilia treatment center 
laboratories are currently able to diagnose disorders of the $brinolytic system.
In chapter 6, we have shown the long diagnostic delay in patients with autosomal 
inherited bleeding disorders. !is delay may not only be due to a lack of sensitive 
laboratory assays and doctors delay, but there can also be a result of patient responsiveness. 
Interestingly, the diagnostic delay was much longer in females when compared to males, 
which can be due to the fact that females more o&en present with female-speci$c bleeding 
symptoms such as heavy menstrual bleeding and postpartum hemorrhage. !ese 
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symptoms are o&en not associated with a bleeding disorder by both doctors and patients. 
As these disorders are inherited, females with heavy menstrual bleeding may believe their 
blood loss is actually normal if their mother and sisters have the same amount of monthly 
blood loss. However, timely diagnosis of bleeding disorders is important, as most of these 
disorders can be treated well and preventative measures can be taken before an invasive 
procedure or delivery of a child.
Global hemostasis assays
To improve the diagnostic arsenal of hemostatic assays, the general acceptance of 
hemostasis being a physiologic process of the sequential steps without any interplay 
between primary hemostasis and the intrinsic and extrinsic pathways of secondary 
hemostasis has to be abandoned. !ere is a need to implement better diagnostic assays 
for the detection of bleeding disorders. In recent years, several global hemostasis assays 
have been developed. An advantage of these assays, such as thrombin generation, plasma 
turbidity assays and thromboelastography or thromboelastometry, is that they provide an 
overview of the complete system of hemostasis, instead of measuring only one separate 
pathway.17 !e most important limitation of global hemostasis assays is a lack of validation 
and standardization, making it di'cult to compare results of di%erent studies and 
di%erent laboratories.17 Another limitation of these assays is that in case of an abnormal 
result, i.e. a low thrombin generation curve, it remains unclear which coagulation factor 
is responsible for the abnormality. However, this altered thrombin generation level still 
provides the clinician important information about the reduced capacity of coagulation. 
In general, these assays may be useful to determine the risk of bleeding for patients with 
either an increased bleeding tendency without a diagnosis yet, or with a known bleeding 
disorder, as the correlation between coagulation factor activity levels and clinical bleeding 
severity is poor, especially in RBDs.18 However, studies so far show con/icting results for 
the use of global hemostasis assays in patients with bleeding of unknown cause (BUC), 
and thus more prospective studies incorporating global hemostasis assays in association 
with clinical outcomes are warranted.19,20 
In chapter 3, we described the results of a simultaneous thrombin and plasmin 
generation assay (the Nijmegen Hemostasis Assay, NHA) in patients with disorders of 
$brinolysis (PAI-1 de$ciency and plasminogen de$ciency). Despite equal genetic variants 
in PAI-1 de$cient patients, each patient demonstrated an individual thrombin and plasmin 
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generation pro$le. Interestingly, not only abnormalities in plasmin generation were seen 
in these patient groups with disorders of $brinolysis, but also di%erences in thrombin 
generation. !is illustrates our hypothesis that each patient with a bleeding disorder has 
an individual hemostatic balance that can be monitored by global hemostatic assays. 
!e next step would be to correlate results of global hemostasis assays, like the NHA, 
with clinically relevant outcomes, such as bleeding or monitoring of speci$c coagulation 
treatments.
Genome diagnostics
Functional hemostatic assays do not always lead to a de$nite diagnosis of a bleeding 
disorder.21 !e interest to apply genome diagnostics in clinical practice is growing due 
to decreasing costs, increasing possibilities of genome diagnostics, and the limitations of 
current laboratory assays in thrombosis and hemostasis. At the Hemophilia Treatment 
Center Nijmegen – Eindhoven – Maastricht (HTC NEM), whole exome sequencing 
(WES) is used in combination with a $lter of genes (panel) known to be involved in 
thrombosis and hemostasis.22 !is panel is evaluated every 3-4 months and adjusted if 
necessary in case novel genes have been discovered that are proven to be involved in 
thrombosis and hemostasis with an associated clinical phenotype. !e hypothesis 
behind the analysis of a panel including all genes known to be involved in thrombosis 
and hemostasis, is that the clinical phenotype of a patient is determined by the sum of 
all procoagulant and anticoagulant factors. !erefore, it is interesting to analyze both 
procoagulant and anticoagulant genes in patients with either a thrombotic or bleeding 
phenotype. In chapter 4, the results of this diagnostic strategy in patients without a de$nite 
diagnosis are described. !e overall diagnostic yield was 17% in a small population of 
patients with thrombocytopenia, thrombocytopathy or BUC. !e patient group with 
a thrombocytopenia had the highest diagnostic yield of 24%. !is was consistent with 
the only other research group who incorporated WES into routine diagnostics at that 
time.23 Other study groups used WES and other next generation sequencing (NGS) 
techniques in a research setting and not in routine diagnostics. Targeted NGS, whole 
genome sequencing (WGS) and WES showed promising results in patients with inherited 
bleeding, thrombotic and platelet disorders (BTPDs).24-27 Since the publication of our 
study, more similar results have been published, including a large study of more than 
2000 patients.28-30 Overall, the diagnostic yield appears to be quite good in patients with 
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a thrombocytopenia, but not in patients with BUC. However, we showed that some of 
these patients were carriers of an autosomal recessive bleeding disorder. Although they 
are o&en not perceived as having a disease, for most rare bleeding disorders it is known 
that carriers with a mild coagulation factor de$ciency can have a bleeding tendency.18 
!is is consistent with the increasing information on bleeding in female carriers of 
hemophilia.31 In addition, oligogenic variants found by NGS techniques can possibly 
explain a patients’ bleeding or thrombotic tendency. !is was shown by several cases 
in our study, and Downes et al. reported a number of patients with oligogenic variants 
in their large cohort as well.28 !is is an advantage of the use of NGS techniques when 
compared to conventional laboratory assays, as most of the hemostatic system can be 
checked with just one test. In addition, WES provides information on which part of the 
hemostatic system might be dysfunctional.
A limitation of the use of genome diagnostics is the uncertainty whether a pathogenic 
variant can be translated to a disturbance in vivo. If a patient has a pathogenic variant, 
but the functional laboratory test is normal, it is unclear what the consequences are for 
the clinical phenotype of the patient. Acquired disorders of hemostasis will not be picked 
up by genome diagnostics. It is possible that a mild congenital bleeding disorder becomes 
more relevant when an acquired disorder of hemostasis develops in the same patient, 
for instance when a patient is prescribed anticoagulants, develops liver dysfunction or 
disseminated intravascular coagulopathy.
As not all genes involved in thrombosis and hemostasis are known yet, the use of a 
gene panel always has the risk of missing a diagnosis. If a gene is not yet known to be 
involved in thrombosis or hemostasis, it will not be included in the gene panel and a 
pathogenic variant in that gene will not be noticed. An alternative approach to partially 
solve this problem is by using NGS techniques without an in silico $lter to identify more 
genes that are involved in thrombosis and hemostasis. A disadvantage of this approach 
is the risk of incidental $ndings. We have shown the added value of open exome 
sequencing by a case of a woman with BUC, who had a pathogenic variant in a gene 
that was not yet known to be involved in hemostasis, but was probably the cause of her 
thrombocytopathy.32 However, just one case remains inadequate to determine that this 
gene is de$nitely involved in hemostasis and should be incorporated in hemostasis gene 
panels. When more novel genes that predispose to bleeding are identi$ed by the use of 
NGS techniques, the diagnostic yield in all BTPD patients including patients with BUC, 
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may increase. It remains important to realize that not all pathogenic variants are picked 
up with the use of WES, for instance structural variants not leading to alterations in base 
sequence, copy number variants, epigenetic changes and genes in introns.
Another challenge in the use of genome diagnostics is dealing with variants of 
unknown signi$cance (VUSs). If a VUS is found in a patient, it is unclear what the 
clinical signi$cance of the identi$ed variant is. Segregation analysis can be valuable in 
this situation but is not always conclusive. Several tools have been developed to help 
identify the pathogenicity of a VUS.33,34 Reporting of VUSs is important, as this can help 
in determining pathogenicity of a variant, for instance when another HTC $nds the same 
VUS in a patient with a bleeding tendency. However, not all laboratories use the same 
standard in reporting variants.35 More data on VUSs combined with functional studies of 
genes and variants, proper laboratory assays and population-level data with phenotyping 
will improve variant classi$cation and reduce uncertainties.36
Given the abovementioned complex advantages and limitations of genome diagnostics 
for the diagnosis of BTPDs, it is important to discuss all results from genome diagnostics 
in a multidisciplinary meeting including (pediatric) hematologists, laboratory specialists 
and clinical geneticists. Sharing data on genetic variants with the subsequent clinical 
phenotype in recessive disorders, such as in the study of Downes et al., would be of great 
value to strengthen the possibilities of genomic testing.28 Although NGS techniques can 
accomplish a great improvement in the diagnostics of BTPDs, better functional assays 
such as global hemostasis assays are still necessary to get an accurate overview of the 
patients’ coagulation status.
CLINICAL PHENOTYPE OF RARE BLEEDING DISORDERS
!e Rare Bleeding Disorders in the Netherlands (RBiN) study is the $rst to describe the 
Dutch RBD patient population. All patients known with a rare bleeding disorder were 
invited to participate, and 263 patients were included from October 2017 till November 
2019. As described in chapter 5, a high variability in the bleeding tendency of these 
patients was found. Overall, most patients experienced provoked bleeding: e.g. bleeding 
a&er surgery, tooth extractions, heavy menstrual bleeding and postpartum hemorrhage. 
However, the bleeding severity appeared more pronounced when compared to the largest 
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study to date on this topic: the EN-RBD study.37 In our study the previously described 
threshold factor activity levels to remain asymptomatic appeared to be inaccurate in 48% 
of patients.18 !is observation is remarkable and of signi$cance as these levels are o&en 
used in clinical practice at the moment. For some RBDs, threshold factor activity levels 
have never been described and the guidelines are only based on expert opinion. !e 
results from the RBiN study illustrate that the RBD patient population is a heterogeneous 
group and they should not be considered as one disorder, but need a more individualized 
approach. In conclusion, the previously described threshold factor activity levels for 
RBDs should be used with caution.18
!e classi$cation of severity of RBDs is another challenge. A classi$cation has been 
described based on the EN-RBD registry.37 For several RBDs, the de$nition of a severe 
de$ciency is stated as an undetectable factor activity level. However, this is largely 
dependent on the assay that is used for the diagnosis of the patient. For instance, for 
$brinogen de$ciency an undetectable level is categorized as severe, and a moderate 
de$ciency is described as a $brinogen activity level of 0.1-0.5 g/L. Some assays are not 
able to detect $brinogen activity levels below 0.5 g/L, making it impossible to classify 
these patients as either having a severe or moderately severe factor de$ciency. !e same 
issue rises for FXIII de$ciency, where qualitative assays usually have a cut o% level of 
5 IU/dL. For FXI de$ciency, a classi$cation was not possible at all due to the lack of 
correlation between the factor activity levels and bleeding severity.37
A gap in our knowledge about bleeding disorders exists for disorders in $brinolysis. 
In our RBiN study, patients with a $brinolysis-related bleeding disorder are also included. 
To overcome this gap, the clinical features of hemorrhagic disorders of $brinolysis were 
reviewed in chapter 2. An analysis of all case reports and case series that were previously 
published on this topic, showed that most patients su%er from bleeding a&er interventions 
or trauma. In addition, female-speci$c bleeding appeared to be a relevant problem in this 
patient category, with high percentages of heavy menstrual bleeding. Reproductive failure 
was also a common issue in females, especially in PAI-1 de$cient patients, with high 
rates of miscarriages and preterm births. Bleeding at unusual sites, e.g. intramedullary 
hematomas, were the presenting symptom in some patients.
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TREATMENT OF RARE BLEEDING DISORDERS
At this moment, treatment of rare bleeding disorders mainly focuses on tranexamic 
acid, single factor concentrates when available, and plasma or prothrombin complex 
concentrate if single factor concentrates are not available. !e abovementioned threshold 
factor activity levels to remain asymptomatic are not only used in diagnostics, but also 
for the treatment of these patients. As they appear to be inaccurate, it is necessary to 
revise current guidelines, and preferably do so in an international collaboration of 
experts. !e Dutch national guidelines advise to keep factor activity levels >5-50% for 
most factor de$ciencies in case of bleeding or surgery. Tranexamic acid is advised for 
mucosal bleeding and for tooth extractions. !is guideline was last updated in 2009.38 
!e British Committee for Standards in Haematology has a more recent guideline, dating 
from 2014.39 Interestingly, there are quite some di%erences between the two guidelines. 
For FII and FV de$ciency, the British guideline advises to keep factor levels >20% in 
case of major bleeding or surgery, whereas the Dutch guideline advise levels >50%. For 
some of the other RBDs, the di%erences are less pronounced. !ere is no real evidence 
to the minimal factor activity levels required in case of surgery or major bleeding. 
!is information is only based on expert opinion and it is interesting to see the large 
heterogeneity on the minimal levels that are advised by experts in di%erent countries. In 
a more recent report in blood, the advised factor activity levels are similar to those in the 
British guideline.40 !e British guideline recommends physicians to modify treatment 
plans according to the severity of individual bleeds or procedures and to the background 
bleeding phenotype of each case. Given the large interpatient di%erences in bleeding 
severity, this recommendation is very important. At the moment, global hemostasis 
assays are not used in any of the aforementioned guidelines. 
In chapter 7, four pregnancies in two women with congenital a$brinogenemia were 
described. With a $brinogen trough level >0.6 g/L, one pregnancy was complicated by 
a subchorionic hemorrhage, but was successfully stabilized a&er raising the $brinogen 
trough level to ≥1.0 g/L. In the second patient, a trough level ≥1.0 g/L resulted in two 
uncomplicated pregnancies, except for vaginal bleeding a&er missing one dosage of 
$brinogen concentrate. !is last bleeding suggests that a higher trough level was necessary 
to avoid hemorrhagic complications during pregnancy, and that it would be bene$cial 
to maintain $brinogen activity levels ≥1.0 g/L during pregnancy to prevent placental 
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hematoma or miscarriage. Although de$nite evidence for this higher trough level could 
not be established by our case series, there probably never will be de$nite evidence as it 
is impossible to perform a randomized controlled trial due to the rarity of the disorder. 
With the current evidence in mind, it is advisable to maintain a trough level of $brinogen 
of 1.0 g/L during pregnancy, and ≥1.5 g/L during labor. As illustrated by the thrombosis 
of one of the patients during puerperium during treatment with tranexamic acid, it is 
important that this agent and replacement therapy are not overused in this period, and 
guided by blood loss. However, in literature real evidence is lacking that tranexamic acid 
in standard dosages can cause thrombotic adverse events.41
FIGURE 2. 
Potential future $ow diagram for the diagnosis of inherited bleeding disorders.
BAT ≥4 for men
BAT ≥6 for women











Green = positive diagnostic test, Red = negative diagnostic test.
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FUTURE PERSPECTIVES AND RECOMMENDATIONS
Diagnosis
As hemostasis is a balanced system ($gure 1) and current diagnostic assays only focus on 
one piece of the system, global hemostasis assays are likely to become more important 
in the future. Future studies should focus on correlating the results of global hemostasis 
assays, like the NHA, with the bleeding tendency of the individual patient. !ese assays 
may be applied more o&en for the diagnosis of bleeding disorders as well as for the 
follow up of these disorders, to monitor speci$c pro-coagulant therapy during invasive 
procedures. !e utility of these assays in patients with BUC is yet to be determined. 
Although most global hemostasis assays still need to be validated and standardization 
of these assays is important for the comparison of results between di%erent laboratories, 
they are likely to establish their value in the $eld of hemostatic diagnostics. 
In addition, the use of genome diagnostics in the standard diagnostic process is likely 
to increase in the upcoming years. NGS techniques enable the analysis of many genes at 
the same time, and costs are dropping fast. In the future, a gene panel with hemostatic 
genes may be the $rst step in the diagnostic trajectory of patients with a bleeding tendency 
without a clear family history of an established bleeding disorder.42 A potential new /ow 
diagram for diagnostics of bleeding disorders is illustrated in $gure 2. If no pathogenic 
variant is found with WES, it is still necessary to perform extensive functional assays, as 
it is unlikely that all genes involved in thrombosis and hemostasis have been discovered 
yet and a negative WES result does not exclude a hemostatic disorder. However, by 
introducing WES at the beginning of the diagnostic trajectory, speci$c con$rmation 
assays can be performed if pathological variants are found and other extensive laboratory 
assays may be omitted in many patients. Hopefully, these novel diagnostic strategies 
can lead to a more correct diagnosis for patients with a bleeding tendency and withhold 
patients from extensive laboratory testing. In addition, patients with BUC may receive a 
classifying diagnosis more o&en, such as mild coagulation factor de$ciencies. Especially 
combined hemostatic defects are o&en missed by conventional diagnostics, but might be 
diagnosed with these novel diagnostic methods. !e increasing use of NGS techniques 
will increase the number of genes known to be involved in thrombosis and hemostasis, 
and the number of known pathogenic (and non-pathogenic) variants. Instead of only 
searching for class 4 or 5 variants, VUSs are important to investigate when using genome 
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diagnostics, as well as polymorphisms. In the WES panel at the HTC NEM, polymorphisms 
that are known to have a clinical e%ect, such as speci$c polymorphisms in FVII and FXI, 
are reported. However, if a polymorphism is not known to cause a lower reduced factor 
activity levels, it will not be reported. !e additive value of performing NGS techniques 
in the diagnostic trajectory is established by the strength of the multidisciplinary team 
in which the results of genome sequencing, functional assays and clinical phenotype 
come together. Ideally, every HTC should have a well-de$ned multidisciplinary team 
($gure 3) consisting of hematologists, pediatric hematologists, laboratory specialists, 
clinical chemistry specialists and clinical geneticists. Especially concerning VUSs, the 
combination of input from di%erent disciplines will help to unravel whether a de$nite 
diagnosis can be made. In addition to this team of professionals, the patient and his or 
her family play an important role in the genetic work up, e.g. when segregation analysis 
is required for further investigation of a VUS. Aside from NGS techniques, the use 
of proteomics and RNA sequencing in hemostasis are interesting future diagnostic 
strategies, with the potential to better re/ect a patients’ individual coagulation status.43,44
!e rising attention for RBDs including disorders of $brinolysis and the increased use 
of global hemostasis assays and genome diagnostics will probably increase the number 
of patients diagnosed with these disorders. !e diagnosis of disorders of $brinolysis is 
especially challenging with the current laboratory assays, and likely to improve with 
the use of global hemostasis assays and genome diagnostics. A part of the large group 
of patients currently diagnosed with BUC may actually have a disorder of $brinolysis. 
As stated in chapter 2 of this thesis, several studies have found abnormal $brinolytic 
parameters in patients diagnosed with BUC.45,46 A more recent study found shortened 
clot lysis times in patients with BUC.47 However, another recent study did not $nd any 
signs of hyper$brinolysis in patients with BUC, but a prolonged clot lysis time.48 Based 
on these results as well as the research from this thesis, it is likely that a part of these BUC 
patients do have a disorder of $brinolysis. Especially given the diagnostic di'culties in 
$brinolysis, meticulous patient selection for performing these speci$c diagnostic tests 
is necessary to avoid false-positive results. If there are no speci$c clues for a disorder of 
$brinolysis, such as a typical bleeding pattern or family history, testing should not be 
done. However, if a patient with BUC experiences mainly late bleeding a&er interventions 
or has co-occurrence with reproductive failure in females, testing for a disorder of 
$brinolysis should not be withheld. 
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Multidisciplinary team to discuss results of genome sequencing, functional assays and clinical 
phenotype. 
It is important to remember that not all patients diagnosed with BUC actually have a 
bleeding disorder. It is known that a proportion of healthy individuals has a bleeding 
score ≥6 (females) or ≥4 (males).49 Some bleeding symptoms are subjective, o&en present 
in healthy individuals and di'cult to objectify with a bleeding assessment tool, such as 
easy bruising, bleeding from minor wounds and oral bleeding. In addition, tissue speci$c 
factors may play an important role in bleeding a&er surgery and a&er child delivery. !is 
is shown by our study in patients referred for bleeding to the HTC NEM, in which a 
high bleeding score on the separate ISTH BAT items surgery and postpartum bleeding 
correlated with not receiving a de$nite diagnosis of a bleeding disorder at the end of the 
diagnostic trajectory.21 Withholding extensive hemostatic testing should be considered in 
this patient category. Some patients who present with a bleeding tendency but cannot be 
diagnosed with an inherited bleeding disorder may have an acquired bleeding tendency, 
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e.g. due to liver failure, auto-immune disease, vessel malformation, connective tissue 
disorder or the use of medication.
In addition to improved diagnostic strategies, the RBiN study will provide more 
knowledge on RBDs. Laboratory measurements, thrombin and plasmin generation 
as well as whole exome sequencing in these patients will be investigated to provide a 
better explanation for the clinical phenotype of the individual patient. One of the 
most important things that have been learned from the RBiN study so far, is the need 
for individualization of diagnosis and treatment for patients with a (suspected) RBD. 
!e RBDs cannot be considered as one disorder. !e inconsistency of bleeding within 
each of the speci$c coagulation factor de$ciencies triggers the need for individualized-
based treatment approaches. Most RBD guidelines currently focus on recommended 
trough levels, which is understandable and useful for clinicians, similar to patient care 
in hemophilia. However, as described in chapter 5, a high variability in the bleeding 
tendency of patients with RBDs was found in the RBiN study. !e large inter-individual 
di%erences should be better mentioned in guidelines to make clinicians more aware of 
this problem. !e recommended trough levels are not su'cient for every patient and 
every RBD. Given the poor correlation between baseline factor activity levels and bleeding 
tendency, it is highly conceivable that more accurate threshold factor activity levels in 
RBDs do not exist. A recent study on women with a mild FXI de$ciency (20%-70%) 
showed that the risk of PPH a&er caesarian section was related to the individual bleeding 
history, and not to the baseline FXI activity levels.50 !is is another clue that the baseline 
factor activity levels are not the most important predictor of bleeding in individual RBD 
patients. Although it is very helpful for a clinician to have some grip on factor activity 
levels needed for hemostasis, these levels can provide false assurance. !e classi$cation 
of RBDs should not be based solely on the baseline coagulation factor activity level. In 
the most ideal situation, the classi$cation should be based on baseline coagulation factor 
activity level, individual bleeding history and the actual hemostatic balance measured by 
global hemostatic assays. !ese factors should also be the basis for an individual patients’ 
treatment plan. It is important to recognize that patients with a mild coagulation factor 
de$ciency can have a bleeding tendency, just like carriers of hemophilia.4 !ese data 
again highlight the importance of individualized diagnostics and treatment for patients 
with a bleeding tendency.
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Potential results of the Nijmegen Hemostasis Assay (NHA) and matching treatments if no speci"c 
diagnosis of a hemostatic disorder can be made.
A. Normal NHA pro"le of thrombin and plasmin generation. B. Prolonged lag-time indicating poor initiation 
of thrombin generation. C. High plasmin peak with steep slope indicating hyper"brinolysis. D. Low thrombin 
peak height indicating low thrombin generation. Red line: thrombin generation, blue line: plasmin 
generation.
Treatment
Treatment of BUC patients is very cost ine%ective because no targeted therapy is given. 
Treatment varies between blood transfusion and expensive factor concentrates (e.g. 
Novoseven). If an individual diagnosis can be made, the patient treatment will improve 
and be more cost e%ective. Especially in patients without a single factor de$ciency 
explaining their bleeding tendency, global hemostasis assays can be useful to de$ne 
which part of coagulation is not working properly, and adjust the treatment accordingly. 
Examples of potential hemostatic disturbances and matching treatments are shown 
in $gure 4, illustrated by the NHA. Figure 4A shows a normal NHA. In $gure 4B, an 
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example is given of a result with a prolonged lag-time, indicating poor initiation of 
thrombin generation. A clinical example of a disorder potentially causing such a result is 
a congenital FVII de$ciency. In this case, rFVIIa is a proper treatment option to stimulate 
thrombin generation. Figure 4C shows a result of high plasmin generation, indicating 
hyper$brinolysis. An example of such a disorder is a PAI-1 de$ciency. In this case, the 
best treatment is tranexamic acid to inhibit $brinolysis. !ese hemostatic disturbance 
can also be caused by acquired disorders such as acute promyelocytic leukemia causing 
hyper$brinolysis or massive hemorrhage causing low thrombin generation. However, 
these are more complex hemostatic situations and may lead to a variety of patterns in 
thrombin and plasmin generation, whereas the panels shown in $gure 4 are simpli$ed 
examples. !e assessment of thrombin and plasmin generation can help to understand 
the main hemostatic defect in such patients. In accordance, ROTEM is currently o&en 
used as a global hemostasis assay in critical care medicine.51
Several non-replacement therapies have been developed over the past years aimed 
at patients with hemophilia, including an antithrombin RNA interference and anti-
TFPI.52,53 !e principle of these therapies is based on the fact that thrombin generation 
needs te be increased, instead of just adding the missing factor.54 !ese are promising 
tools for the treatment of bleeding disorders including the RBDs, as the correction of 
thrombin generation instead of correcting just one coagulation factor is a potential better 
treatment for patients with multiple factors interacting to cause a bleeding tendency. 
Global hemostasis assays can be useful for the monitoring of these novel therapeutics.52,53 
Figure 4D shows a potential result of the NHA with low thrombin peak height and low 
area under the curve, indicating low thrombin generation. An example of a disorder 
potentially leading to such a result is a severe coagulation factor de$ciency. In this case, 
the novel rebalancing agents are an interesting treatment option. A potential downside 
can be that overdosing of treatment may tip the scale towards an increased risk of 
thrombosis. Good monitoring of the therapy may be helpful to decrease this risk. Overall, 
the hemostatic system may recover its balance, but it will become a more fragile system 
when compared to the normal situation in healthy individuals. !is altered mechanism of 
novel therapies illustrates that bleeding disorders should not be approached as disorders 
of missing single coagulations factors but as disturbances of the hemostatic balance 
that can be recovered by enhancing thrombin generation, slowing down $brinolysis or 
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promoting primary hemostasis. !ese novel therapies might play an important role in the 
treatment of patients with RBDs in the future.40 
In addition to the rebalancing agents, gene therapy has the potential to normalize factor 
activity levels in patients with hemophilia.55 !is development is also very interesting for 
the monogenetic RBDs. For patients with a single severe coagulation factor de$ciency, 
e.g. a$brinogenemia or severe FXIII de$ciency, gene therapy is a potentially interesting 
treatment. However, since hemostasis is a balanced system with many interacting factors, 
it is not desirable to normalize mild coagulation factor de$ciencies. For patients with a 
bleeding tendency despite only a mild coagulation factor de$ciency, other hemostatic 
factors may play a role. If this mild coagulation factor de$ciency would be corrected 
using gene therapy, the balance may change towards a thrombotic tendency. !e goal of 
gene therapy is not to restore coagulation factor activity levels to 100%, but to a su'cient 
level to prevent major bleeding.55
For the disorders of $brinolysis, they can be treated well with tranexamic acid in 
case of bleeding and for the prevention of bleeding during and a&er interventions or 
childbirth, once a correct diagnosis is made.
International cooperation is a prerequisite to gain more insight in these rare disorders. 
A prospective study including more patients with RBDs is important, and this study 
should include not only patients with a severe factor de$ciency, but also mild de$ciencies. 
Asymptomatic patients should not be withheld from studies to avoid overestimation of 
clinical symptoms. In addition to international cooperation to gain information on a 
larger group of patients, it remains important to publish case reports and case series. An 
example is given in chapter 7.
CONCLUSION
Historically, most attention on coagulation disorders was reserved for hemophilia 
and vWD. However, with the increasing knowledge on bleeding in patients with mild 
coagulation factor de$ciencies, the interest in RBDs is rising. In this thesis, the Dutch 
RBD patient population has been described for the $rst time, and they appear to bleed 
more severely than expected. In addition, the current diagnostic assays for bleeding 
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disorders are not su'cient. Global hemostasis assays and genome diagnostics may 
improve the diagnostic accuracy in the future, making individual treatment plans possible. 
Cooperation in multidisciplinary teams and on an international level is important to 
make better treatment guidelines, based on the patients’ individual hemostatic balance 
and not solely on a single coagulation factor activity level.
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Wondjes kunnen in het lichaam afgedicht worden doordat bloed stolt tot een klontje. Dit 
wordt geregeld door het hemostase systeem. Dit systeem is een ingewikkeld samenspel 
van verschillende eiwitten. Het systeem kan gezien worden als een balans, met aan de 
ene kant stollingseiwitten die zorgen dan het bloed samenklontert, en aan de andere 
kant eiwitten die dit proces juist afremmen. Deze balans is weergegeven in $guur 1A. 
Sommige mensen worden geboren met een erfelijk tekort van één of meerdere van deze 
stollingseiwitten. Hierdoor kan het bloed niet goed stollen en kunnen ze gemakkelijk 
bloeden, bijvoorbeeld na een operatie ($guur 1B). Als mensen een tekort hebben aan een 
eiwit aan de andere kant van de balans, hebben ze juist een verhoogd risico op trombose.
Omdat het hemostase systeem ingewikkeld is, is de diagnostiek van bloedingsziekten 
ook vaak lastig. Mensen die naar het ziekenhuis verwezen worden vanwege een 
bloedingsneiging, krijgen vaak geen diagnose. Deels komt dit omdat niet iedereen die 
verwezen wordt ook een bloedingsstoornis hee&. Maar ook de tests die momenteel in 
het laboratorium beschikbaar zijn, kunnen soms een diagnose missen, met name in het 
geval van milde bloedingsziekten. Als patiënten een ernstige bloedingsneiging hebben 
maar er geen diagnose gevonden kan worden, krijgen ze de diagnose ‘bloedingsneiging 
e causa ignota’ (e.c.i., van onbekende oorzaak). Omdat we niet weten waar bij deze 
patiënten het probleem in de stolling zit, kunnen ze niet gericht behandeld worden, maar 
alleen met algemene stollingsmedicijnen. Het is dus belangrijk om de diagnostiek van 
bloedingsziekten te verbeteren.
Een tekort aan de stollingseiwitten factor (F) VIII of FIX komt relatief veel voor (bij 
1:5000 mannen) en wordt hemo$lie A respectievelijk B genoemd. De fout waardoor deze 
eiwitten niet worden gemaakt, ligt op het X chromosoom, en daarom komt hemo$lie 
vrijwel alleen bij mannen voor. Vrouwen kunnen draagster zijn, maar hebben dan nog 
een tweede gezond X-chromosoom dat alsnog voor een gedeeltelijke aanmaak van het 
stollingseiwit kan zorgen. Een tekort aan een van de andere stollingsfactoren is een 
stuk zeldzamer, en dit worden de zeldzame bloedingsstoornissen genoemd. Ze komen 
voor bij ongeveer 1:500.000 tot 1:2.000.000 mensen. Hierbij is een tekort aan een van de 
volgende stollingseiwitten: $brinogeen, FII, FV, FVII, FV+VIII, FX, FXI of FXIII. Deze 
stollingsfactoren worden meestal autosomaal recessief overgeërfd, wat betekent dat je 





geërfd. De ziekten kunnen daardoor bij zowel mannen als vrouwen voorkomen. Een 
ander probleem wat kan leiden tot bloedingen is een stoornis in de $brinolyse. Fibrinolyse 
zorgt ervoor dat nadat een stolsel is gevormd, het weer afgebroken wordt. Als dit proces te 
snel gaat doordat het niet goed geremd wordt, kan een patiënt last krijgen van bloedingen 
omdat het stolsel al afgebroken wordt voordat een wondje geheeld is. Daardoor kan het 
wondje opnieuw kan gaan bloeden.
FIGUUR 1. 
A. Stollingssysteem in balans (normale situatie). B. Tekort aan één van de stollingsfactoren, 





Omdat de zeldzame bloedingsstoornissen weinig voorkomen, wordt er niet veel 
onderzoek naar gedaan en is er nog veel onbekend. Zo is het onduidelijk of patiënten 
die een mild tekort aan een stollingsfactor hebben (bijvoorbeeld 50%) ook kunnen 
bloeden, of alleen patiënten die een stollingsfactor helemaal missen. De laatste jaren is 
hier meer interesse in gekomen, doordat duidelijk werd dat vrouwen die draagster zijn 
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van hemo$lie (met een factor level rond de 50%) ook kunnen bloeden. Daarom werd 
in Nederland de RBiN (Rare Bleeding Disorders in the Netherlands) studie opgezet, die 
de Nederlandse patiëntenpopulatie voor het eerst beschrij&. In dit proefschri& wordt de 
RBiN studie beschreven, en wordt er gezocht naar nieuwe diagnostische mogelijkheden 
om deze groep patiënten beter in kaart te kunnen brengen.
In hoofdstuk 2 wordt een overzicht gegeven van de diagnostiek en kliniek van patiënten 
met $brinolysestoornissen. Het centrale eiwit van de $brinolyse is plasmine, wat ontstaat 
uit activatie van zijn voorloper plasminogeen. Bloedingen door $brinolysestoornissen 
kunnen veroorzaakt worden door een tekort van een van de remmers van de $brinolyse 
(plasminogeen activator inhibitor type 1 (PAI-1) of alfa2-antiplasmine (α2-AP)), of 
een overschot aan een van de activatoren van de $brinolyse: tissue type plasminogeen 
activator (tPA) of urokinase type plasminogeen activator (uPA). De bloedingsneiging 
van patiënten met een $brinolysestoornis wordt gekenmerkt door late nabloedingen 
na een trauma, operaties of tandextracties. Ook neusbloedingen komen vaak voor en 
vrouwen hebben vaak hevige menstruaties. Patiënten met een α2-AP de$ciëntie hebben 
de meest ernstige bloedingsneiging in vergelijking met patiënten met een tekort aan 
PAI-1 of teveel aan tPA/uPA. Vrouwen met $brinolysestoornissen hebben tevens een 
verhoogde kans op zwangerschapscomplicaties, zoals miskramen en vroeggeboorte, met 
name vrouwen met een PAI-1 de$ciëntie. Fibrinolysestoornissen worden waarschijnlijk 
ondergediagnosticeerd door een gebrek aan kennis en aan nauwkeurige diagnostische 
testen. Een deel van de grote groep patiënten die als bloedingsneiging e.c.i. geclassi$ceerd 
zijn, hee& mogelijk een $brinolysestoornis. In geval van een hoge verdenking, bijvoorbeeld 
door een positieve familieanamnese, terugkerende bloedingen of ongewone bloedingen 
zoals bloedingen in de lange botten, moet verdere diagnostiek niet achterwege gelaten 
worden als de standaard hemostatische onderzoeken negatief zijn. Goede diagnostiek is 
belangrijk omdat deze aandoeningen in het algemeen goed behandeld kunnen worden 
met medicatie.
Om de diagnostiek van bloedingsstoornissen te verbeteren, zijn er de afgelopen 
jaren verschillende tests ontwikkeld die een compleet overzicht van het hemostase 
systeem kunnen geven. Deze worden de globale hemostase tests genoemd. Eén van de 
belangrijkste hiervan is de trombinegeneratie test, die de aanmaak van trombine (een 
belangrijk onderdeel van het stollingssysteem) meet in de tijd. In het Radboudumc is 





plasminegeneratie, het centrale eiwit van de $brinolyse. In hoofdstuk 3 worden de resultaten 
beschreven van de NHA bij patiënten met 2 soorten erfelijke $brinolysestoornissen: 
een tekort aan PAI-1, of een tekort aan plasminogeen. Interessant genoeg werden niet 
alleen afwijkingen in de aanmaak van plasmine gezien, zoals verwacht kan worden bij 
patiënten met een stoornis in de $brinolyse. De patiënten lieten ook afwijkingen zien in 
de aanmaak van trombine ten opzichte van normale controles. Dit illustreert het feit dat 
de verschillende fases van het stollingssysteem met elkaar verbonden zijn. Bij patiënten 
met een tekort aan PAI-1 bleek er een groot verschil te zitten in de testuitslagen van de 
individuele patiënten, ondanks dat ze allemaal dezelfde genetische afwijkingen hadden. 
Dit is een indicatie dat er ook andere factoren uit het stollingssysteem een rol spelen. Dat 
kan weer verklaren waarom de ene patiënt een ernstige bloedingsneiging kan hebben, 
terwijl de andere vrijwel nergens last van hee&. Om dit beter te analyseren, moet bij deze 
patiënten in toekomstig onderzoek uitgebreid stollingsonderzoek gedaan worden, om te 
kijken welke factoren hierin een belangrijke rol kunnen spelen. 
Omdat de bloedingsstoornissen die in dit proefschri& beschreven worden erfelijk zijn, 
kan genetisch onderzoek nuttig zijn voor de diagnostiek van deze ziekten. Lange tijd werd 
dit gedaan door middel van Sanger genanalyse, waarmee één gen per keer bekeken kan 
worden. Omdat veel verschillende genen een rol kunnen spelen bij bloedingsstoornissen, 
is dit een tijdrovende en dure techniek. De laatste jaren zijn andere genonderzoeken in 
opkomst, zoals whole exome sequencing (WES). Met deze techniek kunnen alle genen 
die mogelijk betrokken zijn bij een bloedingsstoornis in één keer geanalyseerd worden 
in een panel. Dit maakt de diagnostiek sneller en goedkoper. Bovendien kunnen zo 
gecombineerde afwijkingen gevonden worden die gezamenlijk leiden tot een verstoorde 
balans van het hemostase systeem, en dus tot een bloedingsneiging bij de patiënt. 
Hoofdstuk 4 beschrij& de resultaten van het gebruik van WES voor de diagnostiek van 
bloedingsstoornissen in de eerste 2 jaar dat dit in het Radboudumc gebruikt werd. Voor 
het beoordelen van de resultaten werden de patiënten in 3 groepen verdeeld: groep 
A, patiënten met een te lage hoeveelheid bloedplaatjes, groep B, patiënten met een 
abnormale functie van de bloedplaatjes, en groep C, patiënten met een bloedingsneiging 
e.ci. In groep A kon het vaakst een diagnose gesteld worden met het WES panel. In 
deze groep werd bij 24% van de patiënten een genetische afwijking werd gevonden die 
het lage aantal bloedplaatjes kon verklaren. In groep C was de opbrengst het laagst, en 
ook in andere studies naar met een WES panel werden weinig genetische afwijkingen 
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gevonden bij patiënten met een bloedingsneiging e.ci. In deze groep waren wel een aantal 
patiënten met meerdere genetische afwijkingen die samen de bloedingsneiging van de 
patiënt konden verklaren. In het artikel worden verschillende casus beschreven, zoals van 
een jonge vrouw met hevige bloedingen waarvoor aanvankelijk geen oorzaak gevonden 
kon worden. Het WES panel toonde aan dat zij een genetische afwijking had in het F7 
gen én een afwijking in het F13 gen. Omdat op beide genen maar één afwijking lag en 
de tekorten aan deze stollingsfactoren rond de 50% waren, werd dit niet opgepikt door 
de standaard laboratoriumdiagnostiek. Echter, de combinatie van deze afwijkingen kan 
leiden tot een bloedingsneiging, zoals bij deze patiënt. 
Hoofdstuk 5 gee& een beschrijving van de RBiN studie, en van de bloedingen 
die de patiënten in deze studie hadden. Hieruit kwam naar voren dat patiënten met 
zeldzame bloedingsstoornissen met name bloedingen hebben na een trigger, zoals een 
operatie, kiesextractie of bij vrouwen, hevige menstruaties en ernstig bloedverlies na een 
bevalling. Verder bleek dat de variatie in de bloedingsneiging van deze groep patiënten 
heel groot is. Er zijn patiënten die ondanks lage stollingsfactor concentraties bijna geen 
bloedingen hebben, maar ook patiënten die ondanks een mild stollingsfactor tekort een 
ernstige bloedingsneiging hebben. De correlatie tussen de stollingsfactor concentratie 
en de ernst van de bloedingsneiging was meestal slecht, met name bij patiënten met 
een tekort aan FXI. Dit was ook gebleken uit een eerdere Europese studie. Uit de RBiN 
studie bleek dat de Nederlandse patiënten ernstiger bloedden dan deze eerder beschreven 
Europese populatie. In de Europese studie werden tevens minimale concentraties van 
stollingsfactoren beschreven die nodig zouden zijn om geen bloedingen te krijgen. Als 
gekeken werd naar de minimale factor concentraties, bleek dat 48% van de Nederlandse 
patiënten ernstigere bloedingen hadden dan hiermee voorspeld werd. Dit is relevant, 
omdat deze drempelwaarden nu vaak gebruikt worden door artsen. Een arts kan dan 
denken bij een patiënt met een factor level van 50% dat deze boven de drempelwaarde 
zit en dus niet zal bloeden. Uit de RBiN studie bleek dat dit niet altijd terecht is, en dat 
er meer gekeken moet worden naar de individuele patiënt en naar wat voor bloedingen 
deze wel of niet hee& doorgemaakt. Daar kan de behandeling van de patiënt op aangepast 
worden.
In hoofdstuk 6 worden gegevens van de RBiN studie gecombineerd met andere 
grote Nederlandse studies op het gebied van bloedingsziekten. De WiN (Willebrand 





Nederlandse patiënten met de ziekte van von Willebrand en met een trombocytopathie 
(bloedplaatjesstoornis), respectievelijk. Dit zijn andere bloedingsziekten die ook kunnen 
leiden tot een bloedingsneiging. Deze ziekten worden ook niet X-gebonden overgeërfd, 
waardoor ze bij zowel mannen als vrouwen voorkomen. Omdat vrouwen menstruaties 
hebben en kunnen bevallen, hebben zij meer risico op bloedingen dan mannen 
gedurende het leven. Er is echter nog nooit onderzoek gedaan naar de verschillen tussen 
mannen en vrouwen voor de diagnostiek van bloedingsstoornissen. Na combinatie van 
de data van de RBiN, WiN en TiN studies, bleek dat mannen en vrouwen rond dezelfde 
lee&ijd hun eerste bloeding krijgen. Echter, vrouwen werden op signi$cant latere lee&ijd 
gediagnosticeerd met een bloedingsziekte dan mannen. Hierdoor was de vertraging 
tussen de eerste bloeding en het stellen van de diagnose bij vrouwen duidelijk groter 
dan bij mannen. Dit zou kunnen komen doordat zowel patiënten als artsen hevige 
menstruaties of nabloedingen na bevallingen niet altijd onderkennen als een symptoom 
van een bloedingsstoornis. Het is belangrijk om hier aandacht voor te hebben, want 
zolang een patiënt geen (correcte) diagnose hee&, kan hij/zij ook niet goed behandeld 
worden.
Eén van de zeldzame bloedingsstoornissen is a$brinogenemie, waarbij de belangrijke 
stollingsfactor $brinogeen ontbreekt. Bij deze aandoening worden naast bloedingen ook 
vaak zwangerschapscomplicaties gezien, met name miskramen. Bijna elke zwangerschap 
bij een patiënte met a$brinogenemie zal zonder behandeling in een miskraam 
eindigen. Daarom wordt meestal elke paar dagen $brinogeen via een infuus gegeven 
gedurende de zwangerschap om een miskraam te voorkomen. In hoofdstuk 7 worden 4 
zwangerschappen beschreven bij 2 vrouwen. De eerste zwangerschap, zonder suppletie van 
$brinogeen, eindigde in een miskraam. Bij de tweede zwangerschap werd direct gestart 
met suppletie, maar kreeg de patiënte desondanks een bloeding bij de placenta waardoor 
een miskraam dreigde. Na het ophogen van de suppletie verliep de zwangerschap verder 
ongecompliceerd. Bij de laatste 2 zwangerschappen, bij patiënt 2, werd daarom gekozen 
voor hogere suppletie van $brinogeen. Hiermee verliepen de zwangerschappen zonder 
complicaties, behoudens 1 vaginale bloeding nadat een dosis $brinogeen gemist was. Deze 
ervaringen zijn een aanwijzing dat hogere suppletie aangewezen is voor de behandeling 
van a$brinogenemie tijdens zwangerschap. Aangezien patiënt 1 na de bevalling een 
trombosebeen kreeg, is het echter ook belangrijk om deze stollingsmedicijnen op tijd 
weer te stoppen wanneer het bloedverlies na de bevalling dit toelaat.
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Het proefschri& wordt afgesloten in hoofdstuk 8 met een discussie over de resultaten 
van de hiervoor beschreven hoofdstukken. Daarnaast wordt gekeken naar de toekomst, 
en worden aanbevelingen gegeven hoe de bevindingen uit dit proefschri& in de praktijk 
gebracht kunnen worden. Op basis van het onderzoek dat in dit proefschri& beschreven 
is, mag verwacht worden dat in de toekomst globale hemostase tests en genetische 
onderzoek belangrijker zullen worden in de diagnostiek van bloedingsstoornissen. Voor 
de globale hemostase tests geldt dat deze ook goed gebruikt kunnen worden voor het 
monitoren van de behandeling van bloedingsstoornissen. Omdat uit de RBiN studie 
gebleken is dat patiënten vaak ernstiger bloeden dan op basis van eerdere drempelwaarden 
gedacht werd, moeten deze drempelwaarden met grote voorzichtigheid gebruikt worden. 
Wederom dient naar de individuele patiënt en zijn/haar bloedingsneiging gekeken te 
worden. Aanvullende resultaten van de RBiN studie, zoals laboratoriumuitslagen en 
genetisch onderzoek, kunnen de kennis over zeldzame bloedingsstoornissen verder 
verbeteren. Voor uitbreiding van dit onderzoek is het belangrijk om internationaal samen 
te werken, omdat het aantal patiënten in één afzonderlijk land altijd beperkt zal zijn. Voor 
wat betre& de behandeling van de zeldzame bloedingsstoornissen moet gestreefd worden 
naar individualisatie, waarbij patiënten niet als een groep gezien worden maar gekeken 
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!e data obtained in this thesis are archived according to the Findable, Accessible, 
Interoperable and Reusable (FAIR) principles. !is thesis is based on the results of human 
studies, which were conducted in accordance with the principles of the Declaration of 
Helsinki. !e medical and ethical review board Committee on Research Involving Human 
Subjects Region Arnhem Nijmegen, Nijmegen, the Netherlands has given approval to 
conduct these studies. !is project is stored on the Research disk: (S):Hematstudies\\
umcms039)Lopend Stol/HEMSTOL47 RBIN.
In the RBiN study (chapter 5-6-7), patients received patient information forms 
containing the written informed consent. All patients had the possibility to ask questions 
about the study. A&er informed consent, a study visit was planned at the patients’ own 
hemophilia treatment center. !e patients received a questionnaire, either by e-mail via 
Castor EDC or on print, and the researcher $lled in the case report form in Castor EDC. 
!e paper questionnaires were stored at the department of hematology (Radboudumc, 
hematology 476, room 4.16), in a closed closet. !e informed consent forms from the 
patients included at the Radboudumc are in the same location. Informed consents from 
patients included in other hemophilia treatment centers are stored at the concerning 
center. Data management and monitoring were also performed within Castor EDC. 
An audit trail was incorporated to provide evidence of the activities that has altered 
the original data. !e privacy of the participants in this study is warranted by use of 
encrypted and unique individual subject codes. !e code is stored in each participating 
center for the patients included there. Data where converged from Castor EDC to SPSS 
(SPSS Inc., Chicago, Illinois, USA). 
For the study described in chapter 3, all informed consents and patient data are stored 
at the Indiana Hemophilia & !rombosis Center, IN, US, were the patients were included. 
Laboratory data are stored at the Research disk at the Radboudumc.
!e data will be saved for 15 years a&er termination of the study (January 1, 2020). 
!e datasets analyzed during these studies are available upon request, and will be further 
analyzed during the next part of the RBiN study project.
DATA MANAGEMENT FORM
211
Rare bleeding disorders: diagnostic strategies and clinical features
212
PHD PORTFOLIO
Name PhD candidate: JL Saes
Department: Hematology
Graduate School: Radboud Institute for Health 
Sciences
PhD period: 01-01-2017 – 01-09-2020
Promotor(s): Prof. dr. N.M.A. Blijlevens




a) Courses & Workshops
Workshop Endnote Radboud library 2017 0.1
Workshop Pubmed Radboud library 2017 0.1
AIOS workshop ‘ontwerp wetenschappelijk onderzoek’ 2017 0.1
BROK course 2017 1.5
Course ‘update hemostase’ 2017 0.5
PhD course NVTH (Nederlandse Vereniging voor Trombose & 
Hemostase) 
2017 1.0
How to write a medical scienti"c paper 2017 0.25
Biometrics course PAO Heyendael 2017-2018 3.75
NVTH PhD day 2018 0.25
PhD course NVTH 2018 1.0
Scienti"c Integrity 2020 1.0
b) Seminars & lectures
Referaat MDO hemostase 2017-2020 1.5
c) Symposia & congresses
EAHAD Paris 2017 0.75
Nijmegen symposium incl. oral presentation 2017 0.75
NVTH symposium 2017 0.5
ISTH Berlin incl. poster presentation 2017 2.0
BIC conference Rome incl. 2 poster presentations 2017 1.75
Dutch Hematology Congress 2018 0.25
PHD PORTFOLIO
213
EAHAD incl. 2 poster presentations 2018 1.5
NVTH symposium 2018 0.5
Nijmegen symposium incl. oral presentation 2019 0.75
Dutch Hematology Congress incl. oral presentation 2019 0.75
ISTH Melbourne incl. oral and poster presentation 2019 2.25
BIC conference Genua incl. poster presentation 2019 1.25
WFH Global Forum Montreal 2019 0.5
Dutch Hematology Congress incl. oral presentation 2020 1.0
EAHAD Den Haag incl. poster presentation 2020 1.25




Review scienti"c publication (haemophilia) 2019 0.1
Review scienti"c publication (thrombosis research) 2019 0.1
Review scienti"c publication (blood) 2020 0.1




d) Supervision of internships / other 2019 1.0
TOTAL 29,7

